Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021  
IND 129,003  EUDRA-CT 2019-002907-17CLINICAL STUDY PROTOCOL 
 
A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, Pa rallel- 
Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV1 01 in 
PediaTric IndividUals With AngelmaN SyndromE (NEPTUNE) 
PROTOCOL NUMBER OV101-19-001 
Sponsor:  Ovid Therapeutics Inc. 
1460 Broadway New York, NY 10036 
Sponsor Contact: Mathews Adera, MD 
Vice President, Clinical Development 
Telephone: 570-620-6290 
  
Medical Monitor: Eric J Christopher, MD, FAPA 
Associate Medical Director; PPD 
Eric.Christopher@ppdi.com 
 
Date of Amendment 5:  
26 January 2021 (Version 6.0)   
Date of Amendment 4: 27 June 2020 (Version 5.0) 
Date of Amendment 3: 19 June 2020 (Version 4.0) 
Date of Amendment 2: 18 April 2020 (Version 3.0) 
Date of Amendment 1: 31 January 2020 (Version 2.0) 
Date of Original Protocol: 30 May 2019 (Version 1.0) 
 
 
CONFIDENTIAL 
All financial and nonfinancial support for this study will be p rovided by Ovid Therapeutics Inc.  
The concepts and information contained in this document or gene rated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed, 
written consent of Ovid Therapeutics Inc. The study will be con ducted according to the 
International Council for Harmonisation harmonised tripartite g uideline E6 (R2): Good 
Clinical Practice. Eric J Christopher, MD, FAPA
Associate Medical Director ; PPD 
Eric.Christopher @ppdi.co m Mathews Adera , MD
Vice President, Clinical Development 
Telephone: 570-620-6290 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021  
Mathews Adera, MDProtocol Approval – Sponsor Signatory 
 
Study Title A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, 
Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safe ty of 
OV101 in PediaTric IndividUals With AngelmaN SyndromE 
(NEPTUNE) 
Protocol Number OV101-19-001 
 
Amendment 5  
Version 6.0 
Date: 26 January 2021 
Protocol accepted and approved by: 
 
 
 
 
 
 
03 February 2021 
Date New York, NY 100361460 BroadwayOvid Therapeutics Inc.  Vice President, Clinical Development  
Signature  
 Signature
Signature
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021  
Christopher J. Keary, MD
Coordinating Investigator  Protocol Approval –Coordinating Investigator 
 
Study Title A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, 
Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safe ty of 
OV101 in PediaTric IndividUals With AngelmaN SyndromE 
(NEPTUNE) 
Protocol Number OV101-19-001 
 
Amendment 5  
Version 6.0 
Date: 26 January 2021 
Protocol accepted and approved by: 
 
 
 
 
 
 
 
 
  
 
 
 
Signature  Dateckeary@partners.orgFax: 781-860-1766  Telephone: 781-860-17291 Maguire Rd, Lexin gton, MA 02421  Instructor, Harvard Medical School  Assistant in Psychiatry, Lurie Center/Mass General Hospital for  Children  Child, Adolescent and Adult Psychiatrist  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021  
Ying Yan, PhD  
Signature  Date Protocol Approval – Lead Statistician 
 
Study Title A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, 
Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safe ty of 
OV101 in PediaTric IndividUals With AngelmaN SyndromE 
(NEPTUNE) 
Protocol Number OV101-19-001 
 
Amendment 5  
Version 6.0 
Date: 26 January 2021 
Protocol accepted and approved by: 
 
 
 
 
 
 
 
 New York, NY 100361460 BroadwayOvid Therapeutics Inc.  Vice President, Biostatistics, Programming & Data Mgt  
Date Signatur e
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021   
 
Protocol Amendment 5 (Version 6.0) Summary of Changes 
Rationale for Amendment 5 
 
Protocol Amendment 5 (Version 6.0) includes administrative changes only to clarify the 
serious adverse event reporting process for subjects that do not elect to enter the open-label 
extension study (Section 6.4.1.5). 
 
Changes Implemented With Amendment 5: 
 
Section 6.4.1.5 (new text in bold/underlined type; no deletions were made in this 
amendment): 
 
All SAEs must be reported starting from the time that informed consent for study 
participation is provided. If the investigator becomes aware of an SAE within 30 days after 
the subject’s last dose of study drug or within 30 days after the last study visit, the SAE must 
be reported unless the patient has signed the consent to enroll into the ELARA open 
label extension study . Serious AEs must be followed until the event resolves, the event or 
sequelae stabilize, or it is unlikely that additional information can be obtained after 
demonstration of due diligence with follow-up efforts (i.e., the subject or health care 
practitioner is unable to provide additional information, or the subject is lost to follow-up). 
For subjects who do not sign the informed consent to enroll into the ELARA open label 
extension study, serious AEs that occur more than 30 days after the last dose of study drug 
should be submitted to the sponsor if the investigator becomes aware, however, these do not 
need to be reported to the IRB/EC or regulators unless the investigator or Sponsor considers 
them related to study drug. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021   
 
Declaration of Investigator 
I have read and understood all sections of the protocol entitled “A MulticeNter, Randomized, 
Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy 
and Safety of OV101 in PediaTric IndividUals With AngelmaN SyndromE (NEPTUNE)” 
and the accompanying Investigator’s Brochure. 
 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the current protocol (Version 1.0, dated 30 May 2019), the International 
Council for Harmonisation harmonised tripartite guideline E6 (R2): Good Clinical Practice 
and all applicable government regulations. I will not make changes to the protocol before 
consulting with Ovid Therapeutics Inc. or implement protocol changes without independent 
ethics committee approval except to eliminate an immediate risk to subjects. I agree to 
administer study treatment only to subjects under my personal supervision or the supervision 
of a sub investigator. 
 
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality will be protected. Subject identity will not be disclosed to third parties or 
appear in any study reports or publications. 
 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from Ovid Therapeutics Inc. 
 
 
 
 
Signature of Principal Investigator  Date 
Printed  Name  of Principal  Investigator    
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 7  
  
Table of Contents 
CLINICAL STUDY PROTOCOL ....................................... .... Error! Bookmark not defined. 
Table of Contents ............................................. ............................................................... ........... 7 
List of Tables ................................................ ............................................................... ............ 11 
Protocol Synopsis ............................................. ............................................................... ......... 12 
List of Abbreviations ......................................... ............................................................... ........ 30 
Definition of Terms ........................................... ............................................................... ........ 31 
1 Introduction .................................................. ............................................................... ...... 32 
2 Study Objectives .............................................. ............................................................... .. 36 
2.1 Primary Objective ............................................. ...................................................... 36 
2.2 Secondary Objectives .......................................... .................................................... 36 
2.5 Saf ety Objectives ................................................ ..................................................... 37 
3 Investigational Plan .......................................... ............................................................... . 38 
3.1 Study Design .................................................. ......................................................... 38 
4 Subject Selection and Withdrawal Criteria ..................... .................................................. 42 
4.1 Selection of Study P opulatio n ................................. ................................................ 42 
4.1.1 Inclusion Criteria ............................................ .......................................... 42 
4.1.2 Exclusion Criteria ............................................ ........................................ 44 
4.2 Discontinuation and Withdrawal of Subjects .................... ...................................... 45 
4.2.1 Reasons for Withdrawal ........................................ ................................... 46 
4.2.2 Handling of Withdrawals ....................................... .................................. 46 
4.2.3 Replacements .................................................. ......................................... 47 
5 Study Treatments .............................................. ............................................................... . 48 
5.1 Method of Assigning Subjects to Treatment Groups .............. ................................ 48 
5.2 Treatment Administration ...................................... .................................................. 49 
5.2.1 Dose Titration ................................................ ........................................... 50 
5.3 Identity of Investigat ional Pr oduct ........................... ............................................... 51 
5.4 Management of Clinical S upplie s ............................... ............................................ 51 
5.4.1 Study Drug Packaging and Storage .............................. ........................... 51 2.3 
2.4 Pharmacokinetic Objectives .................................... ................................................ 37  Tertiary Objectives ........................................... ....................................................... 37  
Rationale of Dosing ........................................... ...................................... 39  3.1.1  2.3
2.4
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 8  
  
5.4.2 Test Article Accountab ility .............................. ......................................... 52 
5.4.3 Other Supplies ........................................... ............................................... 52 
5.5 Overdose Management ........................................... ................................................. 52 
5.5.1 Treatment of Overdose .................................... ......................................... 52 
5.5.2 Medication Errors ........................................ ............................................ 52 
5.5.3 Treatment of Medication Errors ........................... .................................... 53 
5.6 Blinding ...................................................... ............................................................. 5 3 
5.6.1 Breaking the Blind ....................................... ............................................ 53 
5.7 Treatment Compliance .......................................... .................................................. 54 
5.8 Prior and Concomitant Therapy ................................. ............................................. 54 
5.8.1 Prohibited Medications and Therapies ..................... ................................ 55 
5.8.2 Restrictions ............................................. .................................................. 55 
6 Study Assessments and Procedures ............................. ..................................................... 56 
6.1 Screening Assessments ......................................... ................................................... 59 
6.2 Efficacy Assessments .......................................... .................................................... 59 
6.2.1 Efficacy Assessments ..................................... .......................................... 59 
6.2.1.1 Clinical Global Impressions Scales ..................... ..................................... 59 
6.2.1.2 Vineland Adaptive Behavior Scale, 3rd Editio n ........................................ 59 
6.2.1.3 Children’s Sleep Habits Questionnaire .................. .................................. 60 
6.2.1.4 Pediatric Quality of Life Inventory .................... ...................................... 60 
6.2.2 Actigraphy ............................................... ................................................. 61 
6.2.3 Sleep Diary .............................................. ................................................. 61 
6.3  
6.4 Safety Assessments............................................. .....................................................62 
6.4.1 Adverse Events ........................................... .............................................63 
6.4.1.1 Definitions of Adverse Events .......................... .......................................63 
6.4.1.2 Serious Adverse Events ................................. ...........................................64 
6.4.1.3 Eliciting and Documenting Adverse Events ............... .............................65 
6.4.1.4 Reporting Adverse Events ............................... .........................................65 
6.4.1.5 Reporting Serious Adverse Events ....................... ....................................66 
6.4.1.6 Suspected Unexpected Serious Adverse Reactions and Nonse rious 
Adverse Events of Special Interest ............................ ..............................67 
6.4.1.7 Assessment of Severity ................................. ...........................................67 
6.4.1.8 Assessment of Ca usality  ................................ ..........................................68 
6.4.1.9 Follow-Up of Subjects Reporting Adverse Events ......... .........................69 
6.4.2 Other Safety Assessments ................................. .......................................69 
6.4.2.1 Assessment of Suicidality .............................. ..........................................69 Pharmacokinetic Assessments ................................... .............................................. 62  ............................................................... ................................. 61Pediatric Quality of Life Inventory ........................... ............................... 60
Sleep Diary ................................................... ............................................ 61Children’s Sleep Habits Questionnaire .......................... .......................... 60
Actigraphy . 6.2.26.2.1.4
6.2.36.2.1.3
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 9  
  
6.4.2.2 Seizure Diary........................................... ................................................. 69 
6.4.2.3 Vital Sign Measurements ................................ ......................................... 70 
6.4.2.4 Physical Examinations .................................. ........................................... 70 
6.4.2.5 Exposure During Pregnancy and/or Lactation ............. ............................ 70 
6.5 Safety Monitoring Committee ................................... .............................................. 71 
6.6 Pregnancy ..................................................... ........................................................... 71 
6.7 Laboratory Analyses ........................................... ..................................................... 73 
6.8 Sample Collections ............................................ ...................................................... 73 
6.9 Contraception and Pregnancy Avoidance Procedure ............... ................................ 74 
7 Statistical and Analytical Plan .............................. ............................................................ 75  
7.1 General Considerations ........................................ ................................................... 75 
7.2 Endpoint s ..................................................... ............................................................ 75  
7.2.1 Efficacy Endpoints ....................................... ............................................ 75 
7.2.1.1 Primary Endpoint ....................................... .............................................. 75 
7.2.1.2 Ke y Second ary E ndpoint s ................................ ........................................ 75 
7.2.1.3 Other Secondary Endpoints .............................. ........................................ 75 
7.2.2 Safety Endpoints ......................................... ............................................. 77 
7.2.3 
7.3 Sample Size and Power ......................................... .................................................. 78 
7.4 Analysis Sets ................................................. .......................................................... 79 
7.5 Subject Dis positio n ........................................... ...................................................... 80 
7.6 Demographic and Baseline Characteristics ...................... ....................................... 80 
7.7 Exposure and Compliance ....................................... ................................................ 80 
7.8 Efficacy Analyses ............................................. ....................................................... 81 
7.8.1 Primary Efficacy Analyses ................................ ....................................... 81 
7.8.2 Key Secondary Efficacy Analyses .......................... ................................. 82 
7.8.3 Other Secondary Analyses ................................. ...................................... 82 
7.8.5 Des cription of Subgroups to be Analyzed ................. ............................... 84 
7.9 Safety Analyses ............................................... ........................................................ 84 
7.9.1 Adverse Events ........................................... ............................................. 84 
7.9.2 Clinical Laboratory Tests ................................ ......................................... 84 
7.9.3 Vital Signs and Physical Examinations .................... ................................ 85 
7.9.4 Suicidality .............................................. .................................................. 85 Tertiary Analyses ............................................. ......................................... 83  7.8.4  Pharmacokinetic E ndpoints ..................................... ................................. 77  Tertiary En dpoint s ............................................ ........................................ 76  7.2.1.4  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 10  
  
7.9.5 Seizure Diary Data ....................................... ............................................ 85 
7.10 Other Analyses ................................................ ........................................................ 85 
7.10.1 Concomitant Medications ................................. ....................................... 85 
7.10.2 
7.11 Interim Analyses .............................................. ........................................................ 86 
7.12 Statistical Testing and Significance Level .................... ........................................... 86 
7.13 Missing Data Handling and Sensitivity Analysis ................ .................................... 87 
8 Data Quality Assurance ....................................... ............................................................. 8 8 
8.1 On-Site Audits ................................................ ......................................................... 88 
8.2 Data Management ............................................... .................................................... 88 
9 Ethics ....................................................... ............................................................... .......... 90 
9.1 Independent Ethics Committee or Institutional Review Board .... ........................... 90 
9.2 Ethical Conduct of the Study .................................. ................................................ 90 
9.3 Subject Information and Consent ............................... ............................................. 90 
10 Investigator’s Obligations .................................. ...............................................................  9 2  
10.1 Confiden tiality  ............................................... .......................................................... 92 
10.2 Financial Disclosure and Obligations........................... ........................................... 92 
10.3 Investigator Documentation .................................... ................................................ 92 
10.4 Study C onduct ................................................. ........................................................ 93 
10.5 Adherence to Protocol ......................................... .................................................... 93 
10.6 Adverse Events and Study Report Requirements .................. .................................. 93 
10.7 Investigator’s Final Report ................................... ................................................... 93 
10.8 Records Retention ............................................. ...................................................... 94 
10.9 Publications .................................................. ........................................................... 94 
11 Study Management ............................................ ...............................................................  95 
11.1 Monitoring .................................................... ........................................................... 95 
11.1.1 Independent Dat a Monitoring Com mittee ................... ............................ 95 
11.1.2 Clinical Trial St eering Com mittee ....................... .................................... 95 
11.1.3 Monitoring of the Study ................................. .......................................... 96 
11.1.4 Inspection of Records ................................... ............................................ 96 
11.2 Management of Protocol Amendments and Deviations .............. ............................ 97 
11.2.1 Modification of the Protocol ............................ ........................................ 97 
11.2.2 Protocol Deviations ..................................... ............................................. 97 Pharmacokinetic Analyses ...................................... ................................. 86  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 11  
 Table 3–1
in Adults  Receiving  an OV101 Dose of 15 mg................................ ................ 40 Receiving  Predicted  Exposure -Matched  OV101  Doses  vs Observed Exposures  Predicted Exposure Parameters in Pediatric Subjects at Various Ages  
Table 3–2
Doses of OV101  for Pediatric Subject  Body  Weight  Ranges  .......................... 40 Model-Predicted Exposure (AUC 0-∞ and C max) on Days 1 and 5 After Fixed
Table 5–1 Daily Dosing and Titration of OV101 by Weight ................. ...........................49  
Table 5–2 Down-Titration of OV101 by Weight ............................. .................................51  
Table 6–1 Schedule of Activities ........................................ ...............................................56  11.3 Study Termination ............................................. ...................................................... 97 
11.4 Final Report .................................................. ........................................................... 98 
12 Reference List .............................................. ............................................................... ...... 99 
13 Pandemic Addendum ........................................... ........................................................... 101  
List of Tables 
 
 
  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 12  
  
Protocol Synopsis 
 
Protocol  Number:  
OV101-19-001 
Title: 
A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 
Study to Evaluate the Efficacy and Safety of OV101 in PediaTric IndividUals With 
AngelmaN SyndromE (NEPTUNE) 
Sponsor: 
Ovid Therapeutics Inc. 
1460 Broadway 
New York, NY 10036 
Study Phase: 
Phase 3 
Study Sites: 
Approximately 15 study sites in the United States, Israel, Australia and/or Europe 
Indication: 
Angelman syndrome (AS) 
Rationale: 
Angelman syndrome is a severe, complex, and rare neurogenetic disorder with a prevalence 
estimated at 1 in every 10,000 to 24,000 live births. The condition is associated with 
impaired expression of the ubiquitin protein ligase E3A gene ( UBE3A ). While ubiquitin 
protein ligase E3A (Ube3a) is expressed from both gene copies in the cells of other tissues, in 
neurons the paternal allele is preferentially silenced through the epigenetic process known as 
imprinting. Therefore, any alteration in the maternal copy of UBE3A results in AS. Clinical 
findings range in severity and include developmental delay/intellectual disability, movement 
and/or balance disorder, and tremulous movement of limbs. Unique behavioral characteristics 
include the combination of a happy, smiling demeanor with easily provoked laughter and 
excitability (exhibited by hand-flapping and stereotypic movements). Individuals with AS 
frequently have motor dysfunction related to gait and balance, severe disruptions in sleep, 
little to no speech, short attention span, anxiety, and seizures with characteristic abnormal 
electroencephalogram patterns. 
Current treatments are aimed at managing symptoms and include antiepileptic medications 
for seizure control and medications for sleep and behavioral problems (e.g., anxiety). Other 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 13  
  
therapies include speech therapy, physical therapy, occupational therapy, and educational 
resources. Notably, current treatments do not target the underlying brain deficits. 
 
OV101 is the first highly-selective, extrasynaptic gamma-aminobutyric acid (GABA) 
receptor agonist that binds as an orthosteric agonist to the α4- and δ-containing subunit of 
extrasynaptic GABA receptors. Research has shown that absence (or dysfunction) of Ube3a 
results in an aberrant increase in the uptake of GABA, which is the main inhibitory 
neurotransmitter in the brain. The extrasynaptic GABA receptors mediate tonic inhibition and 
sleep maintenance. In a mouse model of AS, OV101 was shown to restore tonic inhibition in 
Ube3a-deficient cerebellar neurons and correct motor abnormalities in Ube3a-deficient mice. 
These results suggest that OV101 may alleviate the motor dysfunction observed in 
individuals with AS. Importantly, OV101’s ability to potentiate tonic inhibition is unlike any 
other GABAergic agent, including benzodiazepines, zolpidem, zaleplon, zopiclone, 
barbiturates, neurosteroids, and drugs that act on GABA metabolism or uptake. Unlike many 
of these drugs that are allosteric modulators and therefore require endogenous GABA to 
function, OV101 is a GABA agonist and can function when GABA is deficient or absent. In 
addition to the data on presynaptic dysfunction leading to reduced tonic inhibition, there are 
additional studies which speak to the potential of OV101 in AS, including modulation of 
sleep and cognition domains that are impaired in subjects with AS. 
 
Phase 2 and Phase 3 studies in adult subjects with primary insomnia demonstrated that 
OV101 is effective in restoring classical sleep parameters (sleep induction and sleep 
maintenance) and slow wave sleep, resulting in an improvement in the quality and restorative 
effects of sleep. 
 
A randomized, double-blind, placebo-controlled Phase 2 study (OV101-15-001[STARS]; 
[STUDY_ID_REMOVED]) evaluated the safety, tolerability, and exploratory efficacy measures of 
OV101 in adolescents and adults with AS over 12 weeks of treatment. The STARS study was 
the first industry-sponsored clinical study in AS. Overall, OV101 had a favorable safety 
profile and was well tolerated. OV101 had a statistically significant effect on the CGI-I, a 
measure of global function, included as an exploratory measure. Exploratory and post-hoc 
analyses suggested that improvements seen on the CGI-I were likely driven by sleep, gross 
and fine motor function, behavior, and communication. 
 
NEPTUNE (OV101-19-001) will be a multicenter, randomized, placebo-controlled, 
parallel -group study to evaluate the efficacy and safety of OV101 in pediatric subjects with 
AS. Subjects who complete the study will be eligible to enroll in the ongoing OV101-18-002 
(ELARA) open-label extension study, provided they meet the eligibility criteria for ELARA. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 14  
 The tertiary efficacy objectives of this study are to evaluate the efficacy of OV101 versus  Tertiary Objectives:
xon total sleep time and total activity assessed by actigraphy
xbased on sleep diary data (caregiver reported)  
xbased on the Children’s Sleep Habits Questionnaire (CSHQ)  
x
Multidimensional Fatigue,  andFamily  Impact  modules).  based on the Pediatric Quality of Life Inventory™ (Peds QL™) (C erebral Palsy,Objectives: 
All efficacy study objectives will be assessed in the pediatric  AS study population of subjects 
who are 4 to 12 years old. All safety study objectives will be assessed in the pediatric AS 
study population of subjects who are 2 to 12 years old. 
Primary Objective: 
x To evaluate the efficacy of OV101 versus placebo as assessed by  the Clinical Global 
Impressions-Improvement-Angelman syndrome (CGI-I-AS) score at W eek 12. 
Key Secondary Objectives: 
The purpose of the key secondary objectives is to fulfil a reco mmendation of the EMA for a 
responder analysis. 
x To evaluate the efficacy of OV101 vs placebo as assessed by the  proportion of 
subjects who experience any meaningful improvement on study tre atment (defined as 
CGI-I-AS score of 1, 2, or 3 at Week 12) 
x To evaluate the efficacy of OV101 vs placebo as assessed by the  proportion of 
subjects who experience a response of much improved or very muc h improved 
(defined as CGI-I-AS score of 1 or 2 at Week 12) 
Other Secondary Objectives: 
Other secondary efficacy objectives of this study are: 
x

x To evaluate the efficacy of OV101 versus placebo on Communicati ons, Socialization, 
Daily Living Skills, Motor Skills, and Maladaptive Behavior dom ains assessed by the 
Vineland Adaptive Behavior Scale, 3rd Edition (VABS-3). 
x To evaluate the efficacy of OV101 versus placebo based on the C linical Global 
Impressions-Severity-Angelman syndrome (CGI-S-AS) Symptoms Over all score. 
x To evaluate the relationships of CGI-S-AS Symptoms Overall and CGI-S-AS 
domains at baseline with CGI-I-AS at Week 12. 
 
 placebo:sleep  efficiency,  and daytime  sleep  assessed by actigraphy.To evaluate the efficacy of OV101 versus placebo on latency of sleep onset (LSO),
xxxx
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 15  
  
 
 
 
 
 
 
It is acknowledged that pharmacokinetic sampling may be unduly burdensome for some sites  
to perform in this patient population and may therefore not be performed in some subjects.   
Where a site is unable to perform PK sampling, this should be d iscussed with the Medical 
Monitor or Sponsor, documented and captured in the Trial Master  File.  
Safety Objectives: 
The safety objectives of this study are to evaluate the safety and tolerability of OV101 in 
subjects 2 to 12 years old, including seizure diary data and as sessment of suicidality. physiologically-based PK (PBPK) model for the pediatric study p opulation 2 to 12 years old.  approach as well as to evaluate estimated PK parameters in the context of a validated  curve [AUC]) following a single oral dose using sparse sampling  and a population PK  to OV101 (maximum plasma concentration [C max] and area under the concentration-time  The pharmacokinetic (PK) objectives of this study are to estima te systemic plasma exposurePharmacokinetic Objectives:
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 16  
  
Study Population: 
Inclusion Criteria: 
Each subject must meet all the following criteria to be enrolled in this study: 
1. Is male or female and 2 to 12 years old (inclusive) at the time of informed 
consent. 
2. Has a diagnosis of AS with molecular confirmation. 
3. Has a CGI-S-AS score of 3 or more. 
4. Meets the following age-appropriate body weight criterion: 
a) Subjects 2 to 3 years old must have a minimum body weight of 9 kg. 
b) Subjects 4 years and older must be between 17 kg and 64 kg (inclusive). 
5. Has a legally acceptable representative (LAR)/caregiver capable of providing 
written informed consent and able to attend all scheduled study visits, oversee the 
administration of study drug, and provide feedback regarding the subject’s 
symptoms and performance as described in the protocol. 
6. Provides assent to the protocol (to the extent possible and in accordance with 
local institutional review board [IRB] and regulatory requirements). Subjects 
providing assent must do so at the same visit as LAR/caregiver written informed 
consent is provided. 
7. Can swallow study drug capsules with water or ingest the contents of study drug 
capsules after sprinkling the contents of each capsule onto up to 1 teaspoon of 
low-fat semiliquid food. 
8. If a subject is currently receiving a regimen of concomitant medications such as 
antiepileptic medication, gabapentin, clonidine, trazodone, melatonin, or a 
special diet regimen, that subject’s regimen is stable for at least 4 weeks before 
Day 1 (first day of study drug administration) and will be maintained throughout 
the duration of the study (in the judgment of the investigator). 
9. If a subject is a sibling in a family with multiple children diagnosed with AS, 
then only one of the siblings may enroll in study. The eldest eligible subject 
should be enrolled (investigator discretion may be used to enroll a younger 
sibling instead). 
10. Has LAR(s)/caregiver(s) who agree not to post any of the subject’s personal 
medical data or information related to the study on any website, message 
board(s), online support group(s), or social media site (e.g., Facebook, Instagram, 
Twitter, etc.) until notified that the study is completed. 
11. Female subjects who are of child-bearing potential (defined as having 
experienced their first menarche) must agree to use either a highly effective or 
acceptable form of birth control during the study and for 30 days following the 
last dose of the study. Highly effective contraceptive methods are as follows: 
a. Combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation: 
 Oral 
 Intravaginal 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 17  
  
 Transdermal 
b. Progestogen-only hormonal contraception associated with inhibition of 
ovulation: 
 Oral 
 Injectable 
 Implantable 
c. Intrauterine device 
d. Intrauterine hormone-releasing system 
e. Bilateral tubal occlusion 
f. Vasectomized partner 
g. Sexual abstinence 
 
Acceptable birth control methods that result in a failure rate of more than 1% per 
year include: 
a. Progestogen-only oral hormonal contraception, where inhibition of ovulation 
is not the primary mode of action. 
b. Male or female condom with or without spermicide. 
c. Cap, diaphragm, or sponge with spermicide. 
d. A combination of male condom with either cap, diaphragm, or sponge with 
spermicide (double barrier methods) are also considered acceptable, but not 
highly effective, birth control methods. 
 
Exclusion Criteria: 
Subjects meeting any of the following criteria will be excluded from the study: 
1. Has a circumstance or concomitant disease (e.g., gastrointestinal, renal, hepatic, 
endocrine, respiratory, or cardiovascular system disease), condition, or any 
clinically significant finding at screening that could interfere with the conduct of 
the study or that would pose an unacceptable risk to the subject in the opinion of 
the investigator. 
2. Has poorly controlled seizures defined as any of the following: 
a. Weekly seizures of any frequency with a duration more than 3 minutes. 
b. Weekly seizures occurring more than 3 times per week, each with a duration 
of less than 3 minutes. 
c. Investigator assessment. 
3. Has any of the following laboratory abnormalities: total bilirubin >1.5 × upper 
limit of normal (ULN), unless known Gilbert’s syndrome; alanine 
aminotransferase or aspartate aminotransferase >2.5 × ULN; serum creatinine 
>1.2 × ULN; absolute neutrophil count <1.5 × 109/L; platelets <80 × 109/L; 
hemoglobin <80 g/L; or thyroid-stimulating-hormone >1.25 × ULN or 
<0.8 × lower limit of normal. Retesting of clinical laboratory parameters may be 
allowed after consultation with the medical monitor or designee. 
4. Use of benzodiazepines, zolpidem, zaleplon, zopiclone, eszopiclone, barbiturates, 
or ramelteon for sleep, or minocycline or levodopa within the 4 weeks prior to 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 18  
  
Day 1 or during the study. Benzodiazepines administered as need ed for 
situational anxiety related to occasional procedures or events are permitted, and 
benzodiazepines are also permitted for seizure control. 
5.  
 
 
6. Is at risk of harming self and/or others (based on investigat or assessment). 
7. Has enrolled in any other interventional clinical study or used  any investigational 
agent or device, or has participated in any investigational pro cedure, within the 
30 days before screening or does so concurrently with this stud y. 
8. Is allergic to OV101 or any excipients of study drug. 
9. The subject or LAR/caregiver is unable to comply with study req uirements 
(based on investigator assessment). 
10. Is a family member of the investigator and/or study site sta ff. 3 attempts.consecutive  weekend days) during the 28-day screening period  ofthe study, after Cannot tolerate wearing the actigraph for at least 7 consecutiv e days (including 2  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 19  
 On Day 1, subjects will take their first dose of study drug at the study site during the daytime,  
and blood will be sampled 45 minutes ± 15 minutes, 90 minutes ±  15 minutes and 4 hours ± Study Design: 
The study will comprise a screening period within the 28 days p receding Day 1; a visit on 
Day 1 for baseline assessments, the first dose of study drug, a nd sparse sampling of blood; 
subsequent doses of study drug taken each evening approximately  30 minutes before bedtime 
for 12 weeks starting on Day 2; and study site visits for effic acy and safety assessments over 
a 12-week treatment period. After the baseline visit, the study  site visits will occur at Week 6 
and Week 12 (end of treatment [EOT]). Phone safety visits will occur during up-titration of 
the study drug (Day 6 and Day 11). Unless a subject decides to participate in the ELARA 
open-label extension study, an end of study (EOS) phone safety visit will occur 
approximately 2 weeks after the last dose of study drug to asse ss safety and tolerability 
associated with discontinuation of treatment. Subjects eligible  for and willing to enroll in the 
ELARA study will have the NEPTUNE EOT visit be their NEPTUNE EO S visit, and their 
NEPTUNE EOT visit will serve as their ELARA baseline visit. A s ubject will be considered 
to have completed the NEPTUNE study after completing the EOS vi sit. The total duration of 
the study for a subject will be approximately 18 weeks. 
Random assignment of subjects for efficacy assessment (to eithe r OV101 or placebo 
treatment in a 1:1 ratio) will be stratified by subject age at screening and by region, with a 
maximum of 12 subjects per study site (unless authorized by Spo nsor). The randomization 
strata for age at screening will be 9 to 12 years old (inclusiv e) and 4 to 8 years old 
(inclusive), with at least 24 subjects per age category. The ra ndomization strata for region 
will be US and outside US. Approximately 5 subjects 2 to 3 year s old (inclusive) will be 
enrolled for safety and PBPK assessments only and will be assig ned to treatment with 
OV101. Within each age group, dosing will be assigned based on body weight at screening. 
For each subject, after informed consent is obtained, screening  assessments will be 
completed within the 28 days preceding Day 1 (baseline). On Day  1, each subject who meets 
all eligibility criteria will receive the first assigned bliste r cards of study drug capsules 
according to the treatment code (except for subjects 2 to 3 yea rs old, who will receive study 
drug capsules in bottles), sufficient to last until the Week 6 visit, when blister cards (or 
bottles for ages 2 to 3 years) will be collected and unused stu dy drug will be counted. Study 
drug will be similarly dispensed at the Week 6 visit, and blist er cards  (or bottles for ages 
2 to 3 years) will be collected and unused study drug will be c ounted at the Week 12 visit. 
Caregivers/LARs will be provided an additional blister card in case of unexpected delays for 
study visits (e.g., inclement weather/flight delays). and PBPK 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 20  
 Subject assignment to treatment will be stratified and staged b y age and gated by an   
 
 
 
Each subject’s dose of study drug (OV101 or placebo) will be ad justed from the starting dose  
to the maintenance dose according to the titration schedule, as  tolerated by the subject. On  
Days 1 through 5, each subject will receive the starting dose. On Day 6, each subject will up-  
titrate to the maintenance dose. Phone calls to assess tolerabi lity will occur on Day 6 and  
Day 11. The maintenance dose will be set based on the subject’s  weight at screening and will  
be continued to the EOT.  
Downward dose adjustments may be permitted to mitigate tolerabi lity concerns with OV101.  
These adjustments will be at the investigator’s discretion and should be discussed with the   
medical monitor or his/her delegate. Unscheduled study site vis its are optional at any time to 
confirm tole rability.   
 
 
 
 
 
 
 
 
 
 
 
 
 
The LARs/caregivers will complete sleep diaries on behalf of su bjects over the periods where  
the subject is scheduled to wear the actigraph. An actigraph wi ll be issued to each subject at   
the screening visit, so that actigraphy data can be collected f or 7 consecutive days before  
travel for the baseline visit. Subjects will be given 3 attempt s within the 28-day screening  
window to wear the actigraph for at least 7 consecutive days, a nd subjects will be excluded 
after 3 unsuccessful attempts to wear the actigraph for 7 conse cutive days. Actigraphy data   
collected during the first 7-consecutive day period that includ es 2 weekend days during   
screening will be used as the baseline actigraphy assessment. T hese 7 consecutive daysduring the review).2 to 3 years old may begin treatment (initiation of treatment i n the 4 to 8 age group continues  review and approval of the tolerability in the sentry subjects 4 to 8 years old, subjects  treatment in the 9 to 12 age group continues during the review) . Similarly, following IDMC  PK acceptable, subjects 4 to 8 years old at screening may begin  treatment (initiation of  forwarded to the IDMC for review as blinded data. If the IDMC c onsiders the tolerability and  of the sentry subjects at Day 11, 5 days after initiation of th e maintenance dose, will betolerability and PK in sentry subjects in the previous older co hort. The tolerability assessment  termed “sentry subjects.” No age cohort may begin treatment wit hout IDMC review ofleast 3 evaluable OV101 PK samples in each efficacy age group a nd these subjects will be  will begin treatment first. Initial enrollment of randomized su bjects will be used to collect at  Independent Data Monitoring Committee (IDMC). Subjects 9 to 12 years old at screening  before anticipated bedtime, starting with the evening of Day 2.population PK modeling). Subjects will take all subsequent dose s approximately 30 minutes  30 minutes after dosing for determination of OV101 concentratio ns (sparse sampling for
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 21  
 should include 2 consecutive weekend days and should not includ e any travel days. The 
actigraph it is to be worn for a maximum of 14 days preceding t ravel for the scheduled study 
site visits at Week 6 and Week 12 visits to collect at least 7 consecutive days of data 
including 2 consecutive weekend days. If the subject requires a n additional attempt to keep 
the actigraph on for 7 consecutive days (including 2 consecutiv e weekend days) after the 
Week 6 visit, the subject will be given an actigraph to be worn  for 7 days after Week 6. 
The LAR/caregivers will complete paper seizure diaries on behal f of subjects throughout the 
study, from issuance during screening (and at study visits) thr ough Week 12 (EOT). 
Safety information will be collected during phone calls on Day 6 and Day 11 and during the 
EOS visit, as well as during every study site visit. Each subje ct’s LAR/caregiver will be 
instructed to contact the study center if the subject experienc es any adverse events (AEs), is 
unable to take the study drug as prescribed, or is unable to to lerate wearing the actigraph. 
At the investigator’s discretion throughout the study, subjects  may be evaluated at 
unscheduled clinic visits for reasons related to subject safety . At unscheduled visits, subjects 
will be queried about AEs and changes in concomitant medication s and evaluated for 
suicidality. Safety laboratory assessments may be conducted. Pe riodic interim review of 
safety data will be performed by the IDMC and as part of routin e pharmacovigilance 
activities.   
Estimated Study Duration: 
After informed consent is obtained, screening assessments will be conducted within the 
4 weeks preceding baseline, followed immediately by treatment f or 12 weeks and a 2-week 
follow-up period (for subjects not enrolling into the ELARA stu dy), for a maximum duration 
of individual subject participation of 18 weeks. Four study sit e visits are scheduled for each 
subject. 
 
For subjects choosing to participate in the ELARA open-label ex tension study, the 
NEPTUNE EOT visit will coincide with the baseline visit for ELA RA, and there will be only 
3 scheduled study site visits. For NEPTUNE subjects participati ng in ELARA, the EOS visit 
that occurs approximately 2 weeks after the EOT will take place  in the ELARA study only. 
Efficacy Assessments: 
Efficacy assessments will include the CGI-I-AS; the CGI-S-AS; t he VABS-3; the CSHQ; the 
Peds QL (Cerebral Palsy, Multidimensional Fatigue, and Family I mpact modules); 
actigraphy; and sleep diary. 
Pharmacokinetic Assessments and Analysis: Pharmacokinetic Assessments and Analysis:actigraphy; and sleep diary. Peds QL (Cerebral Palsy, Multidimensional Fatigue, and Family I mpact modules);CSHQ; thejp y ( )
or is unable to tolerate wearing the actigraph.Week 6 visit, the subject will be given an actigraph to be worn  for 7 days after Week 6.the actigraph on for 7 consecutive days (including 2 consecutive  weekend days) after theincluding 2 consecutive weekend days. If the subject requires an  additional attempt to keepsite visits at Week 6 and Week 12 visits to collect at least 7 consecutive days of dataactigraph it is to be worn for a maximum of 14 days preceding t ravel for the scheduled study
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 22  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the EOS, OV101 concentration and time data obtained from spa rse sampling in this study 
will subsequently be subjected to population PK modeling and re sulting exposure estimates 
will be evaluated using validated physiologically-based PK (PBP K) modeling to confirm   
predicted exposure estimates for the pediatric study population  2 to 12 years old at various 
weight bands. The population PK OV101 plasma exposure parameter s will be further  
evaluated using a PBPK model specific for OV101 that was develo ped using a commercially  
available PBPK software platform applied to extant PK data from  adult and adolescent  
subjects. The PBPK modeling details will be reported separately . In addition to C max and 
AUC exposure estimates, elimination half-life and T max values may also be estimated.  
It is acknowledged that pharmacokinetic sampling may be unduly burdensome for some sites  
to perform in this patient population and may therefore not be performed in some subjects.  
Where a site is unable to perform PK sampling, this should be d iscussed with the Medical   
Monitor or Sponsor, documented and captured in the Trial Master  File.  obtained previously from adolescents.IDMC to confirm that individual OV101 concentration-time data a lign with respective data  4 to 8 years of age). Plasma concentrations within each time wi ndow will be evaluated by the  minimum of 3 evaluable sentry subjects receiving OV101 within e ach age band (9 to 12 andfor each of the above 3 time points following the initial dose will be determined from a  bioanalytical facility using a validated bioanalytical assay. P lasma concentrations of OV101  The PK samples will be analyzed for OV101 concentrations by a S ponsor-contractedwill be frozen, stored and shipped according to instructions to  be provided to the study site.during Day 1. Blood samples will be processed to plasma within 2 hours. Plasma samples  necessary. Approximately 2 mL of blood will be collected per PK  sample for a total of 6 mL  blood sampling. Topical application of a cooling agent or local  anesthetic is permitted if  and 4 hours ± 30 minutes. Study site staff will record the time  of dosing and the time of  3 time points following the initial dose: 45 minutes ± 15 minut es; 90 minutes ± 15 minutes  daytime, and blood will be sampled for determination of plasma OV101 concentrations at  On Day 1, all subjects will take their first dose of study drug  at the study site during the  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 23  
  
Safety Assessments: 
Safety assessments will include frequency, severity, and causal ity of AEs (including serious 
AEs [SAEs] and AEs leading to study discontinuation), and other  safety assessments 
including assessment of suicidality (ABC-I), collection of seiz ure diaries, clinical laboratory 
assessments, vital sign measurements, and physical examinations . A total of up to 7 mL of 
blood is expected to be taken for laboratory measurements at ea ch of screening, baseline, 
Week 6, and Week 12 visits. Total blood collected will not exce ed 20 mL in a 30-day period. 
This is in accordance with the US Department of Health and Huma n Services, Office for 
Human Research Protections recommendations of 3 ml/kg, up to 50  ml total within 8 weeks 
(Table 2 in Howie 2011).  
 
Study Drug, Dosage, and Route of Administration: 
All doses of study drug will be administered orally. OV101 will  be formulated as the 
monohydrate form of gaboxadol (4 ,5,6,7-tetrahydro-isoxazolo[5, 4-c]-pyridin-3-ol,  
monohydrate) in white size 2 gelatin capsules, in 2-mg and 0.5- mg strengths (of the  
anhydrous free zwitterion equivalent). Excipients will be micro crystalline cellulose and  
 
Placebo capsules will be identical in appearance to the capsule s containing OV101 and have 
the same excipient ingredients but will not contain the active compound. 
Study drug dosage will be assigned based on body weight at the screening visit. Study drug 
will be titrated from the starting dose to the maintenance dose  according to Table 1. 
If at randomization on Day 1 a subject is assigned to placebo, the number of capsules per 
dose will correspond to the number of OV101 capsules for a subj ect of the same weight. 
Dosing will be initiated at the starting dose for the first 5 d ays. On Day 6, tolerability will be 
assessed by the investigator. If there are no tolerability conc erns (e.g., excessive somnolence, 
dizziness, vomiting, negative behavior changes) and no AE relat ed to the study drug has been 
observed since Day 1 by the LAR/caregiver or the investigator, then the dose of OV101 will 
be increased to the maintenance dose for the duration of the st udy. The maintenance dose 
identified at screening will remain consistent throughout the s tudy. If tolerability concerns 
are observed on Day 6, the subject will discontinue study drug.   
Table  1 Daily Dosing and Titration of OV101 by Weight 
Band Weight Range 
at Screening   Starting Dose    Maint Dose   Maint Dose 
(mg/kg) (mg [capsules]) (mg [capsules])
 Visit (kg)   
1  45-64    6 mg (3× 2 mg)   10 mg (5× 2 mg)    0.222–0.156  magnesium stearate.  
1Maint D ose
(mg/kg) Weight Range
at Screenin gDaily Dosing and Titration of OV101 by Weight
(mg [capsules] )g
(mg [capsules] )Band will be formulated as the
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 24  
 MaintenanceDown-Titration of OV101 by Weight 
Maintenance
a 
bMust  be <4years  ofage atscreening visit.  (mg/kg)  Band  
(mg/kg)  Weight ReducedaReduceda 
(kg) 
45-64  10 mg (5× 2 mg) 8 mg (4× 2 mg) 0.177–0.125  
35-44  8 mg (4× 2 mg) 0.23–0.19  6 mg (3× 2 mg) 0.172–0.136  
25-34  6 mg (3× 2 mg) 0.24–0.176 4 mg (2× 2 mg) 0.16–0.118
17-24  4 mg (2× 2 mg) 0.23–0.16  2 mg (1× 2 mg) 0.118–0.08
9-16b2 mg (4× 0.5 mg) 0.23–0.125 1.5 mg (3× 0.5 mg)  0.167–0.09
The reduced dose results from a down-titration, 1 capsule less per day. 5 4 3 2 0.222 –0.156 1 visitMaintenance Dose  
(mg [capsules]) Range  at 
screening Maintenance Dose 
(mg [capsules]) Table  2 
Dose  Dose  2 35-44 4 mg (2× 2 mg) 8 mg (4× 2 mg) 0.23–0.19 
3  25-34    2 mg (1× 2 mg)   6 mg (3× 2 mg)    0.24–0.176   
4  17-24   2 mg (1× 2 mg)   4 mg (2× 2 mg)    0.23–0.16   
5  9-16a   1 mg (2× 0.5 mg)  2 mg (4× 0.5 mg)  0.23–0.125   
Abbreviation: Maint, maintenance.  
a 
The subject’s maintenance dose for the duration of the study wi ll be set based on the subject’s 
weight at the screening visit, and the subject should continue taking the maintenance dose 
after the Day 6 assessment until the EOS. Tolerability will aga in be assessed during the Day 
11 phone call while the subject is taking the maintenance dose.  The investigator may initiate 
down-titration on Day 11 by 1 capsule (Table 2) based on invest igator assessments of 
tolerability and AEs, or medical necessity. If down-titration i s initiated, then the investigator 
should reassess tolerability with the modified dose regimen wit hin 3 days of the dosing 
change. No further changes in dose regimen should be made after  Day 15. 
If tolerability is not acceptable at any other time during the 12 weeks of treatment, the 
investigator should discuss the situation with the medical moni tor or his/her delegate. Any 
intolerability must be documented as an AE. The daily dose may not be lower for any subject 
than the reduced maintenance dose indicated in Table 2. If a su bject cannot tolerate the 
reduced maintenance dose, that subject must discontinue treatme nt. Any dose adjustments or 
changes in dosing must be documented in the electronic case rep ort form and supporting 
rationale must be documented in the medical record or other app ropriate source document. Must be <4 years of age at screening visit.  a5432 0.23–0.19 8 mg (4× 2 mg) 4 mg (2× 2 mg) 35-44 
Mustbe<4yearsofageatscreenin gvisit.bThe reduced dose results from a down-titration, 1 capsule less per day.a54321(mg [capsules])Maint enanceDose Maint enance (mg [capsules])Maint enance Maint enance DoseDown-Titration of OV101 by Weight
g
Range at
screening 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 25  
 The sample size calculations are based on comparison of the CGI -I-AS score at Week 12  
Assumptions are derived from the results observed in the OV101- 15-001 Phase 2 study: a
As a sensitivity analysis of the assumption of normality, a Wil coxon rank-sum test will be  Sample Size: 
Approximately 90 subjects 4 to 12 years old (inclusive) will be  randomly assigned in a 1:1 
ratio into OV101 or placebo treatment groups for both efficacy and safety assessments. 
Randomization will be stratified by age categories: 9 to 12 yea rs old (inclusive) and 4 to 8 
years old (inclusive), with at least 24 subjects per age catego ry, and by region: US and 
outside US. Approximate ly 5 subject s 2 to 3 years old (inclusiv e) will be included and treated 
with OV101 for safety assessments only. Approximately 95 subjec ts will be enrolled in the 
study at approximately 15 study sites with no more than 12 subj ects per study site (unless 
authorized by the Sponsor).  
Sample size calculations were performed to determine the number  of subjects needed for  
evaluation of efficacy using the primary efficacy endpoint as w ell as the two key s econdary  
endpoints. Based on these calculations, a minimum of 40 evaluab le subjects per treatment  
group are required to ensure sufficient power for significance testing using the primary and  
both key secondary endpoints.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If the primary analysis of CGI-I-AS shows a significant differe nce between OV101 QD and   
placebo, two key secondary endpoints, CGI-I-AS response (at lea st minimally improved) at
Week 12 and CGI-I-AS response (at least much improved) at Week 12 will be used to test the  
difference between OV101 and placebo with a gated sequential te sting procedure at a 2-sided
0.05 level of significance. Power calculations were performed b ased on chi-square test of   QD group.  12 response category in the placebo group, and 0, 0.296, 0.37, 0.334, 0, 0, 0 in the OV1010.074, 0.148, 0.704, 0.074, 0, 0 for the probability of each CG I-I Symptoms Overall at Week  (scaled 1-7) with probability distributions observed in OV101-1 5-001 Phase 2 study: 0,  0.05 level of significance. This calculation is based on the as sumption of 7 ordered categoriestreatment difference of OV101 versus placebo using a Wilcoxon r ank-sum test at a 2-sided  conducted. With 40 subjects per treatment group, there would be  99% power to test thetreatment difference at a 2-sided 0.05 level of significance.  effect size of 1. With 40 subjects per treatment group, there w ould be 99% power to test the  Overall score at Week 12 with a common standard deviation of 0. 8 points, which yields anmean difference of 0.8 points between OV101 QD and placebo in t he CGI-I Symptomsbetween OV101 and placebo, using a two-sample t-test with equal  variances.
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 26  
 Assuming a 10% drop-out rate, 90 subjects 4 to 12 years old wil l be randomized to OV101 
QD and placebo (1:1 randomization).  
 
Endpoint  Primary Endpoint 
CGI-I-AS CGI-I-AS At Least 
Minimally 
Improved CGI-I-AS At Least 
Much Improved  
Test Significance  0.05 0.05 0.05 
Level, α   
1 or 2- Sided Test   Two   Two   Two  
Assumptions   μ₁ - μ₂=0.8 and π₁=0.21, π2=0.67 π₁=0.07, π2=0.32 
  σ=0.8   
Power (%)   99%   99%   81.8%   
Sample Size per   40 40 40 
Group, n   
n, assuming 10%  45 45 45 
Dropout   two proportions. Assumptions regarding response rates are based  on the rates observed in  
summarizes the power calculations for all three endpoints:  OV101-15-001 Phase 2 study. With 40 evaluable subjects, per tre atment group, there would   
be 99% power to test the treatment difference of OV101 versus p lacebo based on the first key  
secondary endpoint, CGI-I-AS response (at least minimally impro ved), assuming a response   
rate of 21% for placebo and 67% for OV101 QD. With 40 subjects per tr eatment gr oup,  
there would be 81.8% power to test the treatment difference of OV101 versus placebo based   
on the second key secondary efficacy endpoint, CGI-I-AS respons e (at least much improved),  
assuming a response rate of 7% for placebo and 32% for OV101 QD .  The following table   
Assuming a 10% drop-out rate, 90 subjects 4 to 12 years old will  be randomized to OV101
QD and placebo (1:1 randomization).45 45 4540 40 40π₁=0.07, π2=0.32 π₁=0.21, π2=0.67 μ₁ - μ₂=0.8 and 0.05 0.05 0.05Improved Minimall y CGI-I-A S At Least
Much ImprovedCGI-I-A S At Least 
CGI-I-A SPrimary Endpoint
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 27  
  
Statistical Methods: 
All statistical analyses will be performed using SAS® Version 9.4 or higher. All clinical 
study data will be presented in subject data listings. Data summaries will be presented for all 
endpoints and will include descriptive statistics (number of subjects, mean, SD, first quartile, 
median, third quartile, minimum, and maximum) for continuous variables, and frequency and 
percentage for categorical and ordinal variables. If there are missing values, the number of 
missing will be presented, but without a percentage. For all analyses, ‘baseline’ will refer to 
the most recent non-missing value obtained immediately prior to administration of first dose. 
 
For the primary efficacy analysis, the CGI-I-AS will be analyzed as a continuous outcome 
variable. A Mixed Model Repeated Measures (MMRM) Analysis of Variance (ANOVA) 
model will be fitted using restricted maximum likelihood (REML) for CGI-I-AS with fixed 
effects for visit, randomized treatment, the visit-by-treatment interaction, age group, and 
region. An unstructured within subject-covariance structure will be specified as the first 
choice, and if the model fails to converge, alternative covariance structures will be tested as 
detailed in the SAP. If a structured covariance is used, then a robust sandwich estimator will 
be utilized for estimating the variance of the treatment effect estimate. From the model, the 
Week 12 difference between least squared means of OV101 and placebo groups will be 
presented along with the corresponding 95% confidence interval and 2-sided P value. 
 
Generalized Estimating Equations (GEE) method will be used for the analysis of key 
secondary endpoints: CGI-I-AS response (at least minimally improved) and CGI-I-AS 
response (at least much improved). GEE models will include the response variable at each 
visit as the dependent variable, and fixed effects for visit (Week 6 and Week 12), randomized 
treatment, the visit-by-treatment interaction, age group (randomization stratification variable: 
age 4 to 8 years versus age 9 to 12 years), and region (randomization stratification variable: 
US versus outside US). An unstructured working correlation for the binary outcome variable 
will be assumed for the model parameter estimation, and if the model fails to converge, 
alternative covariance structures will be tested as detailed in the SAP. If there is no response 
in either treatment arm at the Week 6 visit, the GEE model will be substituted with a logistic 
regression for the Week 12 CGI-I-AS response variable with effects for the randomized 
treatment and the two randomization stratification variables. From the model (GEE or 
logistic regression, as appropriate), the Week 12 odds ratio will be presented along with the 
corresponding 95% confidence interval and 2-sided P value. 
 
All other continuous efficacy endpoints with post baseline assessments at Week 6 and Week 
12 will be analyzed by an MMRM Analysis of Covariance (ANCOVA) model for the change 
from baseline for the endpoint fitted with fixed effects for visit, randomized treatment, the 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 28  
  
visit-by-treatment interaction, age group, region, and the corresponding baseline as a 
covariate. An unstructured within subject -covariance structure will be specified as the first 
choice, and if this analysis fails to converge, alternative covariance structures will be tested 
as detailed in the SAP. From the model, the Week 12 difference between least squared means 
of OV101 and placebo groups will be presented along with the corresponding 95% 
confidence interval and 2-sided P value. 
 
Endpoints based on composite and subdomain scores from VABS-3 assessments will be 
analyzed as continuous outcome variables using an ANCOVA model with effects for 
randomized treatment, age group, region, and the corresponding baseline as a covariate. A 
test for a significant treatment-by-baseline interaction will be performed in a separate model 
(including the above terms plus the interaction term), using a 0.100 alpha level. If the 
treatment-by-baseline interaction is significant, then the ANCOVA assumptions are violated 
and an ANOVA model will be used instead. From the final model(s), the difference between 
least squared means of OV101 and placebo groups will be presented along with the 
corresponding 95% confidence intervals and 2-sided P values. 
 
Descriptive statistics will be used to summarize all safety endpoints by treatment group. 
Two-sided 95% CIs will be presented where meaningful. Data summaries will be displayed 
for incidence of AEs, clinical laboratory variables, vital signs, body weight and body mass 
index, physical examinations, suicidality assessed by ABC-I, and seizure diary data. 
 
For AEs, all treatment-emergent AEs (TEAEs) will be coded using Medical Dictionary for 
Regulatory Activities (MedDRA) and will be summarized by MedDRA system organ class 
and preferred term and treatment group. Detailed listings of TEAEs, SAEs, related AEs, and 
discontinuations due to AEs will be provided. The incidence of TEAEs, discontinuations due 
to TEAEs, drug-related, and serious TEAEs will be summarized. Incidence of TEAEs by 
severity and relationship to study drug will also be presented. Incidence of TEAEs will be 
summarized separately for subjects 2 to 3 years old (inclusive). Other safety data for subjects 
2 to 3 years old (inclusive) will only be presented in listings and will be displayed in 
by -subject graphs, as appropriate. 
 
For clinical laboratory tests, changes from baseline to each post baseline visit with respect to 
clinical chemistry and hematology results will be summarized descriptively. Each laboratory 
parameter will be classified as low, normal, or high relative to the parameter’s reference 
range and will be summarized with shift tables. Listings of subjects with abnormal results 
will be provided. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021
Page 29  
  
Vital signs, weight, and body mass index will be summarized des criptively at baseline and all 
post baseline study visits by treatment group. Change from base line to all post baseline study 
visits will be summarized descriptively by treatment group. 
 
Physical examinations (general appearance; skin; head, ear, eye , nose, and throat; neck; 
lymph node; chest; heart; abdominal cavity; limb; central nervo us system; and 
musculoskeletal) at baseline will be summarized. Shifts from ba seline to post baseline study 
visits in each body system/site will be summarized by treatment  group.  
 
Suicidality and seizure diary data will be summarized descripti vely at baseline and all post 
baseline study visits by treatment group. Change from baseline to all post baseline study 
visits also will be summarized descriptively by treatment group . 
 
The  
population PK-derived exposure estimates (C max and AUC) and other parameters (if derived)  
will be summarized descriptively and geometric means and coeffi cients of variation will be  
presented. OV101 plasma concentrations will be summarized descriptively at  each timepoint.  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 30  
  
List of Abbreviations 
 
Abbreviation Definition  
ABC-I Aberrant Behavior Checklist-Irritability subscale 
AE adverse event 
ANCOVA Analysis of Covariance ANOVA Analysis of Variance AS Angelman syndrome AUC area under the concentration-time curve 
AUC
0-∞ area under the concentration-time curve from 0 to infinite hour s 
ß-hCG beta-human chorionic go nadotrophin 
BID twice daily CFR Code of Federal Regulations 
C
max maximum plasma concentration 
CGI-I Clinical Global Impressions-Improvement 
CGI-I-AS Clinical Global Impressions-Improvement-Angelman syndr ome 
CGI-S-AS Clinical Global Impression s-Severity-Angel man s yndrome  
CSHQ Children’s Sleep Habits Questionnaire 
CSR clinical study report 
CTSC Clinical Trial Steering Co mmittee 
eCRF electronic case report form EDC 
EMA electronic data capture 
European Medicines Agency 
EOS en d of st udy 
EOT end of treatment 
FAS full analysis set 
FDA Food and Drug Administration GABA gamma-aminobutyric acid 
GCP Good Clinical Practice 
ICF informed consent form ICH International Council for Harmonisation 
IDMC Independent Data Monitoring C ommittee 
IEC independent ethics  committee 
IRB institutional review board 
LAR legally acceptable representative 
LSO latency of sleep onset 
MedDRA Medical Dictionary for Regulatory Activities maximum plasma concentration Cmax area under the concentrati on-tim e curve from 0 t o infinit e hoursarea under the concentrati on-tim e curve
AUC 0-∞ AUC  
latency of sleep onset LSOChildren’s Sleep Habits Questionnaire CSHQ
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 31  
  
Abbreviation Definition  
MMRM Mixed Model Repeated Measures 
PBPK physiologically based pharmacokinetic 
Peds QL™ Pediatric Quality of Life Inventory™ 
PK pharmacokinetic(s) 
PPS per protocol set 
QD once daily SAE serious adverse event 
SAP 
SIF/DRF statistical analysis plan 
Seizure Identification Form and Diagnostic Review Form 
SS safety set TEAE treatment-emergent adverse event 
t
max time to maximum plasma concentration 
Ube3a ubiquitin protein ligase E3A 
UBE3A ubiquitin protein ligase E3A gene 
ULN upper limit of normal 
VABS-3 Vineland Adaptive Behavior Scale, 3rd Edition 
 
 
 
 
Definition of Terms 
 
Term  Definition  
Day 1  The first day of study drug administration 
ELARA  Study OV101-18-002, an open-label ext ension s tudy 
NEPTUNE  Study OV101-19-001 
OV101  gaboxadol 
Ovid  Ovid Therapeutics Inc. 
Sentry subject   One of the initially enrolled subjects in an age group required  for 
measuring PK, whose PK and tolerability data are reviewed by th e 
Independent Data Monitoring Committee before subjects are enrol led 
in a younger age group 
STARS  Study OV101-15-001 time to maximum plasma concentration tmax tt
One of the initially enrolled subjects in an age group required  for 
measuring PK, whose PK and tolerability data are reviewed by the
Independent Data Monitoring Committee before subjects are enroll ed 
in a younger age groupSentry subjectpharmacokinetic(s)physiologically based pharmacokinetic
™Pediatric Quality of Life Inventory y™
PKPBPK
™™Peds QL L™
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 32  
  
1 Introduction 
Ovid Therapeutics Inc. (Ovid) is developing OV101 (gaboxadol) for the treatment of rare genetic 
disorders that are associated with severe developmental and behavioral challenges that have no 
approved therapies, such as Angelman syndrome (AS) and Fragile X syndrome. Gaboxadol was 
initially developed for the treatment of insomnia by H. Lundbeck A/S and Merck, but its 
development was discontinued in 2007. Extensive nonclinical and clinical data were generated 
during the initial stages of development, including data from exposure to gaboxadol in more than 
4,300 adult subjects with insomnia and approximately 500 adult subjects in 
non-insomnia -related studies. 
 
Angelman syndrome is a severe, complex, and rare neurogenetic disorder with a prevalence 
estimated at 1 in every 10,000 to 24,000 live births (Petersen et al 1995; Steffenburg et al 1996; 
Mertz et al 2013). The condition is associated with impaired expression of the ubiquitin protein 
ligase E3A gene ( UBE3A ). While UBE3A is expressed from both gene copies in the cells of other 
tissues, in neurons the paternal allele is preferentially silenced through the epigenetic process 
known as imprinting. Therefore, any alteration in the maternal copy of UBE3A results in AS. 
Clinical findings range in severity and include developmental delay/intellectual disability, 
movement and/or balance disorder, and tremulous movement of limbs. Unique behavioral 
characteristics include the combination of a happy, smiling demeanor with easily provoked 
laughter and excitability (exhibited by hand-flapping and stereotypic movements). Individuals 
with AS frequently have motor dysfunction related to gait and balance, severe disruptions in 
sleep, little to no speech, short attention span, anxiety, and seizures with characteristic abnormal 
electroencephalogram patterns (Williams et al 2006). 
 
Current treatments are aimed at managing symptoms and include antiepileptic medications for 
seizure control and medications for sleep and behavioral problems (e.g., anxiety). Other therapies 
include speech therapy, physical therapy, occupational therapy, and educational resources. 
Notably, current treatments do not target the underlying brain deficits. 
 
OV101 is the first highly selective, extrasynaptic gamma-aminobutyric acid (GABA) receptor 
agonist that binds as an orthosteric agonist to the α4- and δ-containing subunit of extrasynaptic 
GABA receptors. Research has shown that absence (or dysfunction) of Ube3a results in an 
aberrant increase in the uptake of GABA, which is the main inhibitory neurotransmitter in the 
brain. The extrasynaptic GABA receptors mediate tonic inhibition and sleep maintenance. In a 
mouse model of AS, OV101 was shown to restore tonic inhibition in Ube3a-deficient cerebellar 
neurons and correct motor abnormalities in Ube3a-deficient mice (Egawa et al 2012). These 
results suggest that OV101 may alleviate the motor dysfunction observed in individuals with AS. 
Importantly, OV101’s ability to potentiate tonic inhibition is unlike any other GABAergic agent, 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 33  
 OV101-16-001 ([STUDY_ID_REMOVED]) was a Phase 1, single-dose pharmacok inetic (PK) study inincluding benzodiazepines, zolpidem, zaleplon, zopiclone, barbi turates, neurosteroids, and drugs 
that act on GABA metabolism or uptake. Unlike many of these dru gs that are allosteric 
modulators and therefore require endogenous GABA to function, O V101 is a GABA agonist and 
can function when GABA is deficient or absent. In addition to t he data on presynaptic 
dysfunction leading to reduced tonic inhibition, there are addi tional studies which speak to the 
potential of OV101 in AS, including modulation of sleep and cog nition domains that are 
impaired in subjects with AS (Ramamoorthi and Lin 2011; Brickle y and Mody 2012; Egawa and 
Fukuda 2013; Deidda et al 2014; Berry et al 2015; Dissel et al 2015).  
Phase 2 and Phase 3 studies in adult subjects with primary inso mnia demonstrated that OV101 is 
effective in restoring classical sleep parameters (sleep induct ion and sleep maintenance) and 
slow wave sleep, resulting in an improvement in the quality and  restorative effects of sleep. 
 
 
 
 
 
 
 
 
 
A randomized, double-blind, placebo-controlled Phase 2 study (O V101-15-001[STARS]; 
[STUDY_ID_REMOVED]) evaluated the safety, tolerability, and explorator y measures of efficacy of OV101 
in adolescents and adults with AS over 12 weeks of treatment. T he STARS study was the first 
industry Sponsored clinical study in AS. Overall, OV101 had a f avorable safety profile and was 
well tolerated. OV101 had a statistically significant effect on  the Clinical Global 
Impressions-Improvement (CGI-I), a measure of global function i ncluded as an exploratory 
measure. Exploratory and post-hoc analyses suggested that impro vements seen on the CGI-I 
were likely driven by sleep, gross and fine motor function, beh avior, and communication. 
 
Eighty-eight subjects with AS (13 to 49 years old) were randoml y assigned to 1 of 3 groups: 
once daily (QD) dose of OV101 nightly (15 mg), twice daily (BID ) dose of OV101 (10 mg 
morning and 15 mg night), and placebo. The safety and tolerabil ity of OV101 from baseline to 
Week 12 was evaluated by comparing the frequency and severity o f adverse events (AEs) and 
serious AEs (SAEs) in the OV101 treatment groups to those in th e placebo group. OV101 was 
generally safe and well tolerated, with a similar incidence and  severity of AEs across all time to C max (tmax) was 1.1 hours after dosing.  Maximum plasma concentration (C max) of OV101 ranged from 71 to 159 ng/mL, and the mean  detectable from 0.25 hours post-dose until the last PK sampling  time point at 10 hours post-dose.  Dosing; Section 3.1.1). In this study, plasma OV101 concentrati ons after a 5-mg oral dose were  bands to achieve exposures similar to those observed in adolesc ents and adults (Rationale of  PK (PBPK) model that served to estimate dose levels across vari ous age groups and weightfrom adolescents, combined with data from adults, were used to develop a physiologically-based  adolescent subjects (13 to 17 years old, inclusive) with Fragil e X syndrome or AS. The PK data  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 34  
 Subsequent analyses of the Aberrant Behavior Checklist, Anxiety , Depression and Mood Scale,  
The MMRM analysis of actigraphy sleep data showed greater decre ases in latency of sleep onset  treatment groups: most AEs were mild. Treatment discontinuation s due to AEs were low 
(placebo, 1; OV101 QD, 0; OV101 BID, 3). The most frequent AEs across all treatment groups 
were vomiting, somnolence, irritability, aggression, pyrexia, a nd upper respiratory infection. The 
AEs occurring in the OV101 treatment groups with greater freque ncy than placebo were pyrexia, 
rash, seizure, enuresis, myoclonic epilepsy, otitis media, and viral infection. Serious adverse 
events of seizure were reported in 2 subjects, both of whom had  a previous history of seizures: 1 
subject in the QD dose experienced a seizure and that was deeme d unrelated to study drug and 
treatment was continued; 1 subject experienced 2 events of seiz ure in the BID dose group that 
was assessed as possibly related to study drug by the investiga tor, and treatment was 
discontinued. Overall, the data are consistent with a favorable  risk profile. 
Clinical efficacy measures used to compare OV101 versus placebo  during the 12 weeks of 
treatment included the CGI-I, Aberrant Behavior Checklist, Anxi ety, Depression and Mood 
Scale, Sleep Diary, and modified Performance-Oriented Mobility Assessment-Gait tool. 
For the CGI-I Symptoms Overall domain at Week 12, the Mixed Mod el Repeated Measures 
(MMRM) analysis showed a significant improvement for OV101 comp ared to placebo for the 
OV101 groups combined ( P=0.0103) and for the OV101 QD group ( P=0.0006). At Week 12, 
subjects in the OV101 QD group showed significant improvement i n CGI-I Symptoms Overall 
regardless of age. 
 
For the CGI-I Sleep domain at Week 12, the MMRM analysis showed  a significant improvement 
for OV101 compared to placebo for the OV101 groups combined ( P=0.0236) and for the OV101 
QD group ( P=0.0141).  
 
 
 
 
 
 
 
 
 
 
 
In post hoc analyses at Week 12, most subjects in the OV101 gro ups combined (54.5%) had 
responses of minimally improved (34.5%) or much improved (20.0% ) for CGI-I Symptoms worsening in the OV101 BID and placebo groups).(17.99) minutes in the OV101 BID group and 12.7 (24.07) minutes  in the placebo group (i.e.,  LSO in the OV101 QD group was –15.1 (36.64) minutes (i.e., impr ovement), compared to 1.0  placebo –18.87 minutes, P=0.0276) compared to placebo. Mean (SD) change from baseline in  25.68 minutes, P=0.0147) and in the OV101 groups combined (LS means difference from(LSO) from baseline to Week 12 in the OV101 QD group (LS means difference from placebo –statistical separation from placebo for the combined OV101 grou ps. and modified Performance-Oriented Mobility Assessment-Gait asse ssments did not showSleep Diary, 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 35  
  
Overall, compared to 22.2% of subjects in the placebo group (14.8% minimally and 7.4% much 
improved). The percentages of subjects with improvement were larger in the OV101 QD group 
(66.6%; 29.6% minimally, 37.0% much improved) than in the OV101 BID group (42.8%; 32.1% 
minimally, 10.7% much improved). 
 
NEPTUNE (OV101-19-001) will be a multicenter, randomized, placebo-controlled, 
parallel-group study to evaluate the efficacy and safety of OV101 in pediatric subjects with AS. 
Subjects who complete the study will be eligible to enroll in the ongoing OV101-18-002 
(ELARA) open-label extension study, provided they meet the eligibility criteria for ELARA. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 36  
  
2 Study Objectives 
All efficacy study objectives will be assessed in the pediatric  AS study population of subjects 
who are 4 to 12 years old. All safety study objectives will be assessed in the pediatric AS study 
population of subjects who are 2 to 12 years old. 
2.1 Primary Objective 
x To evaluate the efficacy of OV101 versus placebo as assessed by  the Clinical Global 
Impressions-Improvement-Angelman syndrome (CGI-I-AS) score at W eek 12. 
2.2 Secondary Objectives 
Key Secondary Objectives: 
The purpose of the key secondary objectives is to fulfil a reco mmendation of the EMA for a 
responder analysis. 
x To evaluate the efficacy of OV101 vs placebo as assessed by the  proportion of subjects 
who experience any meaningful improvement on study treatment (d efined as CGI-I-AS 
score of 1, 2, or 3 at Week 12) 
x To evaluate the efficacy of OV101 vs placebo as assessed by the  proportion of subjects 
who experience a response of much improved or very much improve d (defined as CGI-I- 
AS score of 1 or 2 at Week 12 
Other Secondary Efficacy Objectives: 
x
x To evaluate the efficacy of OV101 versus placebo on Communicati ons, Socialization, 
Daily Living Skills, Motor Skills, and Maladaptive Behavior dom ains assessed by the 
Vineland Adaptive Behavior Scale, 3rd Edition (VABS-3). 
x To evaluate the efficacy of OV101 versus placebo based on the C linical Global 
Impressions-Severity-Angelman syndrome (CGI-S-AS) Symptoms Over all score. 
x To evaluate the relationships of CGI-S-AS Symptoms Overall and CGI-S-AS domains at 
baseline with CGI-I-AS at Week 12. sleep  assessed byactigraphy.  To evaluate the efficacy of OV101 versus placebo on LSO, sleep efficiency, and daytime  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 37  
 The tertiary efficacy objectives of this study are:  
x
assessed by actig raphy.To evaluate the efficacy of OV101 versus placebo on total sleep  time and total activity  
x
reported).To evaluate the efficacy of OV101 versus placebo based on sleep  diary data (caregiver  
x
Questionnaire (CSHQ).To evaluate the efficacy of OV101 versus placebo based on the C hildren’s Sleep Habits  
x
modules).  Inventory ™ (Peds  QL™) (Cerebral Palsy,  Multidimensional Fatigue,  andFamily  Impact  To evaluate the efficacy of OV101 versus placebo based on the P ediatric Quality of Life 
The PK objectives of this study are to estimate systemic plasma  exposure to OV101 (maximum   
 
 
 
 
 
 
2.4 
 
 
 
 
 
2.5 Safety Objectives 
The safety objectives of this study are to evaluate the safety and tolerability of OV101 in subjects 
2 to 12 years old, including seizure diary data and assessment of suicidality. population 2 to 12 years old.estimated PK parameters in the context of a validated PBPK mode l for the pediatric study  single oral dose using sparse sampling and a population PK appr oach as well as to evaluateplasma concentration [C max] and area under the concentration-time curve [AUC]) following a 2.3 Tertiary Objectives
Pharmacokinetic Objectives  xxxx
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 38  
  
3 Investigational Plan 
3.1 Study Design 
This will be a Phase 3, randomized, double-blind, placebo-contr olled, parallel-group study, 
conducted in clinic settings, to evaluate the efficacy and safe ty of OV101 in pediatric subjects 
with AS. Male and female subjects with a previous diagnosis of AS (with molecular 
confirmation) will be eligible for inclusion (Section 4.1). The  study will comprise a screening 
period within the 28 days preceding Day 1; a visit on Day 1 for  baseline assessments, the first 
dose of study drug, and sparse sampling of blood; subsequent do ses of study drug taken each 
evening approximately 30 minutes before bedtime for 12 weeks st arting on Day 2; and study site 
visits for efficacy and safety assessments over a 12-week treat ment period. After the baseline 
visit, the study site visits will occur at Week 6 and Week 12 ( end of treatment [EOT]). Phone 
safety visits will occur during up-titration of the study drug (Day 6 and Day 11). Unless a subject 
decides to participate in the ELARA open-label extension study,  an end of study (EOS) phone 
safety visit will occur approximately 2 weeks after the last do se of study drug to assess safety 
and tolerability associated with discontinuation of treatment. Subjects eligible for and willing to 
enroll in the ELARA study will have the NEPTUNE EOT visit be th eir NEPTUNE EOS visit, 
and their NEPTUNE EOT visit will serve as their ELARA baseline visit. A subject will be 
considered to have completed the NEPTUNE study after completing  the EOS visit. For 
NEPTUNE subjects participating in ELARA, the EOS visit that occ urs approximately 2 weeks 
after the EOT will take place in the ELARA study only. The tota l duration of the study for a 
subject will be approximately 18 weeks. The schedule of activit ies for this study is fully 
presented in Table 6–1. 
Approximately 95 subjects will be enrolled in the study at appr oximately 15 study sites in the 
United States, Israel, Australia and/or Europe. Approximately 9 0 subjects 4 to 12 years old 
(inclusive) will be enrolled for both efficacy and safety asses sments, and not more than 12 of 
these subjects will be enrolled at a study site (unless authori zed by Sponsor). Random 
assignment of subjects for efficacy assessment (to either OV101  or placebo treatment in a 1:1 
ratio) will be stratified by age at screening [9 to 12 years ol d (inclusive) and 4 to 8 years old 
(inclusive)] and by region (US and outside US). There will be a t least 24 subjects per age group. 
Approximately 5 subjects 2 to 3 years old (inclusive) will be e nrolled for safety 
assessments only and will be assigned to treatment with OV101. Within each age group, dosing 
will be assigned based on body weight (Table 5–1). 
For each subject, after informed consent is obtained (Section 9 .3), screening assessments will be 
completed within the 28 days preceding Day 1 (baseline). On Day  1, eligible subjects will 
receive study drug capsules according to treatment code (suffic ient to last until the Week 6 visit). and PBPK
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 39  
 The PBPK model used to derive dose and exposure levels for the present study was validated  
x4 to 8 years old (inclusive): 8 mg  
x2 to 3 years old (inclusive): 5 mg  
x6 months to less than 2 years old: 4 mg (age group not included  in the proposed study)  
While the PBPK model yielded dosing information for children fr om 6 months to 12 years of age  
The OV101 AUC 0-∞ and C max exposure parameters for the above age-based fixed dose levels  Caregivers/LARs will be provided an additional blister card in case of unexpected delays for 
study visits (e.g., inclement weather/flight delays). Study dru g will be similarly dispensed at the 
Week 6 visit. Unused study drug will be collected and counted a t Week 6 and 12. 
3.1.1 Rationale of Dosing 
 
Timing of dosing, each evening at bedtime, was selected based o n the efficacy of evening dosing
in the OV101-15-001 study (Section 1). Selection of the dose fo r each age group was based on   
PBPK modeling for the pediatric population and data derived fro m the OV101-16-001 study 
(Section 1; Ovid Therapeutics Inc 2018) and other OV101 PK stud ies in adults (M erck 2001;  
Merck 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 Table 3–1.  derived from the PBPK model based upon 1000 virtual subjects pe r age group are shown in  (below), only subjects between 2 and 12 years of age will be ev aluated in this study.9 to 12 years old (inclusive): 10 mgxdose levels are shown below:regimen yielded dose levels for pediatric subjects age 12 years  to 6 months of age. The age-basedadolescents while minimizing the risk of AEs associated with C max. This age-based dosingage, were determined to align overall OV101 exposure (AUC 0-∞) with that achieved in adults and  tmax. The following dose levels based upon age, for pediatric subje cts 12 years to 6 months of  adolescent subjects are typically associated with C max of gaboxadol, with onset occurring aroundCmax, since clinical studies have shown that AEs associated with OV 101 in adult, elderly, and  receiving 15 mg) to avoid C max-related AEs. Dose levels and regimen simulations focused on  dose of 15 mg, while underexposing in terms of C max (approximately 54-63% of that of adults  time curve from 0 to infinite hours [AUC 0-∞]) in adults and adolescents receiving a fixed oral  across various pediatric age bands to match the OV101 exposure (area under the concentration-with both adult and adolescent PK data and was used to establis h a fixed-dose level regimen  
xxx
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 40  
 mo, month;  QD, once daily; SD, single  dose;  y,year.
Although exposure matching to adults receiving 15 mg of OV101 a llowed for dose levels to be
In this weight-based regimen (Table 5–1), older subjects (9 to1 2 years old) will be dosed first, 
Table 3–2  
Fixed Doses of OV101 for Pediatric  Subject  Body Weight  RangesModel-Predicted Exposure (AUC 0-∞ and C max) on Days 1 and 5 After  
Dose  Dose AUC 0-∞ Cmax 
median wt)  
0.21 0.23 0.22 474.9  475.5  152.5 151.9  (low wt) (Day  5) (Day  1) (Day 5)  (Day 1) (mg/kg, (mg/kg,  Cmax AUC 0-∞ High  Fixed  Dose  
68.5 15 70 65 (mg) high  wt) (kg) (kg) (kg) (mg/kg,  Dose  Wt Wt Wt Median Low 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PBPK model was then used to predict AUC 0-∞ and C max exposure parameters for pediatric  
OV101 oral maintenance weight-based dose levels, with 1000 virt ual subjects for each weight 
range (Study Report PKPD18-1074.00). Table 3–2 summarizes the p redicted weight-based   
maintenance dose exposure parameters on dosing days 1 and 5.  dose level will be allowed.  maintenance dose not be well-tolerated in any subject, 1 down-t itration to a reduced maintenance  to a maintenance dose (approximating a 15-mg equivalent dose in  adults). Should theknown to be well-tolerated in more sensitive elderly subjects) for 5 days, followed by up-titration  will first receive a lower starting dose (approximating a 10-mg  equivalent dose in adults, a dose  dose groups, with lower doses per kg body weight in the younges t subjects. In addition, children  (Section 5.1). The weight-based maintenance dose levels would b e less than 0.23 mg/kg for all  followed by younger subjects if the dose levels given to older children are well toleratedrisk of over- or under-dosing.  a weight-based dosing regimen across the 2- to 12-year-old age range was chosen to reduce the  considerable, with outliers driving the greatest risk of either  over- or under-dosing. Accordingly,  estimated for various ages, weight variations in children of va rious age bands can be  Exposures  inAdults  Receiving  an OV101  Dose  of 15 mg Receiving  Predicted Exposure -Matched OV101  Doses  vs Observed  Predicted Exposure Parameters in Pediatric Subjects at Various Ages Table 3–1
Predicted  Ratio Predicted  Ratio Predicted  Ratio Predicted  Ratio  
adult
538 458.4  0.85 540.4 1.00 491 0.91 485.6  0.90 
389 208.5  0.54 233.5 0.60 220.4  0.57 244.1  0.63 
Abbreviations:  AUC 0-∞, area under the concentration-time  curve from 0 to infinite ho urs; C max, maximum plasma concentration;  (ng/mL)  Cmax (ng×h/mL)AUC 0-∞ SD2y/ 4 mg QD adult adult  5 mg QD 8 mg QD adult  10 mg QD 15 mg6 mo- 2-4 y/ 6mo-2 y 2-4 y 4-8 y/ 4-8 y 9-12 y/ 9-12 y AdultObserved Parameter  
15 highwt)(gg ,
(mg)
70 (kg)
65(kg) (lowwt)(gg , (Day5) (Day1)Abbreviations: AUC 0-∞, area under the concentration-time  curve from 0 to infinite hou rs; Cmax, maximum plasma concentration;SD4 mgQD6mo-2y
adult2-4y/
5 mgQDy
adulty 6mo-
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 41  
 Overall, simulated OV101 exposures (C max and AUC 0-∞) produced by maintenance dose levels of  43 64 54 10 0.16 0. 23 0.187 482.8 4 83.2 182.4 182.3 
 35  42   39   8   0.19   0.23   0.21   392.2   392.4    166.1    165.9   
           
 26  34   30   6   0.18   0.23   0.2   305.6   305.8    138.7    138.4   
           
17 25 21 4 0.16 0.24 0.19 307.1 306.9  133.4  133 
           
 9   16   13   2   0.13   0.22   0.16  197.4   197.2    91.5   90.9  
           
Abbreviations: AUC 0-∞, area under the concentration-time  curve from 0 to infinite ho urs; C max, maximum plasma concentration;  
 wt, weight.
Note: Units for AUC 0-∞ are ng×h/mL and for C max are ng/mL.   
Sources: Arithmetic means of model-predicted PK parameters were  derived from the following appendices in Study Report   
 PKPD18 -1074.00: Appendices 13,20,21,22, 23, and24.  
 
 
 
 
 
 weight band (10 mg).  predicted AUC 0-∞ and at most 76% of maximally predicted C max levels observed in the 43-64 kg  produces exposure levels in subjects less than 34 kg that are a t most 64% of the maximally  the initial age-based dosing bands. It is notable that the prop osed dosing based on weight bands OV101 across the various weight ranges are similar to or lower than the exposures predicted for  182.3 182.4 483.2 482.8 0.187 0.23 0.16 10 54 64 43 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 42  
  
4 Subject Selection and Withdrawal Criteria 
4.1 Selection of Study Population 
Approximately 95 subjects will be enrolled at approximately 15 study sites, with a goal of having 
80 subjects evaluable for efficacy by completing 12 weeks of treatment (Section 3.1). Subjects 
will be assigned to study treatment only if they meet all inclusion criteria and none of the 
exclusion criteria. 
 
Deviations from the inclusion and exclusion criteria are not allowed because they can potentially 
jeopardize the scientific integrity of the study, regulatory acceptability, and/or subject safety. 
Therefore, adherence to the criteria as specified in the protocol is essential. 
 
4.1.1 Inclusion Criteria 
Each subject must meet all the following criteria to be enrolled in this study: 
 
1. Is male or female and 2 to 12 years old (inclusive) at the time of informed consent. 
2. Has a diagnosis of AS with molecular confirmation. 
3. Has a CGI-S-AS score (Section 6.2.1.1) of 3 or more. 
4. Meets the following age-appropriate body weight criterion: 
a) Subjects 2 to 3 years old must have a minimum body weight of 9 kg. 
b) Subjects 4 years and older must be between 17 kg and 64 kg (inclusive). 
5. Has an LAR/caregiver capable of providing written informed consent and able to 
attend all scheduled study visits, oversee the administration of study drug, and 
provide feedback regarding the subject’s symptoms and performance as described in 
the protocol. 
6. Provides assent to the protocol (to the extent possible and in accordance with local 
institutional review board [IRB] and regulatory requirements). Subjects providing 
assent must do so at the same visit as LAR/caregiver written informed consent is 
provided. 
7. Can swallow study drug capsules with water or ingest the contents of study drug 
capsules after sprinkling the contents of each capsule onto up to 1 teaspoon of low- 
fat semiliquid food. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 43  
  
8. If a subject is currently receiving a regimen of concomitant medications such as 
antiepileptic medication, gabapentin, clonidine, trazodone, melatonin, or a special 
diet regimen, that subject’s regimen is stable for at least 4 weeks before Day 1 (first 
day of study drug administration) and will be maintained throughout the duration of 
the study (in the judgment of the investigator). 
9. If a subject is a sibling in a family with multiple children diagnosed with AS, then 
only one of the siblings may enroll in study. The eldest eligible subject should be 
enrolled (investigator discretion may be used to enroll a younger sibling instead). 
10. Has LAR(s)/caregiver(s) who agree not to post any of the subject’s personal medical 
data or information related to the study on any website, message board(s), online 
support group(s), or social media site (e.g., Facebook, Instagram, Twitter, etc.) until 
notified that the study is completed. 
11. Female subjects who are of child-bearing potential (defined as having experienced 
their first menarche) must agree to use either a highly effective or acceptable form of 
birth control during the study and for 30 days following the last dose of the study. 
Highly effective contraceptive methods are as follows: 
12. Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation: 
13. Oral 
14. Intravaginal 
15. Transdermal 
16. Progestogen-only hormonal contraception associated with inhibition of ovulation: 
17. Oral 
18. Injectable 
19. Implantable 
20. Intrauterine device 
21. Intrauterine hormone-releasing system 
22. Bilateral tubal occlusion 
23. Vasectomized partner 
24. Sexual abstinence 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 44  
  
Acceptable birth control methods that result in a failure rate of more than 1% per year 
include: 
 
a. Progestogen-only oral hormonal contraception, where inhibition of ovulation is 
not the primary mode of action. 
 
b. Male or female condom with or without spermicide. 
 
c. Cap, diaphragm or sponge with spermicide. 
 
d. A combination of male condom with either cap, diaphragm, or sponge with 
spermicide (double barrier methods) are also considered acceptable, but not 
highly effective, birth control methods 
 
4.1.2 Exclusion Criteria 
Subjects meeting any of the following criteria will be excluded from the study: 
 
1. Has a circumstance or concomitant disease (e.g., gastrointestinal, renal, hepatic, 
endocrine, respiratory, or cardiovascular system disease), condition, or any clinically 
significant finding at screening that could interfere with the conduct of the study or that 
would pose an unacceptable risk to the subject in the opinion of the investigator. 
 
2. Has poorly controlled seizures defined as any of the following: 
 
a. Weekly seizures of any frequency with a duration more than 3 minutes. 
 
b. Weekly seizures occurring more than 3 times per week, each with a duration of 
less than 3 minutes. 
 
c. Investigator assessment. 
 
3. Has any of the following laboratory abnormalities: total bilirubin >1.5 × upper limit of 
normal (ULN), unless known Gilbert’s syndrome; alanine aminotransferase or aspartate 
aminotransferase >2.5 × ULN; serum creatinine >1.2 × ULN; absolute neutrophil count 
<1.5 × 109/L; platelets <80 × 109/L; hemoglobin <80 g/L; or 
thyroid-stimulating-hormone >1.25 × ULN or <0.8 × lower limit of normal. Retesting of 
clinical laboratory parameters may be allowed after consultation with the medical 
monitor or designee. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 45  
 consecutive weekend days) during the 28-day screening period of  the study, after 34. Use of benzodiazepines, zolpidem, zaleplon, zopiclone, eszopi clone, barbiturates, or 
ramelteon for sleep, or minocycline or levodopa within the 4 we eks prior to Day 1 or 
during the study. Benzodiazepines administered as needed for si tuational anxiety related 
to occasional procedures or events are permitted, and benzodiaz epines are also permitted 
for seizure control.   
 
5. 
 
6. Is at risk of harming self and/or others (based on investigat or assessment). 
7. Has enrolled in any interventional clinical study or used any  investigational agent or 
device, or has participated in any investigational procedure, w ithin the 30 days before 
screening or does so concurrently with this study. 
8. Is allergic to OV101 or any excipients of study drug. 
9. The subject or LAR/caregiver is unable to comply with study r equirements (based on 
investigator assessment). 
10. Is a family member of the investigator and/or study site sta ff. 
4.2 Discontinuation and Withdrawal of Subjects 
Subjects who discontinue treatment during the study will be enc ouraged by investigators to 
continue to participate in all scheduled study site visits and assessments, and study data will be 
collected for these subjects per protocol. Study drug administr ation may be stopped early at the 
discretion of the investigator (or designee) if a subject does not tolerate the dosing regimen. 
Every effo rt should be made to keep s ubjects in  the study. 
Early withdrawal of a subject from the study (before Week 12) w ill initiate procedures for ending 
all subject participation in the study, including EOT and EOS a ssessments (Section 4.2.2). For 
subjects who are withdrawn early, an EOT visit should be conduc ted within 2 weeks after the last 
day of study drug. After completing the EOT visit, an EOS phone  visit should be completed 
within 2 weeks after completing the EOT visit. The duration of the study is defined for each 
subject as the date signed written informed consent is provided  through the EOS phone visit. The 
Sponsor may continue to enroll subjects to account for disconti nuations, withdrawals, early 
terminations, etc. attempts.  Cannot tolerate wearing the actigraph for at least 7 consecutiv e days (including 2
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 46  
  
4.2.1 Reasons for Withdrawal 
Subjects may withdraw from the study at any time and for any reason without prejudice to their 
future medical care by the investigator or at the study site. The reasons for subjects not 
continuing in the study will be recorded. A subject may be withdrawn from the study for any of 
the following reasons: 
 
1. The subject does not continue to meet the protocol inclusion or exclusion criteria. 
 
2. The subject has a serious or intolerable AE that, in the investigator’s opinion, requires 
withdrawal from the study. 
 
3. The subject has laboratory safety results that reveal clinically significant changes from 
baseline in hematological or biochemical assessments. 
 
4. The subject has symptoms (or an intercurrent illness) that are not consistent with the 
protocol requirements or that justify withdrawal. 
 
5. The subject is lost to follow-up. 
 
6. Other reasons (e.g., development of contraindications to use of study drug). 
 
7. The subject (or his LAR/caregiver) withdraws assent (consent) or the investigator or 
Sponsor decides to discontinue the subject’s participation in the study. 
 
The investigator will also withdraw a subject if the Sponsor terminates the study. Upon 
occurrence of a serious or intolerable AE, the investigator will confer with the medical monitor 
and/or Sponsor. If a subject is discontinued because of an AE, the event will be followed until it 
is resolved. 
 
4.2.2 Handling of Withdrawals 
Subjects are free to withdraw from the study or study treatment at any time upon request. Subject 
participation in the study may be stopped at any time at the discretion of the investigator or at the 
request of the Sponsor. 
 
Subjects who stop study treatment or active participation in the study will no longer receive 
study drug. When a subject withdraws from the study treatment or active participation in the 
study, the reason(s) for withdrawal shall be recorded by the investigator on the relevant page of 
the electronic case report form (eCRF) using the electronic data capture (EDC) system. 
Whenever possible, all subjects who stop study treatment or withdraw from the study 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 47  
  
prematurely will complete the EOT and EOS assessments. Subjects who fail to return for final 
assessments will be contacted by the site (2 documented phone calls followed by 1 registered 
letter, as applicable) in an attempt to have them comply with the protocol. 
 
It is vital to obtain follow-up data on any subject withdrawn or who withdraws because of an AE 
or SAE. In every case, efforts must be made to undertake protocol-specified safety follow-up 
procedures. 
 
4.2.3 Replacements 
A sufficient number of subjects will be enrolled to ensure that at least 80 evaluable subjects (4 to 
12 years old) complete 12 weeks of treatment. 
 
A subject who does not meet the inclusion criterion or who meets an exclusion criterion will be 
considered a screen failure. Whether rescreening is acceptable will be discussed with the medical 
monitor or his designee. Rescreening may be allowed if the subject passed screening but could 
not be randomly assigned within the 28-day screening window due to logistical, personal, or 
other unforeseeable reasons. Rescreening will only be allowed once and only in cases where no 
safety risk is posed to the subject. 
 
If a screening test result (laboratory or any other test) is considered uncertain or abnormal, the 
test may be repeated to confirm the result after approval from the medical monitor. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 48  
 Not more than 12 subjects 4 to 12 years old (inclusive) will be  assigned to treatment at a study  
At Day 1, subjects 4 to 12 years old who meet all eligibility c riteria will be randomly assigned to  
At Day 1, Approximately 5 subjects 2 to 3 years old (inclusive)  will be assigned to receive  
5 Study Treatments 
5.1 Method of Assigning Subjects to Treatment Groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects assigned to OV101 treatment will be assigned a maximum  daily dose an d titration
schedule based on their weight at the screening visit, accordin g to Table 5–1. If a subject is 
assigned to placebo, the number of capsules per dose will corre spond to the number of OV101  
capsules for a subject of the same weight.   OV101. No subject in the 2- to 3-year-old age group will be ass igned to placebo treatment. with at least 24 subjects per age category. The regions are US and outside US.block size. The age groups will be 9 to 12 years old (inclusive ) and 4 to 8 years old (inclusive),  stratified by age and region according to 2 age groupings and 2  regions, using an appropriate  receive OV101 or matching placebo in a 1:1 allocation ratio. Ra ndom assignment will bethe IDMC charter (S ection 11.1.1).align with data previously observed in adults and adolescents. This will be described in detail in data in a blinded fashion to evaluate whether these individual values within each  time window  continues during the review). The IDMC will examine the plasma OV101 concentration-time  subjects 2 to 3 years old may begin treatment (initiation of tr eatment in the 4 to 8 age groupfollowing IDMC review and approval of the tolerability in the s entry subjects 4 to 8 years old,initiation of treatment in the 9 to 12 age group continuing dur ing the review). Similarly,  tolerability and PK acceptable, subjects 4 to 8 years old (at s creening) may begin treatment (with  dose, will be forwarded to the IDMC for review as blinded data.  If the IDMC considers thetolerability assessment of the sentry subjects at Day 11, 5 day s after initiation of the maintenanceIDMC review of tolerability and PK in sentry subjects in the pr evious older cohort. The  these subjects will be termed “sentry subjects.” No age cohort may begin treatme nt wit hout will be used to collect at least 3 evaluable OV101 PK samples i n each efficacy age group and  12 years old (at screening) will begin treatment first. Initial  enrollment of randomized subjectsstratified and staged by age and region and gated by an IDMC (S ection 6.5). Subjects 9 to  site (unless authorized by Sponsor), and subject assignment to and initiation of treatment will be  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 49  
   
 
Band Weight Range 
at Screening 
Visit 
(kg) Starting Dose 
(mg [capsules]) Maint Dose 
(mg [capsules]) Maint Dose 
(mg/kg) 
1 45-64 6 mg (3× 2 mg) 10 mg (5× 2 mg) 0.222–0.156  
2 35-44 4 mg (2× 2 mg) 8 mg (4× 2 mg) 0.23–0.19 
3 25-34 2 mg (1× 2 mg) 6 mg (3× 2 mg) 0.24–0.176 
4 17-24 2 mg (1× 2 mg) 4 mg (2× 2 mg) 0.23–0.16 5 9-16
a 1 mg (2× 0.5 mg) 2 mg (4× 0.5 mg) 0.23–0.125 
 
 
 
An interactive web response system will be used to administer t he randomization schedule. The 
PROMETRIKA biostatistics group will generate the randomization schedule using SAS® 
software (SAS Institute Inc, Cary, NC) Version 9.3 or later, wh ich will link sequential subject 
randomization numbers to treatment codes.  
 
5.2 Treatment Administration 
Subjects will take all doses orally each evening (assisted by a n LAR/caregiver, if necessary), at 
approximately the same time, approximately 30 minutes before an ticipated bedtime, for the 
duration of the 12-week treatment period. Capsules may be opene d, with the contents of each 
capsule sprinkled onto up to 1 teaspoon of low-fat semiliquid f ood (e.g., applesauce, yogurt, 
pudding) for ingestion, but this approach must be followed cons istently throughout the study. 
The capsule contents must not be placed directly in liquid. The  LAR/caregiver must document 
how capsules were taken (i.e., swallowed whole with water or op ened with the contents of each 
capsule taken in up to 1 teaspoon of semiliquid food). 
 
On Day 1, subjects will take their first dose of study drug at the study site during the daytime, 
taking all subsequent doses at night, starting with the evening  of Day 2. The LAR/caregiver 
should make every effort to administer the drug at approximatel y the same time each night. 
 
If a subject misses a dose of study drug for any reason, unless  within a 3-hour window of the 
usual administration time, the subject should not make up the m issed dose. The subject should 
wait to take the next dose as scheduled and take a single dose at that time. It is important that the 
dosing regimen be documented in the medication diary by the LAR /caregiver and monitored by 
the study site to ensure that appropriate dosing is being follo wed. Subjects experiencing dose 
interruptions should be evaluated by the investigator in conjun ction with the medical monitor. Abbreviation: Maint,  maintenance.
aMust be <4 years ofage at screening visit.  Daily Dosing and Titration of OV101 by Weight Table 5–1
PROMETRIKA bMustbe<4yearsofageatscreenin gvisit.aAbbreviation:Maint ,maintenance.0.23–0 .1250.23–0 .160.24–0.1760.23–0.19 0.222–0 .156
2 mg (4× 0.5 mg)4 mg (2× 2 mg) 6 mg (3× 2 mg) 8 mg (4× 2 mg) 10 mg (5× 2 mg) 
1 mg (2× 0.5 mg ) 2 mg (1× 2 mg ) 2 mg (1× 2 mg ) 4 mg (2× 2 mg ) 6 mg (3× 2 mg ) 
9-16a17-24 25-34 35-44 45-64 Weight Range
at Screening
Visit 
(kg)
54321Maint D ose
(mg/kg) Maint D ose
(mg [capsules])Starting Dose 
(mg [capsules])Band 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 50  
 The subject’s maintenance dose for the duration of the study wi ll be set based on the subject’s  
If tolerability is not acceptable (e.g., excessive somnolence, dizziness, vomiting, or change in5.2.1 Dose Titration 
Dosing will be initiated at the starting dose (Table 5–1) for t he first 5 days. On Day 6, tolerability 
will be assessed by the investigator. If there are no tolerabil ity concerns (e.g., excessive 
somnolence, dizziness, vomiting, negative behavior changes) and  no AE related to the study drug 
has been observed since Day 1 by the LAR/caregiver or the inves tigator, then the dose of OV101 
will be increased to the maintenance dose for the duration of t he study. If tolerability concerns 
are observed on Day 6, the subject will discontinue study drug.  Time windows for titrations and 
safety phone visits are presented in Table 6–1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 document.  supporting rationale must be documented in the medical record o r other appropriate source  treatment. Any dose adjustments or changes in dosing must be do cumented in the eCRF and  If a subject cannot tolerate the reduced maintenance dose, that  subject must discontinue  dose may not be lower for any subject than the reduced maintena nce dose indicated in Table 5–2.at any time to confirm tolerability. Any intolerability must be  documented as an AE. The daily  situation with the medical monitor or his/her delegate. Unsched uled study site visit s are optional behavior) -at any time during the 12 weeks of treatment, the in vestigator should discuss the  changes in dose regimen should be made after Day 15.  tolerability with the modified dose regimen within 3 days of th e dosing change. No further  AEs, or medical necessity. If down-titration is initiated, then  the investigator should reassess  on Day 11 by 1 capsule (Table 5–2) based on the investigator as sessments of tolerability and  call while the subject is taking the maintenance dose. The inve stigator may initiate down-titration  the Day 6 assessment until the EOS. Tolerability will again be assessed during the Day 11 phone  weight at the screening visit, and the subject should continue taking the maintenance dose after  
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 51  
 Yourway Transport  TransportOV101 will be formulated as the monohydrate form of gaboxadol ( 4,5,6,7-tetrahydro-    
Band Weight 
Range at 
Screening 
Visit 
(kg) Maint Dose 
(mg [capsules]) Maint Dose 
(mg/kg) Reduceda Maint 
Dose 
(mg [capsules]) Reduceda 
Maint Dose 
(mg/kg) 
1 45-64 10 mg (5× 2 mg) 0.222–0.156 8 mg (4× 2 mg) 0.177–0.125
2 35-44 8 mg (4× 2 mg) 0 .23–0.19 6  mg (3× 2 mg) 0.172–0.136
3 25-34 6 mg (3× 2 mg ) 0.24–0.176 4  mg (2× 2 mg) 0.16–0.118 
4 17-24 4 mg (2× 2 mg) 0 .23–0.16 2  mg (1× 2 mg) 0.118–0.08 
5 9-16b 2 mg (4× 0.5 mg) 0.23–0.125 1.5 mg (3× 0.5 mg) 0.167–0.09 
 
 
The study site will document each titration step in the eCRF an d in source documents. AEs 
triggering any down titration must be reported.  
5.3 Identity of Investigational Product 
 
 
 
 
Placebo capsules will be identical in appearance to the capsule s containing OV101 and have the 
same excipient ingredients but will not contain the active comp ound.  
 
Metrics Contract Services (Greenville, NC) will manufacture the  OV101 and placebo capsules. 
 
5.4 Management of Clinical Supplies 
Bulk capsules of OV101 will be shipped to 
will package and label kits.  
 
 
will ship the kits directly to each study 
site. 
 
5.4.1 Study Drug Packaging and Storage 
 
Study drug will be supplied as capsules on blister cards for su bjects 4 to 12 years old. A clinical   
label will be affixed to the outside of each card. The label wi ll specify the Sponsor name (Ovid 
Therapeutics Inc.); subject number; protocol number; card numbe r; number of capsules (each  
card); “Evening,” and “Take as directed.” Cards will be dispens ed at Day 1 and at the Week 6
visit. The recommended storage conditions and expiry date (wher e required) will be stated on themicrocrystalline cellulose and magnesium stearate.0.5-mg strengths (of the anhydrous free zwitterion equivalent).  Excipients will be  isoxazolo[5,4-c]-pyridin-3-ol, monohydrate) in white size 2 har d gelatin capsules, in 2-mg and  Abbreviation: Maint,  maintenance.
a
b The reduced dose results from a down-titration, 1 capsule less per day.
Must be <4 years ofage at screening visit.  Down-Titration of OV101 by Weight Table 5–2
Yourway Transport (Allentown, PA). YourwayMetrics Contract Services (Greenville, NC) wMustbe<4yearsofageatscreenin gvisit.The reduced dose results from a down-titration, 1 capsule less per day .aAbbreviation:Maint ,maintenance.
b0.167–0.090.118–0.080.16–0.1180.172–0.1360.177–0.125
1.5 mg (3× 0.5 mg) 2 mg (1× 2 mg) 4 mg (2× 2 mg) 6 mg (3× 2 mg) 8 mg (4× 2 mg) 
0.23–0.1250.23–0.16 0.24–0.176 0.23–0.19 0.222–0.156 
2 mg (4× 0.5 mg) 4 mg (2× 2 mg) 6 mg (3× 2 mg) 8 mg (4× 2 mg) 10 mg (5× 2 mg) 
9-16b17-24 25-34 35-44 45-64 Visit
(kg)Range at
ScreeningWeight g
5 4 3 2 1 Maint D ose
(mg/kg) Reduceda
Dose
(mg [capsules])Reduceda Maint aMaint D ose
(mg/kg) (mg [capsules])Maint D ose Band 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021
Page 52  
 Subjects 2 to 3 years old will be supplied with study drug caps ules in bottles, to be labeled and  
Subjects and LARs/caregivers must be instructed to keep all stu dy drug in the original cards and
Actigraphs (Section 6.2.2) will be supplied to study sites and managed throughout the study as 
 
 
 
 
 
 
 
5.4.2 Test Article Accountability 
The investigator will maintain accurate records of receipt of a ll study drug, including dates of 
receipt. In addition, accurate records will be kept regarding w hen and how much study drug is 
dispensed and used by each subject in the study. Reasons for de parture from the expected 
dispensing regimen must also be recorded. At the completion of the study, to satisfy regulatory 
requirements regarding drug accountability, all study drug will  be reconciled and retained or 
destroyed according to applicable regulations.  
 
5.4.3  
 
 
 
5.5 Overdose Management 
An overdose is any dose of study treatment given to a subject o r taken by a subject that exceeds 
the dose described in the protocol. Any overdose, with or witho ut associated AEs, must be 
recorded in the eCRF. Any AEs associated with an overdose shoul d be reported on relevant 
AE/SAE sections in the eCRF. Any associated SAEs must be prompt ly reported to Ovid using 
the SAE reporting procedures (Section 6.4.1.5). Overdoses witho ut signs or symptoms do not 
need to be recorded as AEs. 
 
5.5.1 Treatment of Overdose 
In the event of a suspected overdose, the appropriate supportiv e clinical care should be provided 
as dictated by the subject’s clinical status. 
 
5.5.2 Medication Errors 
A medication diary will be maintained by the LAR/caregiver on b ehalf of the subject for the 
duration of the treatment period to confirm dosing dates and ti mes and to permit monitoring for described in the study manual.  maintain the cards at room temperature.  stored as described for blister cards.  to 25°C).cabinet), protected from moisture, and kept at a controlled roo m temperature, 59°F to 77°F (15°C  product label. At the study site, study drug must be stored in a secure area (e.g., a locked  
Other Supplies
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 53  
  
medication compliance and medication errors. The medication diary will be reviewed at the 
Week 6 and Week 12 clinic visits by either the site investigator or the study coordinator. If a dose 
is missed, this should be noted, and the dose should not be doubled at the next scheduled dose. 
 
5.5.3 Treatment of Medication Errors 
An example of a medication error includes overdose (treatment of overdose is described in 
Section 5.5.1). 
 
5.6 Blinding 
The study will be performed in a double-blind manner for subjects 4 to 12 years old (inclusive), 
with the subjects, LAR/caregivers, investigators, study personnel, monitors, and study Sponsor 
blinded to the identity of all study drug. All study drug will be supplied in identical packaging 
and will be similar in color, smell, taste, and appearance to enable double-blind conditions. 
Titrations will be conducted identically for all subjects in a weight band (Table 5–1), regardless 
of assignment to OV101 or placebo. 
 
The study will not be blinded for subjects 2 to 3 years old, inclusive. 
 
5.6.1 Breaking the Blind 
A subject’s treatment assignment will not be broken until after the last subject has completed the 
study and the database has been locked, unless medical treatment of the subject depends on 
knowing the study treatment the subject received. If the blind needs to be broken because of a 
medical emergency where medical management depends on knowing treatment allocation, the 
investigator may unblind an individual subject’s treatment allocation. Before unblinding a 
subject’s treatment assignment and as soon as possible, the investigator should make every effort 
to contact the medical monitor to discuss the medical emergency and the reason for revealing the 
treatment received by that subject. The treatment assignment will be unblinded through an 
interactive web response system. Reasons for treatment unblinding must be clearly explained and 
justified in the eCRF. The date on which the code was broken and the identity of the person 
responsible must also be documented. If a subject’s treatment is unblinded, the Sponsor must be 
notified immediately. Unblinding should only be considered for the safety of the subject. The 
investigator should inform the Sponsor that the subject was unblinded; however, they are not 
required to reveal to the Sponsor the subject’s treatment allocation. 
 
When an AE is an unexpected related SAE, the blind will be broken by the Sponsor only for that 
specific subject. The blind will be maintained for persons responsible for the ongoing conduct of 
the study (e.g., monitors, investigators) and those responsible for data analysis and interpretation 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 54  
  
of results at the conclusion of the study, such as biometrics personnel. Unblinded information 
will only be accessible to those who need to be involved in the safety reporting to health 
authorities, independent ethics committees (IECs), or IRBs. Investigators will receive only 
blinded information unless unblinded information is judged necessary for safety reasons. 
 
The IDMC (Section 11.1.1) will have the ability to review unblinded data as needed to evaluate 
risk during the study. 
 
5.7 Treatment Compliance 
Subject compliance will be determined by comparing the capsule counts of returned study drug 
cards at the Week 6 and Week 12/EOT visits to the capsule count of study drug dispensed at the 
previous visit. The number of capsules remaining will be tracked and recorded. The 
LAR/caregiver will be questioned as to the reason(s) why unexpected remaining capsules have 
not been administered (e.g., forgot, subject refused, subject experienced AE or LAR/caregiver 
decided to reduce dose), the reason(s) will be recorded, and the approximate date and time of any 
missed doses will be also be recorded in the eCRF. 
 
5.8 Prior and Concomitant Therapy 
Subjects should be on stable doses of prescribed medications and on stable nonmedication 
interventions (e.g., speech therapy, physical therapy, occupational therapy) for 4 weeks before 
Day 1 and should remain on the stable regimens until after the EOS visit. If subjects are to enroll 
in the ELARA open-label extension study, study drug will be provided so that the baseline visit 
can be conducted in conjunction with the NEPTUNE EOT visit. Additionally, unless required to 
treat AEs, there should be no new medications or changes to concomitant medications, approved 
dietary and herbal supplements, and nonmedication interventions during the study until after the 
EOS visit. 
 
Use of all concomitant medications will be recorded in the subject’s eCRF. The minimum 
requirement is that the drug name and the dates of administration are recorded. Concomitant 
medications include all prescription drugs, herbal products, vitamins, minerals, and 
over-the-counter medications. Any changes in concomitant medications will also be recorded in 
the subject’s eCRF. 
 
Any concomitant medication deemed necessary for the welfare of the subject during the study 
may be given at the discretion of the investigator. However, it is the responsibility of the 
investigator to ensure that details regarding the medication are recorded in full in the eCRF. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 55  
  
5.8.1 Prohibited Medications and Therapies 
Use of any GABAergic agents (e.g., acamprosate, baclofen, vigabatrin, tiagabine, riluzole, and 
gabapentin) on a regular schedule is prohibited from the time informed consent is obtained to the 
end of a subject’s participation in the study. Subjects who entered the study on a stable dose of 
gabapentin (i.e. stable dose for at least 4 weeks prior to randomization), may continue on the 
treatment as long as no dose modifications are expected during the study. Any change in 
gabapentin dose during the study must be captured and documented as a protocol deviation. 
 
Use of benzodiazepines, zolpidem, zaleplon, zopiclone, eszopiclone, barbiturates, or ramelteon 
for sleep is prohibited within the 4 weeks prior to Day 1 or during the study. Benzodiazepines 
administered as needed for situational anxiety related to occasional procedures or events are 
permitted, and benzodiazepines are also permitted for seizure control. 
 
Minocycline and levodopa are prohibited from 4 weeks prior to Day 1 to the end of a subject’s 
participation in the study 
 
Use of other investigational agents is prohibited during the study. 
 
5.8.2 Restrictions 
Any concomitant medication, including antiepileptic and/or behavioral medications, 
supplements, or special diets, must be at a stable dose for at least 4 weeks before Day 1 and must 
be maintained throughout the duration of the study. 
 
Benzodiazepines administered as needed for situational anxiety (e.g., for occasional procedures 
or events) are permitted, as are benzodiazepines for seizure control. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021   
The schedule of activities by clinic visit for this study is pr esented in Table 6–1. Detailed instructions for the conduct of study  
assessments and procedures will be provided in the study manual . 
Table 6–1  Schedule of Activities  6 Study Assessments and Procedures 
 
 
 
Visit Name Screening Baseline  Phone/  Week 6   EOT/  EOS Phone/ 
Titration   Week  12   Week  14  
 Window    D –28 to D –1    +1 Day   ±3 Days   +3 Days   ±2 Days   
 Day    Day 1    Days 6 and 11    Day 43   Day 85   Day 99  
Event         
 Informed consent and assenta X      
 Demographics   X      
 Inclusion/exclusion criteria  X Xb     
 Medical history  X  Xb,c      
 Clinical assessmentd for AS  X Xb,c X X X X 
 Molecular AS teste  X      
 Dose titration    Xf    
Physical examination  X Xb,c X X 
 Vital signs  X Xb  XX  
 Clinical laboratory tests   X  Xb,c   X X  
 Adverse events   X Xb X X X X 
 Concomitant medications  X  Xb,c  X X X X 
 Assessment of suicidality: ABC-Im X X X X X X 
 Seizure diary issued   X X  X   
 Seizure diary collected and reviewed,   X  X X  
 SIF/DRF forms completed/submitted l
 Sleep diary issued   X X  X   
 Sleep diary collectedg   X  X X  
 
Page 56 X XX
XX XX XXXXXXXX
XXX
XXXXXXX
XXX
XXXXXX
XXX Xb XXb XXf XXXXXX
X X X XXb XWeek 6 Baseline Screening Visit Name EOS Phone / assessments and procedures will be provided in the study manual .The schedule of activities by clinic visit for this study is pr esented in Table 6–1. Detailed instructions for the conduct of study
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101
26 January 2021   
Page 57   
Visit Name  Screening BaselinePhone/ 
Titration Week 6  EOT/ 
Week 12 EOS Phone/ 
Week 14 
Window  D –28 to D –1  +1 Day ±3 Days  +3 Days ±2 Days 
Day  Day 1 Days 6 and 11 Day 43  Day 85 Day 99 
Event      
Actigraph issuedh X 
Actigraph collected     X  
Dispense study drug  X  X   
Collect unused study drug    X X  
Review medication diary    X X  
PK samplingi  X     
CGI-S-AS X Xb  X X  
CGI-I-ASj    X X  
VABS-3k  X   X  
Children’s Sleep Habits Questionnaire  X  X X  
Pediatric Quality of Life Inventory  X   X  
 
 
 
    
 
  
 Abbreviations: ABC-I, Aberrant Behavior Checklist-Irritability subscale; AS, Angelman syndrome; CGI-I-AS, Clinical Global Impr essions-Improvement 
Angelman syndrome; CGI-S-AS, Clinical Global Impression-Severit y Angelman syndrome; D, day(s); EOS, end of study; EOT, end of treatment; PK, 
pharmacokinetic; VABS-3, Vineland Adaptive Behavior Scale, 3rd Edition. 
Notes:  Phone visits may take the form of a video phone call. For subj ects completing the study per protocol, the Week 12 visit will be the EOT, and the EOS 
phone visit will occur at Week 14. For subjects discontinuing t reatment before Week 12, the EOT visit will occur within 2 week s after discontinuing 
treatment, and the EOS phone visit will occur 2 weeks after the EOT visit.
a 
b There will be separate informed consent and assent forms for th e caregivers and subjects, respectively. 
Baseline  visit assessment that must be completed  prior to administration  ofstudy drug onDay 1.Day 99±2 Days +3 Days Week 12Phone / 
Titrati on 
Actigraph issuedhddEvent
Baselinevisitassess mentthatmust becomplete dpriortoadministrationofstudydrugonDay1.There will be separate informed consent and assent forms for th e caregivers and subjects, respectively.Notes:Phone visits may take the form of a video phone call. For subje cts completing the study per protocol, the Week 12 visit will b e the EOT, and the EOS
phone visit will occur at Week 14. For subjects discontinuing t reatment before Week 12, the EOT visit will occur within 2 week s after discontinuing
treatment, and the EOS phone visit will occur 2 weeks after the E OT visit .XXX VABS-3kCGI-I-ASjSSXb XReview medication diar y XX Dispense study dru g Actigraph collected 
baAbbreviations: ABC-I, Aberrant Behavior Checklist-Irritability subscale; AS, Angelman syndrome; CGI-I-AS, Clinical Global Impr essions-Improvement 
Angelman syndrome; CGI-S-AS, Clinical Global Impression-Severit y Angelman syndrome; D, day(s); EOS, end of study; EOT, end of treatment; P
; VABS-3, Vineland Adaptive Behavior Scale, 3rd Edition.dXX XX X X CGI-S-AS X XX Collect unused study dru g XDay 85 Day 4 3 Days 6 and 11 Day 1 Day±3 Day s +1 Da y D –28 to D –1 WindowEOS Phone / 
Week 14Week 6 Baseline Screening Visit NameEOT/ 
gy
pharmacokinetic;PK,X Pediatric Quality of Life Inventor y X X Children’s Sleep Habits QuestionnaireX PK samplin giXX
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0OV101  
26 January 2021  
Page 58  
 c If the screening and baseline visits can be completed within 1 4 days, the following assessments do not need to be repeated at  the baseline visit: medical 
history, clinical assessment, physical examination, clinical la boratory tests, and determination of concomitant medications. F emale subjects who have 
experienced menarche will undergo serum beta-human chorionic go nadotrophin pregnancy testing. 
d Signs and symptoms of AS. 
e Only required if no written evidence for molecular diagnosis i s available in the subject records. 
f  Down-titration may be initiated on Day 11 by 1 capsule based on the Investigator’s assessments of tolerability and adverse e vents, or medical necessity. If 
down-titration is initiated, then the investigator should reass ess tolerability with the modified dose regimen within 3 days o f the dosing change. No further 
changes in dose regimen should be made after Day 15. 
g  Caregivers will complete sleep diaries on behalf of subjects during the days the subject is wearing the actigraph. Study sit e staff will call LAR/caregivers to 
remind them when to start recording data in the sleep diary. 
h  An actigraph must be issued to each subject at the screening visit, so th at actigraphy data c an be collecte d for 7 days (3 a ttempts within the 28-day screening 
period are allowed) before the baseline visit. 
i At baseline, sampling of blood for determination of concentrat ions of OV101 will occur 45 minutes ± 15 minutes, 90 minutes ± 15 minutes, and 4 hours ± 
30 minutes after dosing at the study site. Subjects will take a ll subsequent doses approximately 30 minutes before anticipated  bedtime, starting with the 
evening of Day 2 Study site staff will record the time of dosin g and the times of blood sampling after the initial dose. 
j  Within 24 hours prior to the subject’s visit at Week 6, the i nvestigator must review the subject’s baseline CGI-S-AS score a nd investigator notes. Within 24 
hours prior to the subject’s visit at Week 12, the investigator  must review the subject’s baseline CGI-S-AS score and investig ator notes and the Week 6 
CGI-I-AS score and investigator notes. The same clinician rater , trained in CGI-S-AS and CGI-I-AS rating by the Sponsor, must be used throughout the 
study to assess a given subject. It is recommended that the sam e rater be used at a given site. As an exception, a clinician s ub-investigator, trained in 
CGI-S-AS and CGI-I-AS rating by the Sponsor, may be used. 
k The VABS-3 will be assessed by a trained qualified rater based  on an interview of the subject’s caregiver. For each study sit e, the same rater is to be used 
throughout the study. As an exception, another Sponsor-trained qualified rater in VABS-3 may be used 
lA Seizure Identification Form and Diagnostic Review Form (SIF/D RF) will be completed by site personnel for every eligible subj ect. This information will be 
faxed or emailed to The Epilepsy Study Consortium (TESC) for re view and approval. The SIF/DRF will be used to ensure that the seizures are classified 
accurately. SIF and DRF forms will be collected for patients wh o have enrolled/completed the study if feasible. 
m The entire Aberrant Behavior Checklist – Community (ABC-C) wil l be administered. Only ABC-I will be used to evaluate the pote ntial for self-harm lA Seizure Identification Form and Diagnostic Review Form (SIF/DR F) will be completed by site personnel for every eligible subje ct. This information will be
faxed or emailed to The Epilepsy Study Consortium (TESC) for re view and approval. The SIF/DRF will be used to ensure that the seizures are classified 
accurately. SIF and DRF forms will be collected for patients wh o have enrolled/completed the study if feasible.
The entire Aberrant Behavior Checklist – Community (ABC-C) will  be administered. Only ABC-I will be used to evaluate the poten tial for self-harm mmThe VABS-3 will be assessed by a trained qualified rater based on an interview of the subject’s caregiver. For each study site , the same rater is to be used
throughout the study. As an exception, another Sponsor-trained qualified rater in VABS-3 may be usedkk Within 24 hours prior to the subject’s visit at Week 6, the in vestigator must review the subject’s baseline CGI-S-AS score an d investigator notes. Within 24
hours prior to the subject’s visit at Week 12, the investigator  must review the subject’s baseline CGI-S-AS score and investig ator notes and the Week 6
CGI-I-AS score and investigator notes. The same clinician rater , trained in CGI-S-AS and CGI-I-AS rating by the Sponsor, must be used throughout the
study to assess a given subject. It is recommended that the sam e rater be used at a given site. As an exception, a clinician s ub-investigator, trained in
CGI-S-AS and CGI-I-AS rating by the Sponsor, may be used.jii.hgffOnly required if no written evidence for molecular diagnosis is  available in the subject records.eeSigns and symptoms of AS.ddIf the screening and baseline visits can be completed within 14  days, the following assessments do not need to be repeated at the baseline visit: medical
history, clinical assessment, physical examination, clinical la boratory tests, and determination of concomitant medications. F emale subjects who have
experienced menarche will undergo serum beta-human chorionic go nadotrophin pregnancy testing.cc
At baseline, sampling of blood for determination of concentrati ons of OV101 will occur 45 minutes ± 15 minutes, 90 minutes ± 1 5 minutes, and 4 hours ± 
30 minutes after dosing at the study site. Subjects will take a ll subsequent doses approximately 30 minutes before anticipated  bedtime, starting with the
evening of Day 2 Study site staff will record the time of dosin g and the times of blood sampling after the initial dose.An actigraph must be issued to each subject at the screening vi sit, so th at actigraphy data c an be collecte d for 7 days (3 att empts within the 28-day screening
period are allowed) before the baseline visit.Caregivers will complete sleep diaries on behalf of subjects du ring the days the subject is wearing the actigraph. Study site staff will call LAR/caregivers to
remind them when to start recording data in the sleep diary.Down-titration may be initiated on Day 11 by 1 capsule based on  the Investigator’s assessments of tolerability and adverse eve nts, or medical necessity. If 
down-titration is initiated, then the investigator should reass ess tolerability with the modified dose regimen within 3 days o f the dosing change. No further 
changes in dose regimen should be made after Day 15.
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 59  
 6.1 Screening Assessments 
Screening assessments, used only for determining eligibility for the study or establishing a 
baseline medical history, include confirmation of the molecular diagnosis of AS. 
 
6.2 Efficacy Assessments 
Efficacy assessments will be conducted only for patients in the 4 to 12 year age groups according 
to the schedule presented in Table 6–1. 
 
6.2.1 Efficacy Assessments 
Detailed instructions for the conduct of study assessments and procedures will be provided in the 
study manual. 
 
6.2.1.1  Clinical Global Impressions Scales 
The CGI-S-AS scale with AS-specific anchors will be used by the investigator to assess the 
severity of symptoms, and the CGI-I-AS scale will be used by investigators to assess 
improvement from baseline. The CGI-S-AS captures specific characteristics commonly present 
in the AS population; the CGI-I-AS captures clinical impression that reflects the rater’s estimate 
of change from the initiation (baseline) of treatment. Both the CGI-S-AS and the CGI-I-AS 
assessments will be conducted by a rater with experience in AS and trained in CGI-S-AS and 
CGI-I-AS rating by the Sponsor. It is recommended that each site uses the same rater. The same 
rater (the principal investigator) at each site must evaluate a given subject throughout the study. 
As an exception, a clinician sub-investigator, trained in CGI-S-AS and CGI-I-AS rating by the 
Sponsor, may be used. The baseline CGI-S-AS will be accompanied by detailed investigator 
notes. Each subsequent CGI-I-AS rating (at Week 6 and Week 12 visits) will also be 
accompanied by detailed investigator notes. To reduce recall bias, within 24 hours before the 
Week 6 CGI-I-AS rating, the rater will review the CGI-S-AS rating and investigator notes from 
the baseline visit. Similarly, within 24 hours before the Week 12 CGI-I-AS rating, the rater will 
review the CGI-S-AS ratings and investigator notes from the baseline visit and from Week 6. If 
the CGI-I-AS assessment is missing at Week 6 or Week 12, the reason for the absence will be 
noted on the eCRF. 
 
6.2.1.2  Vineland Adaptive Behavior Scale, 3rd Edition 
The VABS-3 is a standardized psychometric instrument designed to measure personal and social 
skills needed for everyday living (Sparrow et al 2005; Sparrow et al 2016). The VABS-3 is 
administered via a caregiver using a semi-structured interview format and assesses 4 main 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 60  
 The CSHQ is a retrospective, 33-item caregiver questionnaire th at has been used in studies to
The Peds QL Cerebral Palsy, Multidimensional Fatigue, and Famil y Impact modules will be  adaptive domains: communication (receptive, expressive and writ ten), socialization 
(interpersonal relationships, play and leisure, coping skills),  daily living skills (personal, 
domestic, community), and motor skills (fine and gross). It als o includes a maladaptive behavior 
scale for identifying behavior problems in children through 18 years of age. The scale has been 
found to have good internal consistency, test-retest reliabilit y and validity (Sparrow et al 2016). 
The VABS-3 interview form will be used to evaluate subjects on the communication, 
socialization, daily living skills, motor skills and maladaptiv e behavior domains to assess their 
overall functioning. This assessment is an interview of the car egiver by a trained qualified rater, 
and for each study site, the same rater is to be used throughou t the study. As an exception, 
another Sponsor-trained qualified rater in VABS-3 may be used. 
6.2.1.3   
 
 
 
 
 
 
 
 
 
 
 
6.2.1.4   
 
 
  
 
 
 
 
 
and family relationships.  functioning, communication, and worry. It also assesses caregiv er-reported family daily activities  including caregiver-reported assessments of physical, emotional , social, and cognitive  module assesses the impact of pediatric chronic health conditio ns on caregi vers and fa mily, assesses general fatigue, sleep/rest fatigue, and cognitive fat igue. The 36-item Family Impact  eating activities, and speech and communication. The 18-item Mu ltidimensional Fatigue modulemodule assesses daily activities, school activities, movement a nd balance, pain and hurt, fatigue,  administered in this study (Varni et al 2004; Varni et al 2005) . The 22-item Cerebral Palsyconsistently make a higher score indicative of more disturbed s leep.  times/week; and “rarely” for 0 to 1 time/week. The scoring of s ome items can be reversed to  scale: “usually” if the sleep behavior occurred 5 to 7 times/we ek; “sometimes” for 2 to 4immediately preceding the baseline, Week 6, and Week 12 visits.  Items are rated on a 3-point  sleepiness. Caregivers will be asked to recall sleep behaviors occurring over the 7 days  night wakings, parasomnias, sleep-disordered breathing, and mor ning waking/daytimeresistance, sleep-onset delay, sleep duration, anxiety around s leep, behavior occurring aroundevaluating the child’s sleep based on sleep behaviors within 8 different subscal es: bedtime  to sleep domains that encompass the major presenting sleep comp laints in this age group,examine sleep behavior in young children (Owens et al 2000). Th e CSHQ includes items relating  
Pediatric Quality of Life InventoryChildren’s Sleep Habits Questionnaire
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 61  
 Actigraphy is a noninvasive method of monitoring human rest/act ivity cycles. A small wearable  
Each subject will be provided a wearable 510(k) -approved actigraph, preferably to be worn on  
An actigraph will be issued to each subject at the screening vi sit, so that actigraphy data can be  6.2.2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.3  
 
A sleep diary will be completed by each subject’s LAR/caregiver , on behalf of the subject.   
Endpoints assessed by the sleep diary are presented in Section 7.2.1.3. The sleep diary will be  
completed each day during the days the subject is wearing the a ctigraph preceding study site 
visits at baseline, Week 6, and Week 12.   will collect the actigraph.be given an actigraph to be worn for 7 days after Week 6. At th e Week 12 visit, study site staff consecutive days (including 2 consecutive weekend days) after t he Week 6 visit, the subject will of continuous use). If the subject requires an additional attem pt to keep the actigraph on for 7data including 2 consecutive weekend days (it is recommended to  charge the device after 7 days scheduled study site visits at Week 6 and Week 12 visits to col lect at least 7 consecutive days of  travel days. The actigraph it is to be worn for a maximum of 14  days preceding travel for the These 7 consecutive days should include 2 consecutive weekend d ays and should not include any  includes 2 weekend days during screening will be used as the ba seline actigraphy assessment.consecutive days. Actigraphy data collected during the first 7- consecutive day period that  days, and subjects will be excluded after 3 unsuccessful attemp ts to wear the actigraph for 7attempts within the 28-day screening window to wear the actigra ph for at least 7 consecutive collected for 7 consecutive days before travel for the baseline  visit. Subjects will be given 3actigraph will remai n in the study.  Subjects who are assigned study drug but are subsequently not c ompliant with wearing theactigraph for 7 consecutive days prior to the baseline visit) w ill be excluded fr om the study.with the actigraph guidel ines during th e scree ning per iod (subj ects must be able to wear theto tolerate wearing the device. Subjects who are not able to to lerate the actigraph and/or comply sensitivities exist in the study population, and it is anticipa ted that some subjects will not be able  effort should be made to keep the location the same throughout the study. Severe sensory  acceptable for the subject. Once a body location is selected fo r attachment of the actigraph, every  the ankle or hip. The actigraph can be attached with a hospital  band if that makes it more  time, and the data must be uploaded to an actigraphy database f or analysis.  actigraph measures sleep and daytime activity. The actigraph un it stores motion data by clock  
Sleep Diary  Actigraphy  
scheduled study site visits at Week 6 and Week 12 visits to coll ect at least 7 consecutive days of
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 62  
 On Day 1, all subjects will take their first dose of study drug  at the study sit e during the day time,  At each clinic visit when a sleep diary is issued (Table 6–1), a calendar will be issued to remind  
the LAR/caregiver when next to start recording data in the slee p diary. In addition, study site   
staff will remind the LAR/caregiver by phone call when it is ti me to start recording data in the   
sleep diary. Sleep diaries will be collected at visits per Tabl e 6–1.   
6.3  
 
 
 
 
 
 
 
 
 
At the EOS, OV101 concentration and time data obtained from spa rse sampling in this study will  
subsequently be subjected to population PK modeling and resulti ng exposure estimates will be   
evaluated using validated physiologically-based PK (PBPK) model ing to confirm predicted   
exposure estimates for the pediatric study population 2 to 12 y ears old at various weight bands.   
Pharmacokinetic e ndpoints are pres ented in Section  7.2.3.   
6.4 Safety Assessments 
Safety assessments will include frequency, severity, and causal ity of AEs (including SAEs and 
AEs leading to study discontinuation), and other safety assessm ents including assessment of 
suicidality, collection of seizure diaries, clinical laboratory  assessments, vital sign measurements, 
and physical examinations. Safety assessments will be conducted  according to the schedule 
presented in Table 6–1 for all age groups (2 to 12 years of age ). that individual OV101 concentration-time data align with respec tive data obtained previously  
from adolescents. Further details will be provided in the IDMC charter. age). Plasma concentrations within each time window will be eva luated by the IDMC to confirm  3 evaluable sentry subjects receiving OV101 within each age ban d (9 to 12 and 4 to 8 years of  each of the above 3 time points following the initial dose will  be determined from a minimum of is permitted if necessary. Approximately 2 mL of blood will be collected per PK sample for a 
total of 6 mL during Day 1. Blood samples will be processed to plasma within 2 hours. Plasma 
samples will be frozen, stored and shipped according to instruc tions to be provided to the study 
site. The PK samples will be analyzed for OV101 concentrations by a Sponsor-contracted 
bioanalytical facility using a validated bioanalytical assay. P lasma concentrations of OV101 for  dosing and the time of blood sampling. Topical application of a  cooling agent or local anesthetic and blood will be sampled for determination of plasma OV101 con centrations at 3 time points 
following the initial dose: 45 minutes ± 15 minutes; 90 minutes  ± 15 minutes, and 4 hours ± 30 
minutes (sparse sampling for population PK modeling). Study sit e staff will record the time of Pharmacokinetic Assessments
from adolescents. Further details will be provided in the IDMC charter.that individual OV101 concentration-time data align with respect ive data obtained previousl y3 evaluable sentry subjects receiving OV101 within each age ban d (9 to 12 and 4 to 8 years ofbioanalytical facility using a validated bioanalytical assay. P lasma concentrations of OV101 fo rsite. The PK samples will be analyzed for OV101 concentrations b y a Sponsor-contractedsamples will be frozen, stored and shipped according to instruct ions to be provided to the studytotal of 6 mL during Day 1. Blood samples will be processed to p lasma within 2 hours. Plasmais permitted if necessary. Approximately 2 mL of blood will be collected per PK sample for aminutes (sparse sampling for population PK modeling). Study site  staff will record the time of following the initial dose: 45 minutes ± 15 minutes; 90 minutes  ± 15 minutes, and 4 hours ± 30and blood will be sampled for determination of plasma OV101 con centrations at 3 time points
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 63  
 or is unable to tolerate wearing the actigraph.  6.4.1 Adverse Events 
6.4.1.1  Definitions of Adverse Events 
The investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug or severi ty. Each subject’s LAR/caregiver 
will be instructed to contact the study center if the subject e xperiences any adverse events (AEs), 
is unable to take the study drug as prescribed, 
 
An AE is defined as any untoward medical occurrence in a subjec t enrolled into this study 
regardless of its causal relationship to study drug. Subjects w ill be instructed to contact the 
investigator at any time after enrollment if any symptoms devel op. 
 
Treatment-emergent AEs (TEAEs) are defined as AEs that start or  increase in severity after the 
first dose of study drug in the study. 
 
Situations where an untoward medical occurrence did not occur ( social and/or convenience 
admission to a hospital) and anticipated day-to-day fluctuation s of preexisting disease(s) or 
condition(s) present or detected at the start of the study that  do not worsen are not AEs. Lack of 
drug effect is not an AE in clinical studies, because the purpo se of the clinical study is to 
establish drug effect. 
 
Cases of pregnancy that occur during maternal or paternal expos ures to study drug are to be 
reported. Data on fetal outcome and breastfeeding are collected  for regulatory reporting and drug 
safety evaluation. 
 
Study site personnel will record the occurrence and nature of e ach subject’s preexisting 
conditions, including clinically significant signs and symptoms  of the disease under treatment in 
the study (e.g., seizures, motor dysfunction, sleep disruption,  anxiety), as part of the medical 
history. 
 
As seizures are often a baseline condition in subjects with AS,  seizures should be reported as an 
AE in any of the following circumstances: 
 
x There is a clear increase in the frequency of seizures compared  to the subject’s baseline. 
 
x There is an emergence of a new seizure type. 
 
x The subject experiences status epilepticus. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 64  
  The investigator believes the seizure should be captured as an AE (in which case the 
investigator should document his/her reasoning). 
 
Seizures in this subject population will be detected and assessed using the seizure diary 
(Section 6.4.2.2). Diaries will be collected at the study site during the study and will be analyzed by 
the Sponsor along with the reportable SAEs in evaluating risks and benefits. The Sponsor will report 
the SAE events of seizure that meet these criteria in an aggregated, unblinded report at the end of the 
study. 
 
After the informed consent form (ICF) is signed, site personnel will record any change in the 
condition(s) and the occurrence and nature of any AEs. If a subject experiences an AE after the 
ICF has been signed but before receiving study drug, the event will be reported and will be 
included in the subject’s medical history unless the event is serious or the investigator feels the 
event may have been caused by a protocol procedure. 
 
In addition, all AEs occurring after the subject receives the first dose of study drug must be 
reported to Ovid or its designee via the eCRF. 
 
6.4.1.2  Serious Adverse Events 
An SAE is defined as any event that 
 
 Results in death. 
 Is immediately life threatening. 
 Requires inpatient hospitalization or prolongation of existing hospitalization. 
 Results in persistent or significant disability/incapacity. 
 Is a congenital anomaly or birth defect. 
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the subject or may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 65  
 6.4.1.3  Eliciting and Documenting Adverse Events 
Adverse events will be assessed beginning on the date of signed informed consent and up to 
14 days after the last dose of study drug (unless a subject decides to participate in the ELARA 
open-label extension study) and must be followed until resolution or for 14 days after the 
subject’s last study drug dose, whichever comes first. 
 
Serious AEs that occur more than 30 days after the last dose of study drug need not be reported 
unless the investigator considers them related to study drug. 
 
After informed consent is obtained, at every clinic visit and phone visit, subjects and their 
LAR/caregiver will be asked a standard nonleading question to elicit any medically-related 
changes in their well-being. They will also be asked if they have been hospitalized, had any 
accidents, used any new medications, or changed concomitant medication regimens (both 
prescription and over-the-counter medications). 
 
In addition to subject observations, AEs identified from any study data (e.g., laboratory values, 
physical examination findings) or identified from the review of other documents (e.g., subject 
diaries) that are relevant to subject safety or considered to be clinically significant, in the medical 
and scientific judgment of the investigator, will be documented on the AE page in the eCRF. 
 
6.4.1.4  Reporting Adverse Events 
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. 
Information to be collected includes the following: 
 
 Drug treatment 
 
 Dose 
 
 Event term 
 
 Time of onset 
 
 Investigator-specified assessment of severity and relationship to study drug 
 
 Time of resolution of the event 
 
 Seriousness 
 
 Any required treatment or evaluations 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 66  
  Outcome 
 
Adverse events resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to 
concurrent medications, or progression of disease states must also be reported. All AEs will be 
followed to adequate resolution. The Medical Dictionary for Regulatory Activities (MedDRA) 
will be used to code all AEs. 
 
Any medical condition that is present at the time the subject is screened and remains stable 
should not be reported as an AE. However, if the condition worsens at any time during the study, 
it should be recorded as an AE. 
 
Any abnormal laboratory test results (hematology or clinical chemistry) or other safety 
assessments (e.g., vital sign measurements), including those that worsen from baseline, that are 
felt to be clinically significant in the medical and scientific judgment of the investigator are to be 
recorded as AEs. 
 
6.4.1.5  Reporting Serious Adverse Events 
All nonserious AEs must be recorded in the eCRF upon awareness. 
 
Any AE that meets SAE criteria (Section 6.4.1.2) must immediately (i.e., within 1 business day) 
inform Ovid Drug Safety upon learning of any SAE that occurs (whether or not attributable to 
the study drug). It is the investigator’s responsibility to ensure that SAE reporting procedures are 
followed appropriately. All SAE reports and any revisions to an SAE report must be sent to the 
email provided. All supporting source information concerning the SAE (e.g., hospital records) 
should also be provided by fax or email. 
 
Country-specific fax numbers will be provided in a separate document. 
Email : ovidCTsafety@ovidrx.com 
 
If there is a question concerning an SAE, the site needs guidance regarding the reporting of an 
SAE, the site is returning a call from an Ovid Drug Safety specialist, the site urgently needs to 
report an SAE or make Ovid Drug Safety aware of an SAE, the safety hotline should be used 
(country-specific hotline numbers provided in a separate document). 
 
If an SAE is reported via the hotline, the site should first submit the SAE paper form and then 
enter the SAE in the eCRF. Any AE that meets SAE criteria (Section 6.4.1.2) must be entered 
into the EDC system immediately (i.e., within 1 business day) after site personnel first learn 
about the event, in addition to faxing/emailing the SAE Report form. Once the qualifying SAE 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 67  
 data are entered into the EDC system, Ovid will be notified by an email alert, which will contain 
high-level safety information. 
 
All SAEs must be reported starting from the time that informed consent for study participation is 
provided. If the investigator becomes aware of an SAE within 30 days after the subject’s last 
dose of study drug or within 30 days after the last study visit, the SAE must be reported unless 
the patient has signed the consent to enroll into the ELARA open label extension study. Serious 
AEs must be followed until the event resolves, the event or sequelae stabilize, or it is unlikely 
that additional information can be obtained after demonstration of due diligence with follow-up 
efforts (i.e., the subject or health care practitioner is unable to provide additional information, or 
the subject is lost to follow-up). For subjects who do not sign the informed consent to enroll into 
the ELARA open label extension study, serious AEs that occur more than 30 days after the last 
dose of study drug should be submitted to the sponsor if the investigator becomes aware, 
however, these do not need to be reported to the IRB/EC or regulators unless the investigator or 
Sponsor considers them related to study drug. 
 
6.4.1.6  Suspected Unexpected Serious Adverse Reactions and Nonserious 
Adverse Events of Special Interest 
The Sponsor will promptly evaluate all suspected unexpected serious adverse reactions and 
nonserious AEs of special interest against cumulative product experience to identify and 
expeditiously communicate possible new safety findings to investigators, IRBs and IECs, and 
applicable health authorities based on applicable legislation. 
 
To determine reporting requirements for single AE cases, the Sponsor will assess the 
expectedness of these events using the current OV101 investigator’s brochure (Ovid 
Therapeutics Inc. 2018). 
 
The Sponsor or its legal representative is responsible for notifying the relevant regulatory 
authorities of SAEs meeting the reporting criteria. This protocol will use Appendix 1 of the 
current investigator’s brochure as the Reference Safety Document. The expectedness and 
reporting criteria of an SAE will be determined by the Sponsor from the Reference Safety 
Document. 
 
6.4.1.7  Assessment of Severity 
The severity, or intensity, of an AE refers to the extent to which an AE affects the subject’s daily 
activities. The intensity of the AE will be rated as mild, moderate, or severe using the following 
criteria: 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 68  
  
Mild:  An AE that is transient in nature and generally does not interfere with the 
subject’s normal activities. 
Moderate: An AE that is sufficiently discomforting to interfere with the subject’s normal 
activities. 
Severe: An AE that is incapacitating and prevents normal activities. 
 
 
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
intermittent do not require documentation of onset and duration of each episode. 
 
6.4.1.8  Assessment of Causality 
The investigator’s assessment of an AE’s relationship to study drug is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the study. If there is any 
doubt as to whether a clinical observation is an AE, the event should be reported. 
 
The relationship or association of the study drug in causing or contributing to the AE will be 
characterized using the following classification and criteria: 
 Unrelated:  This relationship suggests that there is no association between the study drug 
and the reported event. 
Possible: This relationship suggests that treatment with the study drug caused or 
contributed to the AE, i.e., the event follows a reasonable temporal sequence 
from the time of drug administration or follows a known response pattern to the 
study drug but could also have been produced by other factors. 
Probable: This relationship suggests that a reasonable temporal sequence of the event 
with drug administration exists and, based upon the known pharmacological 
action of the drug, known or previously reported adverse reactions to the drug 
or class of drugs, or judgment based on the investigator’s clinical experience, 
the association of the event with the study drug seems likely. The event 
disappears or decreases on cessation or reduction of the dose of study drug. 
Definite: This relationship suggests that a definite causal relationship exists between drug 
administration and the AE, and other conditions (concurrent illness, 
progression/expression of disease state, or concurrent medication reaction) do 
not appear to explain the event. The event reappears or worsens if the study 
drug is re-administered. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 69  
 6.4.1.9  Follow-Up of Subjects Reporting Adverse Events 
All AEs must be reported in detail on the appropriate page in the eCRF and followed to 
satisfactory resolution, until the investigator deems the event to be chronic or not clinically 
significant, or until the subject is considered stable. 
 
6.4.2 Other Safety Assessments 
Safety assessments other than AEs (Section 6.4.1) include assessment of suicidality, collection of 
seizure diaries, clinical laboratory analyses (Section 6.7), vital sign measurements, and physical 
examinations. 
 
6.4.2.1  Assessment of Suicidality 
The ABC-I will be used to assess suicidality instead of the Columbia-Suicide Severity Rating 
Scale, since cognitive impairment in Angelman syndrome patients interferes with the 
understanding of the concept of suicide. Most individuals with AS are not able to communicate 
thoughts of suicidality, so the subject’s irritability reported by the LAR/caregiver is being used as 
a surrogate measure of suicidality. The investigator will review the scale items with the 
LAR/caregiver at each scheduled time point. If grading worsens, the investigator must decide 
whether that indicates a potential for self-harm by the subject, and if so, must document it as an 
AE and closely monitor it until resolution. The entire Aberrant Behavior Checklist – Community 
(ABC-C) will be administered although only the ABC-I will be used to assess the potential for 
self-harm. 
 
6.4.2.2  Seizure Diary 
The seizure diary is a caregiver-reported clinical outcome assessment measure that captures the 
total number and duration of seizures. Caregivers will record the number, duration, and type of 
seizures each day using the paper seizure diary. Also, refer to Section 6.4.1.1 for AE reporting 
criteria for these seizure events. 
 
The caregiver will be trained by the site with specific instructions beginning with the screening 
visit to ensure compliance in recording seizures. The seizure diary will be completed each day 
during 12 weeks of treatment beginning at screening and continuing through the EOT. Seizure 
diaries will be collected and reviewed by the investigator with the subject’s caregiver for proper 
recording at the baseline, Week 6, and Week 12 (or EOT) study site visits. Seizure Identification 
Form and Diagnostic Review Forms (SIF/DRF) will be completed by site personnel for every 
eligible subject. This information will be faxed or emailed to The Epilepsy Study Consortium 
(TESC) for review and approval. The SIF/DRF will be used to ensure that the seizures are 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 70  
 classified accurately. SIF and DRF forms will be collected for patients who have 
enrolled/completed the study if feasible. 
 
For the prospective baseline period, the seizure frequency (expressed as a 28-day frequency) will 
be calculated as 
 
(# of seizures) / (# of days seizures were assessed)  28 
 
Seizure frequency calculated through this method will be used to confirm the eligibility. 
 
6.4.2.3  Vital Sign Measurements 
Vital sign measurements will include blood pressure, temperature, heart rate, and respiratory rate. 
Measurement of vital signs should be attempted after the subject has been resting in a supine or 
sitting position for at least 10 minutes. 
 
6.4.2.4  Physical Examinations 
Height, weight, and head circumference will be measured as part of the physical examination, 
but height will be measured only at the screening visit. A physical examination will include a 
relevant general assessment of: general appearance; skin; head, eyes, ears, nose and throat; neck; 
lymph nodes; chest (including lungs); heart; abdomen; extremities; nervous system; and 
musculoskeletal system. 
 
6.4.2.5  Exposure During Pregnancy and/or Lactation 
OV101 should not be administered to pregnant or lactating females because the potential for 
adverse reactions to OV101 in pregnant females, fetuses, and nursing infants is unknown. 
 
Pregnancy data will be collected during this study for all subjects. Exposure during pregnancy 
(also referred to as exposure in-utero) can be the result of either maternal exposure or 
transmission of drug product via semen following paternal exposure. 
 
For all Ovid products, both in development or post-approval, exposure during pregnancy must be 
recorded and the subject followed until the outcome of the pregnancy is known (spontaneous 
miscarriage, elective termination, normal birth, or congenital abnormality), even if the subject 
discontinues study drug or discontinues from the study. 
 
If a subject within this study or a subject’s partner becomes pregnant while treated or exposed to 
study drug, the investigator must submit a pregnancy form to Ovid via the same method as SAE 
reporting. Pharmacovigilance will supply the investigator with a copy of a “Pregnancy Reporting 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 71  
 and Outcome Form/Breastfeeding.” When the outcome of the pregnancy becomes known, the 
form should be completed and returned to Ovid or Ovid Pharmacovigilance delegate. If 
additional follow-up is required, the investigator will be requested to provide the information. 
 
Exposure of an infant to an Ovid product during breastfeeding must also be reported and any 
AEs experienced by the infant must be reported to Ovid Pharmacovigilance or designee via 
email or fax (Section 6.4.1.5). 
 
Pregnancy is not regarded as an AE unless there is a suspicion that study drug may have 
interfered with the effectiveness of a contraceptive medication. However, complications of 
pregnancy and abnormal outcomes of pregnancy are AEs and may meet criteria for an SAE (such 
as ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or 
congenital anomaly). Elective abortions without complications should not be reported as AEs 
 
6.5 Safety Monitoring Committee 
An IDMC (Section 11.1.1) will provide safety monitoring. Oversight of the study conduct and 
IDMC will be provided by the Clinical Trial Steering Committee (CTSC; Section 11.1.2). 
 
Routine pharmacovigilance oversight will be provided by Ovid Drug Safety. 
 
6.6 Pregnancy 
Female subjects who are of childbearing potential (defined as having experienced their first 
menarche) must agree to use either a highly effective or acceptable form of birth control during 
the study and for 30 days following the last dose of the study. Highly effective contraceptive 
methods are as follows: 
 
a. Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation: 
 
 Oral 
 Intravaginal 
 Transdermal 
b. Progestogen-only hormonal contraception associated with inhibition of ovulation: 
 
 Oral 
 Injectable 
 Implantable 
c. Intrauterine device 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 72  
 d. Intrauterine hormone-releasing system 
 
e. Bilateral tubal occlusion 
 
f. Vasectomized partner 
 
g. Sexual abstinence 
 
Acceptable birth control methods that result in a failure rate of more than 1% per year include: 
 
a. Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mode of action. 
 
b. Male or female condom with or without spermicide. 
 
c. Cap, diaphragm or sponge with spermicide. 
 
d. A combination of male condom with either cap, diaphragm, or sponge with spermicide 
(double barrier methods) are also considered acceptable, but not highly effective, birth 
control methods 
 
For male subjects with women of child-bearing potential partners, there are no restrictions. 
Female subjects who have experienced menarche will undergo serum beta-human chorionic 
gonadotrophin (ß-hCG) pregnancy testing at study site visits shown in Table 6–1 (as part of the 
sampling for clinical laboratory tests). Any female subject with a positive pregnancy test result at 
Screening must be excluded from the study. A serum ß-hCG pregnancy test must be performed if 
any female subject is suspected of becoming pregnant during the study. 
 
If pregnancy occurs at any time during the study, study drug must be discontinued immediately 
(or not started). Pregnancy is not regarded as an AE unless there is a suspicion that a study drug 
may have interfered with the effectiveness of a contraceptive medication. Any pregnancy that 
occurs during study participation must be reported using the same procedures as an SAE 
(Section 6.4.1.5) but using a clinical study pregnancy form. The pregnancy must be followed-up 
to determine outcome (including spontaneous miscarriage, elective termination, normal birth, or 
congenital abnormality) and status of mother and child, even if the subject is discontinued from 
the study. Pregnancy complications and elective terminations for medical reasons should not be 
reported as an AE or SAE. Spontaneous miscarriages must be reported as an SAE. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 73  
 Any SAE occurring in association with a pregnancy, brought to t he investigator’s attention after 
the subject has completed the study and considered by the inves tigator as possibly related to the 
study treatment, must be promptly reported to Ovid Drug Safety.  
 
6.7 Laboratory Analyses 
The following clinical analytes will be assayed as safety asses sments: 
 
Hematology: hematocrit; hemoglobin; red blood cell count with indices (mean  corpuscular 
volume, mean corpuscular hemoglobin, and mean corpuscular hemog lobin concentration); 
reticulocytes; white blood cell count and differential (neutrop hils, lymphocytes, monocytes, 
eosinophils, and basophils) reported as percentages and absolut e values; and platelets (platelet 
count, prothrombin time and partial thromboplastin time, intern ational normalization ratio). 
Clinical chemistry: albumin; alkaline phosphatase; blood urea nitrogen; gamma-gluta myl 
transferase; calcium; creatinine; glucose; cholesterol (high-de nsity lipoprotein and low-density 
lipoprotein [calculated] and homogenous low-density lipoprotein ); triglycerides; magnesium, 
phosphate; potassium; alanine aminotransferase; aspartate amino transferase; lactate 
dehydrogenase; sodium; chloride; bilirubin (total, direct); tot al protein; uric acid; and creatine 
phosphokinase. 
Pregnancy testing : Serum ß-hCG for female subjects who have experienced menarche . Serum 
pregnancy testing will be conducted at screening and baseline. Serum pregnancy testing is 
recommended at subsequent visits; however, urine pregnancy test ing is allowed if serum is not 
obtainable. If serum cannot be collected, the reason should be documented in the source 
document and, for sexually active female subjects, the results of the serum pregnancy test 
obtained at Visit 1 must be confirmed to be negative by the inv estigator before randomization. 
 
6.8 Sample Collections 
Blood samples collected from subjects will be forwarded to a ce ntral laboratory for analysis. 
Further details regarding sample collections and processing and  specific testing can be found in 
the study manual (provided to study sites as a separate documen t). 
 
All samples for clinical laboratory analysis will be collected as described in the study manual, 
according to the schedule of activities (Table 6–1). Samples fo r hematology and clinical 
chemistry will be used only for the evaluation of safety and to lerability. 
 
Blood samples will be collected for clinical laboratory, safety  assessments, 
A total of up to 7 mL of blood is expected to be taken for labo ratory measurements at assays.and for sparse PK
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 74  
 plasma will be frozen until analyzed.  Blood samples for PK assays will be processed to plasma within 2 hours of being drawn, and  each of the screening, baseline, Week 6, and Week 12 visits. To tal blood collected will not 
exceed 20 mL in a 30-day period. This is in accordance with the  US Department of Health and 
Human Services, office for Human Research Protections recommend ations of 3 ml/kg, up to 50 
ml total within 8 weeks (Table 2 in Howie 2011). 
6.9 Contraception and Pregnancy Avoidance Procedure 
Subjects will be provided with information on acceptable method s of contraception as part of the 
subject informed consent process and will be asked to sign a co nsent form stating that they 
understand the requirements for avoidance of pregnancy, donatio n of ova, and sperm donation 
during the course of the study and for 90 days after the last d ose of study drug. This may be 
signed by the LAR/caregiver of the subject. For additional deta ils, refer to Section 6.6 for 
detailed contraception requirements. 
Female subjects who have experienced menarche must have a negat ive serum/urine hCG 
pregnancy test at screening (Visit 1) and a negative serum hCG pregnancy test on Day 1 (Visit 
2), before receiving any dose of study drug. If pregnancy resul ts cannot be collected at Visit 2, 
the reason should be documented in the source document, the res ults of the serum pregnancy test 
obtained at Visit 1 must be confirmed to be negative by the Inv estigator prior to randomization, 
and results of a serum pregnancy test at Visit 2 must be confir med to be negative before the 
subject can receive the first dose of study drug. During the st udy, subjects will receive continued 
guidance with respect to the avoidance of pregnancy and ova or sperm donation as part of the 
study procedures. An additional serum/urine hCG pregnancy test will be performed at the final 
visit. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 75  
 7 Statistical and Analytical Plan 
7.1 General Considerations 
All statistical analyses will be performed using SAS® Version 9.4 or higher. All clinical study 
data will be presented in subject data listings. Data summaries  will be presented for all endpoints 
and will include descriptive statistics (number of subjects, me an, SD, first quartile, median, third 
quartile, minimum, and maximum) for continuous variables, and f requency and percentage for 
categorical and ordinal variables. If there are missing values,  the number of missing values will 
be presented, but without a percentage. 
 
For all analyses, “baseline” refers to the most recent non-miss ing value obtained immediately 
prior to administration of first dose, unless it is otherwise c learly defined. 
 
Any substantial change to the data analysis methods described i n the protocol will require an 
amendment. Any other change to the data analysis methods descri bed in the protocol, and the 
justification for making the change, will be described in the S AP. Additional post hoc analyses of 
the data may be conducted as deemed appropriate. 
 
7.2 Endpoints 
7.2.1 Efficacy Endpoints 
7.2.1.1  Primary Endpoint 
x The CGI-I-AS score at Week 12 
 
7.2.1.2  Key Secondary Endpoints 
The key secondary endpoints will be utilized to fulfil a recomm endation of the EMA for a 
responder analysis.  
x CGI-I-AS response (at least minimally improved) defined as CGI- I-AS score of 1, 2, or 3 
at Week 12 
x CGI-I-AS response (at least much improved) defined as CGI-I-AS score of 1 or 2 at 
Week 12 
7.2.1.3  Other Secondary Endpoints 
x
x
sleep onsetLatency of sleep onset (LSO), defined as time from beginning of  rest period to start ofActigraphy assessment scores, change from baseline to Week 12
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 76  
 Total sleep time at night defined from subject time of sleep on set to time of  Sleep efficiency defined as the percentage of total sleep time out of the duration  xTotal daytime sleep, defined as duration of sleep time in the a ctive interval  
7.2.1.4 Tertiary Endpoints  
xSleep diary assessment scores, change from baseline to Week 12  
o
oLatency of sleep onset defined from subject in bed to time of s ubject sleep onset
o
xCSHQ assessment scores, change from baseline to Week 12  x
x VABS-3 assessment scores; change from baseline to Week 12 
o Communication domai n and its s ubdomains 
o Socialization domain and its subdomains 
o Daily Living Skills doma in and its s ubdomains 
o Motor Skills domain and its subdo mains 
o Maladaptive Behavior do main and its s ubdomains 
x The CGI-S-AS scores, change from baseline to Week 12. 
o The CGI-S-AS symptoms overall score 
o The CGI-S-AS domain scores 
x The relationship between CGI-S-AS at baseline and CGI-I-AS at W eek 12 
x The relationship between each of CGI-S-AS domains at baseline a nd CGI-I-AS at 
Week 12 
x





awakening  of time in bed periodSleep efficiency, defined as the percentage of total sleep time  out of duration of the rest
Daytime sleep defined as duration of napping  Number of disruptive behaviors while in bed Duration of night awakenings  Number of night awakenings 
HQo 
o 
o 
oDaily activity level (counts/minute) in the daily interval  Total sleep time at night defined as duration of sleep time in the sleep interval  
eepo
oActigraphy assessment scores, change from baseline to Week 12x
xTotal sleep time at night defined from subject time of sleep on set to time of Total sleep awakeningTotal  sleep Total sleepSleep efficiency defined as the percentage of total sleep time out of the duration Sleep efficiencofSleSltimeeep eeep einfficffibedciencienx
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 77  
 x
minutes ± 15 min, 4 hours ± 30 min).OV101 plasma concentration at each PK sampling window (45 minut es ± 15 min, 90
x
model.  estimates  (Cmax andAUC)  will also beevaluated in the context  of a validated PBPK  OV101 PK parameters derived from population PK modelling: Popul ation PK e xposure   





 
7.2.2 Safety Endpoints 
x Incidence of AEs 
x Change in clinical laboratory parameters from baseline to each post baseline assessment 
x Shift in clinical laboratory parameters from baseline to each p ost baseline assessment 
x Change in vital sign measurements from baseline to each post ba seline assessment 
x Shift in physical examination parameters from baseline to each post baseline assessment 
x Change in suicidality assessment (ABC-I) from baseline to each postbaseline as assessed 
by ABC-I. The ABC-I will serve as a surrogate measure for suici dality 
x Percent change in seizure frequency (expressed as a 28-day freq uency) from baseline to 
each post baseline timepoint 
 
7.2.3  
 
 12 Pediatric Quality of Life Inventory™ assessment scores, change from baseline to Week  xSleep-Onset Delay Subscale score
Family Impact module scores by dimension, total scores includin g the Parent 
HRQL Summary Score, the Family Functioning Summary Score Multidimensional Fatigue module by dimension and total score  Cerebral Palsy module by dimension score  o
o 
o Morning Waking/Daytime Sleepiness Subscale score  Sleep-Disordered Breathing Subscale score  Parasomnias Subscale score  Behavior Occurring Around Night Wakings Subscale score  Anxiety Around Sleep Subscale score  Sleep Duration Subscale score  Bedtime Resistance Subscale score  Total score  o 
o 
o 
o 
o 
o 
o 
o 
o
Pharmacokinetic Endpoints
xxSleep-Onset Delay Subscale scor e
x
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 78  
 Sample size calculations were performed to determine the number  of subjects needed for
The sample size calculations are based on comparison of the CGI -I-AS score at Week 12
As a sensitivity analysis of the assumption of normality, a Wil coxon rank sum test will be   
 
Approximately 95 subjects will be included in the study at appr oximately 15 study sites with no   
more than 12 subjects 4 to 12 years old per study site (unless authorized by the  
Sponsor).Approximately 90 subjects 4 to 12 years old (inclusive ) will be randomly assigned in a  
1:1 ratio into OV101 or placebo treatment groups for both effic acy and safety assessments.   
Randomization will be stratified by age categories: 9 to 12 yea rs old (inclusive) and 4 to 8 years   
old (inclusive) and region (US and Outside US). It is intended that a minimum of 24 subjects are  
randomized for each age category. Approximately 5 subjects 2 to  3 years old (inclusive) will be 
included and treated with OV101 for safety assessments only.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
If the primary analysis of CGI-I-AS shows a significant differe nce between OV101 QD and   
placebo, two key secondary endpoints, CGI-I-AS response (at lea st minimally improved) at
Week 12 and CGI-I-AS response (at least much improved) at Week 12 will be used to test the  
difference between OV101 and placebo with a gated sequential te sting procedure at a 2-sidedthe placebo group, and 0, 0.296, 0.37, 0.334, 0, 0, 0 in the OV 101 QD group.  0.074, 0, 0 for the probability of each CGI-I Symptoms Overall at Week 12 response category in  with probability distributions observed in OV101-15-001 Phase 2  study: 0, 0.074, 0.148, 0.704, significance. This calculation is based on the assumption of 7 ordered categories (scaled 1-7)  difference of OV101 versus placebo using a Wilcoxon rank-sum te st at a 2-sided 0.05 level ofconducted. With 40 subjects per treatment group, there would be  99% power to test the treatmentdifference at a 2-sided 0.05 level of significance.  variances, with 40 subjects per treatment group, there would be  99% power to test the treatmentof the CGI-I-AS at Week 12 between OV101 and placebo, using a t wo-sample t-test with equal  common standard deviation of 0.8 points, which yields an effect  size of 1. Based on comparison  points between OV101 QD and placebo in the CGI-I Symptoms Overa ll score at Week 12 with a  derived from the results observed in the OV101-15-001 Phase 2 s tudy: a mean difference of 0.8between OV101 and placebo, using a two-sample t-test with equal  variances. Assumptions are  secondary endpoints.  are required to ensure sufficient power for significance testin g using the primary and both key  endpoints. Based on these calculations, a minimum of 40 evaluab le subjects per treatment group  evaluation of efficacy using the primary efficacy endpoint as w ell as the two key s econdary  7.3 Sample Size and Power  
of the CGI-I-AS at Week 12 between OV101 and placebo, using a tw o-sample t-test with equal
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 79  
 With 40 subjects per treatment group, there would be 99% power to test the treatment difference  
Table 7–1 summarizes the power calculations for all thre e endpo ints:
Table 7–1  Power Calculations 
 
 
 
 
 
 
 
 
 
 
 
Endpoint   Primary Endpoint   CGI-I-AS At Least CGI-I-AS At Least    
  CGI-I-AS   Minimally    Much Improved  
 Improved   
Test Significance    0.05   0.05   0.05 
Level, α     
1 or 2 Sided Test   Two   Two   Two 
Assumptions    μ₁-μ₂=0.8 and   π₁=0.21,  π2=0.67   π₁=0.07,  π2=0.32   
  σ=0.8    
Power (%)   99%   99%   81.8%  
Sample Size per  40 40 40 
Group, n   
n, assuming 10%  45 45 45 
Dropout   
Assuming a 10% drop-out rate, 90 subjects aged 4 to 12 years ol d will be randomized to OV101  
QD and placebo (1:1 randomization).  
7.4 Analysis Sets 
The following analysis sets will only include subjects 4 to 12 years old (inclusive). The analysis 
for subjects 2 to 3 years old (inclusive) will be conducted sep arately. 
The intent-to-treat set will consist of all subjects who are ra ndomized, whether or not study drug 
is received. Subjects will be analyzed according to their rando mized group OV101 QD.response (at least much improved), assuming a response rate of 7% for placebo and 32% fordifference of OV101 versus placebo based on the second key seco ndary endpoint, CGI-I-ASWith 40 subjects per treatment group, there would be 81.8% powe r to test thminimally improved), assuming a response rate of 21% for placeb o and 67% for OV101 QD.  
of OV101 versus placebo based on the first key secondary endpoi nt, CGI-I-AS response (at least  15-001 Phase 2 study.  proportions. Assumptions regarding response rates are based on the rates observed in OV101-  0.05 level of significance. Power calculations were performed b ased on chi-square test of two
45 45 45 40 40 40 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 80  
 and least 1 valid PK measurement.  The PK data set will consist of all subjects who receive at lea st 1 dose of study drug and have at  The full analysis set (FAS) will include all subjects who are r andomized, receive at least 1 dose 
of study drug, and have at least 1 post baseline assessment of the primary efficacy endpoint. The 
FAS will be used for efficacy analyses based on the randomized treatment for each subject. 
The per protocol set (PPS) is a subset of the FAS that includes  subjects who complete the Week 
12 visit and have no major protocol deviations that are deemed to impact efficacy. The PPS will 
be used for efficacy analyses based on the randomized treatment  for each subject.  
The safety set (SS) will consist of all subjects who are random ized and receive at least 1 dose of 
study drug and will be used for all safety analyses. The safety  analyses will be based on the 
treatment that was actually administered to each subject. 
7.5 Subject Disposition 
The number of subjects screened and who failed screening will b e displayed. The number and 
percentage of subjects who are randomized, dosed, withdrawn fro m the study (including reasons 
for withdrawal), and complete the study will be displayed by tr eatment group and overall for the 
intent-to-treat set. The number and percentage of randomized su bjects in the SS, FAS, PPS, 
PK data set will also be displayed by treatment group and overa ll. 
The number of subjects screened, dosed, completed study, and wi thdrawn from the study will be 
summarized separately for subjects 2 to 3 years old (inclusive) . 
7.6 Demographic and Baseline Characteristics 
Demographic characteristics include age at screening and at bas eline, age group (randomization 
stratification variable: age at screening 4 to 8 years versus a ge 9 to 12 years), region 
(randomization stratification variable: US versus outside US), gender, race, ethnicity, study 
center, and country. Baseline characteristics include baseline body weight, height, body mass 
index (kg/m2), and molecular diagnosis. All demographic and baseline charac teristics data will 
be summarized descriptively by treatment group and overall for the SS. 
 
Data for subjects 2 to 3 years old (inclusive) will be presente d separately in listings. 
 
7.7 Exposure and Compliance 
Treatment compliance will be summarized by treatment group over  the entire treatment period. 
Compliance rates during the treatment period will be derived us ing the following formula: PK 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 81  
 100× (Total number of capsules dispensed–Total number of capsules returned) / (Expected 
number of capsules) 
 
The expected number of capsules to be taken is based on the date of first study drug dose and the 
date of last study drug dose, the subject’s weight range band at screening that determines the 
number of capsules expected each study week, following the titration schedule (Section 5.1), and 
any dose down-titrations (Section 5.2.1). Compliance rates will be presented for the SS using 
summary statistics and percentage for the frequency distributions (0% to <20%, 20% to 40%, 
40% to <60%, 60% to <80%, 80% to <100%, 100% to ≤120%) by treatment group and overall. 
 
Data for subjects 2 to 3 years old (inclusive) will be presented separately in listings. 
 
7.8 Efficacy Analyses 
All efficacy analyses will be based on the FAS. Additionally, the analysis of the primary endpoint 
will be repeated on the PPS to assess the sensitivity of the results to major protocol violations. 
All efficacy variables will be summarized descriptively by treatment group and visit. 
 
7.8.1 Primary Efficacy Analyses 
The CGI-I-AS scale assessed by the clinician rater will be collected at the Week 6 and Week 12 
visits. This is an ordinal variable with scores ranging from 1 (very much improved), to 4 (no 
change), to 7 (very much worse) which will be analyzed as a continuous outcome variable in 
these analyses. 
 
An MMRM Analysis of Variance (ANOVA) model will be fitted using restricted maximum 
likelihood (REML) for CGI-I-AS with fixed effects for visit (Week 6 and Week 12), randomized 
treatment, the visit-by-treatment interaction, age group (randomization stratification variable: age 
4 to 8 years versus age 9 to 12 years), and region (randomization stratification variable: US 
versus outside US). An unstructured within -subject covariance structure will be specified as the 
first choice, and if the model fails to converge, alternative covariance structures will be tested as 
detailed in the SAP. If a structured covariance is used, then a robust sandwich estimator will be 
utilized for estimating the variance of the treatment effect estimate. From the model, the Week 12 
difference between least squared means of OV101 and placebo groups will be presented along 
with the corresponding 95% confidence interval and 2-sided P value. 
 
As a sensitivity analysis for the assumption of normality, a Wilcoxon rank sum test will be used 
for treatment group comparison. The Hodges–Lehmann (Hodges and Lehmann 1963) estimate of 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 82  
 For each subject, the average of daily values for each actigrap hy variable (LSO, sleep efficiency,  
An MMRM Analysis of Covariance (ANCOVA) model for the change fr om baseline (7daythe median CGI-I-AS difference between OV101 and placebo groups , and its 95% confidence 
interval will be presented along with the 2-sided P value. 
 
7.8.2 Key Secondary Efficacy Analyses 
Generalized Estimating Equations (GEE) method will be used for the analysis of key secondary 
endpoints: CGI-I-AS response (at least minimally improved) and CGI-I-AS response (at least 
much improved). GEE models will include the response variable a t each visit as the dependent 
variable, and fixed effects for visit (Week 6 and Week 12), ran domized treatment, the visit-by- 
treatment interaction, age group (randomization stratification variable: age 4 to 8 years versus 
age 9 to 12 years), and region (randomization stratification va riable: US versus outside US). An 
unstructured working correlation for the binary outcome variabl e will be assumed for the model 
parameter estimation, and if the model fails to converge, alter native covariance structures will be 
tested as detailed in the SAP. If there is no response in eithe r treatment arm at the Week 6 visit, 
the GEE model will be substituted with a logistic regression fo r the Week 12 CGI-I-AS response 
variable with effects for the randomized treatment and the two randomization stratification 
variables. From the model (GEE or logistic regression, as appro priate), the Week 12 odds ratio 
will be presented along with the corresponding 95% confidence i nterval and 2-sided P value. 
7.8.3 Other Secondary Analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
The VABS-3 composite scores (Communications, Socialization, Dai ly Living Skills, Motor 
Skills, and Maladaptive Behavior domains) and scores of their s ubdomains will be assessed at 
baseline and Week 12 and analyzed as continuous outcome variabl es. interval and 2-sided P value.  OV101 and placebo groups will be presented along with the corre sponding 95% confidencedetailed in the SAP. From the model, the Week 12 difference bet ween least squared means of choice, and if this analysis fails to converge, alternative cov ariance structures will be tested as  a covariate. An unstructured within-subject covariance structur e will be specified as the first(randomization stratification variable: US versus outside US), and the corresponding baseline as  (randomization stratification variable: age 4 to 8 years versus  age 9 to 12 years), region  (Weeks 6 and 12), randomized treatment, the visit-by-treatment interaction, age group  average) will be fitted for each actigraphy endpoint defined ab ove with fixed effects for visit  Week 12).  and total daytime sleep) will be calculated for 7 days prior to  each visit (baseline, Week 6, and
An MMRM Analysis of Covariance (ANCOVA) model for the change fro m baseline (7da y
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 83  
 7.8.4 Tertiary Analyses
The CSHQ total score and scores of its subscales will be treate d as a continuous outcome
The Peds QL module scores will be treated as continuous outcome  variables. F or each m odule  Change from baseline to Week 12 in each VABS-3 domain score and  scores of their subdomains 
will be analyzed using an ANCOVA model with effects for randomi zed treatment, age group 
(randomization stratification variable: age 4 to 8 years versus  age 9 to 12 years), region 
(randomization stratification variable: US versus outside US), and the corresponding baseline as 
a covariate. A test for a significant treatment-by-baseline int eraction will be performed in a 
separate model (including the above terms plus the interaction term), using a 0.100 alpha level. If 
the treatment-by-baseline interaction is significant, then the ANCOVA assumptions are violated 
and an ANOVA model will be used instead. From the final model(s ), the difference between least 
squared means of OV101 and placebo groups will be presented alo ng with the corresponding 
95% confidence intervals and 2-sided P values. 
 
The CGI-S-AS Symptoms Overall and CGI-S-AS domains will be coll ected at baseline, Weeks 
6, and 12, and will be treated as a continuous outcome variable . An MMRM ANCOVA 
methodology similar to the one described previously for actigra phy variables will be used to 
analyze the change from baseline in CGI-S-AS Symptoms Overall s core and in scores of CGI-S- 
AS domains. 
 
The relationships between CGI-S-AS Symptoms Overall score at ba seline and CGI-I-AS at 
Week 12 will be explored. The relationships between each of CGI -S-AS domain scores at 
baseline and CGI-I-AS at Week 12 will also be explored.  
 
 
The sleep diary endpoints will be analyzed as continuous outcom e variables. An average of daily  
values for each sleep diary endpoint will be calculated for the  7 consecutive days prior to each   
visit when sleep diaries are collected. An MMRM ANCOVA methodol ogy will be applied to the 
change from baseline endpoint as described previously.   
 
 
 
 
 endpoint as described previously.scale, an ANCOVA methodology will be applied to the change from  baseline to Week 12  used to analyze the change from baseline in CSHQ score.variable. An MMRM ANCOVA methodology similar to the one describ ed previously will be  actigraphy v
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 84  
 7.8.5 Description of Subgroups to be Analyzed 
Descriptive statistics will be presented separately by age group (randomization stratification 
variable: age 4 to 8 years versus age 9 to 12 years) for the primary endpoint and the two key 
secondary endpoints. Observed values will be reported by treatment group. The difference in 
means or proportions for OV101 versus placebo groups will also be presented with the 
corresponding 95% confidence intervals. Similar subgroup analysis will be conducted for region 
(US versus outside US). 
 
If for a given endpoint, the results in the 2 subgroups appear different from a clinical perspective, 
the appropriate model (MMRM, GEE, or logistic) could be constructed as described above, 
including an age-by-treatment interaction term. This interaction term will be tested at alpha level 
of 0.10 to assess whether the treatment effects are statistically different for the 2 age subgroups. 
 
7.9 Safety Analyses 
All safety analyses will be based on the SS. Descriptive statistics will be used to summarize all 
safety endpoints by treatment group. Two-sided 95% CIs will be presented where meaningful. 
Data summaries will be displayed for incidence of AEs, clinical laboratory variables, vital signs, 
body weight and body mass index, physical examinations, clinical assessment of suicidality, and 
seizure diary data. 
 
Unless otherwise specified below, safety data for subjects 2 to 3 years old (inclusive) will only 
be presented in listings and will be displayed in by-subject graphs, as appropriate. 
 
7.9.1 Adverse Events 
All TEAEs will be coded using MedDRA and will be summarized by MedDRA system organ 
class and preferred term and treatment group. Detailed listings of TEAEs, SAEs, related AEs, 
and discontinuations due to AEs will be provided. 
 
The incidence of TEAEs, discontinuations due to TEAEs, drug-related, and serious TEAEs will 
be summarized. Incidence of TEAEs by severity and relationship to study drug will also be 
presented. 
 
Incidence of TEAEs will be summarized separately for subjects 2 to 3 years old (inclusive). 
 
7.9.2 Clinical Laboratory Tests 
Changes from baseline to each post baseline visit with respect to clinical chemistry and 
hematology results will be summarized descriptively. Each laboratory parameter will be 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 85  
 classified as low, normal, or high relative to the parameter’s reference range and will be 
summarized with shift tables. Listings of subjects with abnormal results will be provided. 
 
7.9.3 Vital Signs and Physical Examinations 
Vital signs (systolic and diastolic blood pressure, temperature, heart rate, and respiratory rate), 
weight, and body mass index will be summarized descriptively at baseline and all post baseline 
study visits by treatment group. Change from baseline to all post baseline study visits will be 
summarized descriptively by treatment group. 
 
Physical examinations (general appearance; skin; head, ears, eyes, nose, and throat; neck; lymph 
nodes; chest (including lungs); heart; abdomen; extremities; nervous system; and 
musculoskeletal system) at baseline will be summarized. Shifts from baseline to post baseline 
study visits in each body system/site will be summarized by treatment group. 
 
7.9.4 Suicidality 
Suicidality assessed by ABC-I will be summarized descriptively at baseline and all post baseline 
study visits by treatment group. Change from baseline to all post baseline study visits also will 
be summarized descriptively by treatment group. 
 
7.9.5 Seizure Diary Data 
Seizure diary data will be summarized descriptively at baseline and all post baseline study visits 
by treatment group. Additionally, the seizure frequency (expressed as a 28-day frequency) will 
be calculated for the following study periods: Baseline (Screening to Day 1), Week 6 (Day 1 to 
Week 6 visit date), and Week 12 (Week 6 visit date + 1 to Week 12 visit date). Percent change in 
seizure frequency from baseline to all post baseline study visits also will be summarized 
descriptively by treatment group. 
 
7.10 Other Analyses 
7.10.1  Concomitant Medications 
Concomitant medications will be coded using the World Health Organization Drug Dictionary 
(WHO-DD) and will be summarized according to their WHO-DD Anatomic Therapeutic 
Chemical class level 4 and preferred drug name within Anatomic Therapeutic Chemical class 
level 4. The number and percentage of subjects who took at least 1 medication post baseline as 
well as the number and percentage of subjects who took each type of medication will be 
presented for each treatment group. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 86  
 The PK data set will be used for all PK analyses.  
At the end of the study, OV101 concentration and time data obta ined from this study will
The population PK OV101 plasma exposure parameters will be furt her evaluated using a PBPK  
OV101 plasma concentrations will be summarized descriptively at  each timepoint. The  
The population PK-derived exposure estimates (C max and AUC) and other parameters (if derived) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.11 Interim Analyses 
No interim analyses of efficacy data are planned for this study . 
 
7.12 Statistical Testing and Significance Level 
The primary analysis will be performed on the FAS and the PPS. However, the PPS analysis will 
only be considered a sensitivity analysis. 
 
Inferential treatment comparison of the primary efficacy endpoi nt, CGI-I-AS at Week 12, will be 
conducted at the 0.050 level of significance using a 2-tailed t est. If the null hypothesis of no presented.  will be summarized descriptively and geometric means and coeffi cients of variation will bemissing.  variation. Plasma concentrations below the lower limit of quant ification will be treated as  descriptive statistics to be presented will include geometric m ean and geometric coefficient of  may also be estimated.  separately. In addition to C max and AUC exposure estimates, elimination half-life and t max values  as age-related hepatic, and renal function estimates). The PBPK  modeling details will be reported  organ size, blood flow, tissue perfusion, protein binding, tran sporter/enzyme expression as wellpediatric anatomy, developmental and physiologic data (includin g body weight, composition,  distribution, metabolism, and excretion data as well as appropr iate age -specific adult and  simulations are based upon known OV101-related physicochemical,  formulation, and absorption,  platform applied to extant PK data from adult and adolescent su bjects. The PBPK model and  model specific for OV101 that was developed using a commerciall y available PBPK software  pediatric study population 2 to 12 years old at various weight bands.  evaluated using validated PBPK modeling to confirm predicted ex posure estimates for the  subsequently be subjected to population PK modeling and resulti ng exposure estimates will be7.10.2 Pharmacokinetic Analyses
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 87  
 treatment difference for the primary endpoint is rejected, the alpha (0.05) will be passed to the 
significance testing for the key efficacy endpoints, CGI-I-AS response (at least minimally 
improved) at Week 12 and CGI-I-AS response (at least much improved) at Week 12, which will 
be tested using the corresponding 2-sided tests at 0.05 level of significance in a fixed sequence. 
If and only if the null hypothesis of no treatment difference based on CGI-I-AS response (at least 
minimally improved) is rejected at 0.05 level of significance, testing will continue and the null 
hypothesis of no treatment difference based on CGI-I-AS response (at least much improved) will 
be tested at 0.05 level of significance. 
 
No formal statistical testing of other secondary endpoints will be performed. All P values 
presented for secondary and tertiary endpoints will be considered descriptive in nature. 
 
7.13 Missing Data Handling and Sensitivity Analysis 
The MMRM model used in the analysis of key efficacy endpoints implicitly adjusts for missing 
data. If missing data are 5% or more for the primary endpoint, a sensitivity analysis will be 
performed, with missing outcomes be imputed in the analysis models. Multiple imputation 
techniques will be used for imputation, under the assumption of data missing not at random. 
Additionally, a tipping point analysis will be performed. Details will be specified in the SAP. 
 
Rules for imputation of missing dates for AEs and concomitant medications will be stated in the 
SAP. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 88  
 8 Data Quality Assurance 
This study will be conducted according to the International Cou ncil for Harmonisation (ICH) E6 
(R2) risk and quality processes described in the applicable pro cedural documents. The quality 
management approach to be implemented in this study will be doc umented and will comply with 
the current ICH guidance on quality and risk management. 
 
Standard operating procedures are available for all activities relevant to the quality of this study. 
Designated staff will be responsible for implementing and maint aining quality assurance and 
quality control systems to ensure that the study is conducted a nd that data are generated, 
documented, and reported in compliance with the study protocol,  Good Clinical Practice (GCP), 
and Good Laboratory Practice requirements as well as applicable  regulatory requirements and 
local laws, rules, and regulations relating to the conduct of t he clinical study. 
 
An authorized quality assurance auditor will audit the study da ta and procedures at periodic 
intervals as indicated. Domestic or foreign regulatory authorit ies, the IRB or IEC, and a Sponsor- 
authorized auditor may request access to all study documentatio n for an on-site inspection or 
audit. The investigator must notify the Sponsor of any regulato ry authority inspections and 
forward copies of the inspection report to the Sponsor. 
 
Electronic data systems will be in accordance with applicable a spects of US Title 21 Code of 
Federal Regulations (CFR) Part 11, ICH Guidelines, GCP, local l aws and legislation, and the 
Health Insurance Portability and Accountability Act. 
 
8.1 On-Site Audits 
At any time, quality assurance representatives of the Sponsor a nd/or regulatory bodies may visit 
the unit to carry out an audit of the study in compliance with regulatory guidelines and company 
policy. Such audits will require access to study records, docum entation, and regulatory files. At 
all times, subject privacy will be of utmost importance and mai ntained. Typically, sufficient 
(minimum of 2 weeks) notice will be given to the investigator t o prepare for the visit. 
 
8.2 Data Management 
As part of the responsibilities assumed by participating in the  study, the investigator agrees to 
maintain adequate case histories for the subjects treated as pa rt of the research under this 
protocol. The investigator agrees to maintain accurate eCRFs an d source documentation as part 
of the case histories. These source documents may include such documents as questionnaire 
results, sleep diaries, and computerized or otherwise automated  assessments (e.g., actigraph). sleep diaries, (e.g., actigraph).
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 89  
 Investigative site staff will enter subject data into Medidata RAVE® (the eCRF program). The 
analysis data sets will be a combination of these data and data  from other sources (e.g., 
laboratory data). 
 
Clinical data management will be performed in accordance with a pplicable Sponsor standards 
and data cleaning procedures to ensure the integrity of the dat a, e.g., removing errors and 
inconsistencies in the data. Adverse event terms will be coded using MedDRA, an internal 
validated medical dictionary, and concomitant medications will be coded using the World Health 
Organization Drug Dictionary. Concomitant medications will be c oded using the World Health 
Organization Drug Dictionary. 
 
After database lock, each study site will receive a CD-ROM cont aining all its site specific eCRF 
data as entered into the EDC system for the study, including fu ll discrepancy and audit history. 
Additionally, a CD-ROM copy of all the site’s data from the stu dy will be created and sent to the 
Sponsor for storage. PPD will maintain a duplicate CD-ROM copy for their records. In all cases, 
subject initials will not be collected or transmitted to the Sp onsor. PPD w
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 90  
 9 Ethics 
9.1 Independent Ethics Committee or Institutional Review Board 
Federal regulations and the ICH guidelines require that approval be obtained from an IRB/IEC 
before participation of human subjects in research studies. Before study onset, the protocol, 
informed consent, assent, advertisements to be used for the recruitment of study subjects, and 
any other written information regarding this study to be provided to the subject or the subject’s 
legal guardian must be approved by the IRB/IEC. Documentation of all IRB/IEC approvals and 
of the IRB/IEC compliance with ICH harmonised tripartite guideline E6 (R2): GCP will be 
maintained by the site and will be available for review by the Sponsor or its designee. 
 
All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must identify 
the IRB/IEC name and address, the clinical protocol by title or protocol number or both, and the 
date approval or a favorable opinion was granted. 
 
The investigator is responsible for providing written summaries of the progress and status of the 
study at intervals not exceeding 1 year or otherwise specified by the IRB/IEC. The investigator 
must promptly supply the Sponsor or its designee, the IRB/IEC, and, where applicable, the 
institution, with written reports on any changes significantly affecting the conduct of the study or 
increasing the risk to subjects. 
 
9.2 Ethical Conduct of the Study 
The study will be performed in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki, ICH GCP, the protocol, and all applicable regulations. 
 
9.3 Subject Information and Consent 
A written informed consent in compliance with applicable regulatory authority regulations shall 
be obtained from the LAR/caregiver of a minor before the subject enters the study or any unusual 
or nonroutine procedure that involves risk to the subject is performed. For minors an assent 
document will be presented, and assent will be obtained before the subject participates in any 
study procedure. Informed consent and assent template documents may be provided by the 
Sponsor to investigative sites. If any institution-specific modifications to study-related 
procedures are proposed or made by the site, the consent and assent should be reviewed by the 
Sponsor or its designee or both before IRB submission. Once reviewed, the consent and assent 
will be submitted by the investigator to his or her IRB for review and approval before the start of 
the study. If the ICF is revised during the study, all active participating subjects and 
LAR/caregivers (as applicable) must sign the revised forms. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 91  
 Before recruitment and enrollment, each prospective subject’s LAR/caregiver and subject (as 
applicable) will be given a full explanation of the study and will be allowed to read the approved 
ICF/assent. Once the investigator is assured that the LAR/caregiver and subject understand the 
implications of participating in the study, the LAR/caregiver and subject will be asked to give 
consent/assent to participate in the study by signing/approving the ICF/assent. 
 
The investigator shall retain the signed original ICFs/assents and give copies of the signed 
original forms to the LAR/caregivers and subjects, as applicable. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 92  
 10 Investigator’s Obligations 
The following administrative items are meant to guide the inves tigator in the conduct of the 
study but may be subject to change based on industry and govern ment standard operating 
procedures, working practice documents, or guidelines. Changes will be reported to the IRB/IEC 
but will not result in protocol amendments. 
 
10.1 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain subject confidentiality. All record s will be kept in a secure storage 
area with limited access. Clinical information will not be rele ased without the written permission 
of the subject (or the subject’s legal guardian or LAR/caregive r), except as necessary for 
monitoring and auditing by the Sponsor, its designee, the US Fo od and Drug Administration 
(FDA) or other applicable regulatory agency, or the IRB/IEC. 
 
The investigator and all employees and coworkers involved with this study may not disclose or 
use for any purpose other than performance of the study any dat a, record, or other unpublished, 
confidential information disclosed to those individuals for the  purpose of the study. Prior written 
agreement from the Sponsor or its designee must be obtained for  the disclosure of any said 
confidential information to other parties. 
 
10.2 Financial Disclosure and Obligations 
Investigators are required to provide financial disclosure info rmation to allow the Sponsor to 
submit the complete and accurate certification or disclosure st atements required under 21 CFR 
54. In addition, the investigator must provide to the Sponsor a  commitment to promptly update 
this information if any relevant changes occur during the study  and for 1 year following the 
completion of the study. 
 
Neither the Sponsor nor PPD is financially responsible for furt her testing or treatment of any 
medical condition that may be detected during the screening pro cess. In addition, in the absence 
of specific arrangements, neither the Sponsor nor PPD is financ ially responsible for further 
treatment of the subject’s disease.  
 
10.3 Investigator Documentation 
Prior to beginning the study, the investigator will be asked to  comply with ICH E6 (R2) 8.2 and 
Title 21 of the CFR by providing essential documents, including  but not limited to the following: PPD PPD i
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 93  
  IRB/IEC approval. 
 Original investigator-signed investigator agreement page of the protocol. 
 Form FDA 1572, fully executed, and all updates on a new fully executed Form FDA 1572. 
 Curriculum vitae for the investigator and each sub investigator listed on Form FDA 1572. 
 Financial disclosure information to allow the Sponsor to submit complete and accurate 
certification or disclosure statements required under 21 CFR 54. In addition, the 
investigators must provide to the Sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 
1 year after the completion of the study. 
 IRB/IEC-approved informed consent and assent, samples of site advertisements for 
recruitment for this study, and any other written information regarding this study that is to 
be provided to the subject or legal guardian. 
 Laboratory certifications and normal ranges for any local laboratories used by the site, in 
accordance with 42 CFR 493. 
10.4 Study Conduct 
The investigator agrees that the study will be conducted according to the principles of ICH E6 
(R2). The investigator will conduct all aspects of this study in accordance with all national, state, 
and local laws or regulations. Study information from this protocol will be posted on publicly 
available clinical trial registers before the enrollment of subjects begins. 
 
10.5 Adherence to Protocol 
The investigator agrees to conduct the study as outlined in this protocol in accordance with ICH 
E6 (R2) and all applicable guidelines and regulations. 
 
10.6 Adverse Events and Study Report Requirements 
By participating in this study, the investigator agrees to submit reports of SAEs to the Sponsor 
and/or IRB/IEC according to the timeline and method outlined in the protocol. In addition, the 
investigator agrees to submit annual reports to the study site IRB/IEC as appropriate. 
 
10.7 Investigator’s Final Report 
Upon completion of the study, the investigator, where applicable, should inform the institution; 
the investigator/institution should provide the IRB/IEC with a summary of the study’s outcome 
and the Sponsor and regulatory authority(ies) with any reports required. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 94  
 10.8 Records Retention 
Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of 
clinical development of the investigational product. These documents should be retained for a 
longer period, however, if required by the applicable regulatory requirements or by an agreement 
with the Sponsor. It is the responsibility of the Sponsor to inform the investigator/institution as to 
when these documents no longer need to be retained. 
 
10.9 Publications 
After completion of the study, the data may be considered for reporting at a scientific meeting or 
for publication in a scientific journal. In these cases, the Sponsor will be responsible for these 
activities and will work with the investigators to determine how the manuscript is written and 
edited, the number and order of authors, the publication to which it will be submitted, and other 
related issues. The Sponsor has final approval authority over all such issues. 
 
The data are the property of the Sponsor and cannot be published without prior authorization 
from the Sponsor, but data and publication thereof will not be unduly withheld. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 95  
 11 Study Management 
11.1 Monitoring 
11.1.1  Independent Data Monitoring Committee 
An IDMC will monitor the study (Section 6.5): it will include 3  independent representatives 
including a chairperson, a pediatric epileptologist, and a bios tatistician. The IDMC charter 
includes the details for the IDMC including responsibilities, q ualifications, and key processes. 
The IDMC responsibilities will include (but are not limited to)  the following: 
 
x Staged Enrollment Review Meetings. Subject assignment to treatm ent will be stratified 
and staged by age and gated by the IDMC via the evaluation of s entry subjects 
(Section 5.1). No age cohort may begin treatment without IDMC r eview of tolerability 
and PK in sentry subjects in the previous older cohort. 
 
x Meet periodically to review aggregate and individual subject da ta related to safety, data 
integrity, and overall conduct of the trial. 
 
x Work with the Independent Statistical Center to determine the d ata presentations (tables, 
listings, and figures) that are necessary for the IDMC to monit or study conduct and 
safety. 
 
x Review and evaluate the content of all data presentations recei ved before each IDMC 
Meeting. 
 
x Contribute to closed session reviews and recommendations. 
 
11.1.2  Clinical Trial Steering Committee 
The CTSC will include approximately 5 independent representativ es, including a chairperson, 
representatives with relevant expertise in pediatric psychiatry , pediatric epileptology, pediatric 
neurology and psychology, and a parent of a child with AS. In a ddition, 2 Sponsor 
representatives will be included on the CTSC. The CTSC responsi bilities will include (but are 
not limited to) the following: 
 
x Conduct interim review of the trial’s progress including update d data on recruitment and 
data quality. 
 
x Review recommendations of the IDMC including but not limited to : and PK i
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 96  
 o Safety issues which may suggest risk to currently enrolled or future subjects 
 
o Recommendations to modify or terminate the trial if, following review of the data, 
there are safety or efficacy concerns. 
 
 Monitor compliance with IDMC recommendations. 
 
 Monitor recruitment data and accrual within relevant subsets, screen failures, dropouts, 
and losses to follow-up overall and by study site. 
 
 Monitor compliance with the protocol and protocol violations by subjects and 
investigators. 
 
 Advise on protocol modifications suggested by investigators or Sponsors (e.g., 
amendments to inclusion criteria, trial endpoints, or sample size). 
 
 Monitor planned sample size assumptions. 
 
 Monitor continuing appropriateness of subject information. 
 
 Assess the impact and relevance of external evidence. 
 
11.1.3  Monitoring of the Study 
The clinical monitor, as a representative of the Sponsor, has the obligation to follow the study 
closely. In doing so, the monitor will visit the investigator and study site at periodic intervals, in 
addition to maintaining necessary telephone and letter contact. The monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the investigator and personnel. 
 
All aspects of the study will be carefully monitored, by the Sponsor or its designee, for 
compliance with applicable government regulation with respect to current GCP and current 
standard operating procedures. 
 
11.1.4  Inspection of Records 
Investigators and institutions involved in the study will permit study-related monitoring, audits, 
IRB/IEC review, and regulatory inspections by providing direct access to all study records. In the 
event of an audit, the investigator agrees to allow the Sponsor, representatives of the Sponsor, or 
a regulatory agency access to all study records. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 97  
 The investigator should promptly notify the Sponsor and PPD of any audits scheduled by any 
regulatory authorities and promptly forward copies of any audit  reports received to the Sponsor. 
 
11.2 Management of Protocol Amendments and Deviations 
11.2.1  Modification of the Protocol 
Any changes in this research activity, except those necessary t o remove an apparent, immediate 
hazard to the subject, must be reviewed and approved by the Spo nsor or its designee. 
Amendments to the protocol must be submitted in writing to the investigator’s IRB/IEC for 
approval before subjects can be enrolled into an amended protoc ol. 
 
11.2.2  Protocol Deviations 
The investigator or designee must document and explain in the s ubject’s source documentation 
any deviation from the approved protocol. The investigator may implement a deviation from, or 
a change of, the protocol to eliminate an immediate hazard to s tudy subjects without prior 
IRB/IEC approval. As soon as possible after such an occurrence,  the implemented deviation or 
change, the reasons for it, and any proposed protocol amendment s should be submitted to the 
IRB/IEC for review and approval, to the Sponsor for agreement, and to the regulatory 
authorities, if required. 
 
A deviation from the protocol is an unintended or unanticipated  departure from the procedures or 
processes approved by the Sponsor and the IRB/IEC and agreed to  by the investigator. A 
significant deviation occurs when there is nonadherence to the protocol by the subject or 
investigator that results in a significant, additional risk to the subject. Significant deviations can 
include nonadherence to inclusion or exclusion criteria, or non adherence to FDA regulations or 
ICH GCP guidelines, and will lead to the subject being withdraw n from the study (Section 4.2). 
 
Protocol deviations will be documented by the clinical monitor throughout the course of 
monitoring visits. Principal investigators will be notified in writing by the monitor of deviations. 
The IRB/IEC should be notified of all protocol deviations in a timely manner. 
 
11.3 Study Termination 
Although Ovid has every intention of completing the study, Ovid  reserves the right to 
discontinue the study at any time for clinical or administrativ e reasons. 
 
The end of the study is defined as the date on which the last s ubject completes the last visit 
(includes the phone EOS visit). PPD 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 98  
 11.4 Final Report 
Whether the study is completed or prematurely terminated, the Sponsor will ensure that the 
clinical study reports (CSRs) are prepared and provided to the regulatory agencies as required by 
the applicable regulatory requirements. The Sponsor will also ensure that the CSRs in marketing 
applications meet the standards of the ICH harmonised tripartite guideline E3: Structure and 
content of CSRs. 
 
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the CSR. The investigator will be provided reasonable access to 
statistical tables, figures, and relevant reports and will have the opportunity to review the 
complete study results. 
 
Upon completion of the CSR, the Sponsor will provide the investigator with the full summary of 
the study results. The investigator is encouraged to share the summary results with the study 
subjects, as appropriate. The study results will be posted on publicly available clinical trial 
registers. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 99  
 12 Reference List 
 Berry JA, Cervantes-Sandoval I, Chakraborty M, et al. Sleep facilitates memory by 
blocking dopamine neuron-mediated forgetting. Cell. 2015; 161(7):1656-67. 
 
 Brickley SG, Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and 
implications for disease. Neuron. 2012; 73(1):23-34. 
 
 Deidda G, Bozarth IF, Cancedda L. Modulation of GABAergic transmission in 
development and neurodevelopmental disorders: investigating physiology and pathology 
to gain therapeutic perspectives. Front Cell Neurosci. 2014; 8:119. 
 
 Dissel S, Angadi V, Kirszenblat L, et al. Sleep restores behavioral plasticity to Drosophila 
mutants. Curr Biol. 2015; 25(10):1270-81. 
 
 Egawa K, Fukuda A. Pathophysiological power of improper tonic GABA(A) 
conductances in mature and immature models. Front Neural Circuits. 2013; 7:170. 
 
 Egawa K, Kitagawa K, Inoue, K, et al. Decreased tonic inhibition in cerebellar granule 
cells causes motor dysfunction in a mouse model of Angelman syndrome. Sci Transl 
Med. 2012;4(163):163ra157. 
 
 Hodges JL, Lehmann EL. Estimation of location based on ranks. Annals Mathematical 
Statistics. 1963; 34 (2):598–611. 
 
 Howie SRC. Blood sample volumes in child health research: review of safe limits. 
Bulletin of the WHO. [Internet] 2011 [cited 24 May 2019]; 89(1):46-53. Available from: 
https://www.who.int/bulletin/volumes/89/1/BLT-10-080010-table-T2.html. 
 
 Merck. Study # 027: A placebo-controlled, double-blind, multiple dose safety, tolerability 
and pharmacokinetic study of Lu 02-030 following sequentially escalating doses in 
healthy young men and at one dose level in healthy young women and healthy elderly. 
2001 
 
 Merck. Study # P031: A 2-part study to assess the tolerability of gaboxadol (MK-0928) 
administered intravenously (Part 1) and a 6-period crossover to examine the dose 
proportionality of 5 single oral doses of MK-0928 in the range of 2.5 to 20 mg 
administered over periods 1 through 5 followed by a fixed sequence, open IV arm (period 
6) in healthy young adult male and female subjects (Part 2). 2006. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 100  
 xOwens JA, Spirito A, McGuinn M. The Children's Sleep Habits Que stionnaire (CSHQ):  
and adolescents with cerebral palsy: hearing the voices of the children. Dev Med Child
preliminary reliability and validity. Health Qual Life Outcomes . 2004:2:55.  x Mertz LG, Christensen R, Vogel I, et al. Angelman syndrome in D enmark. Birth 
incidence, genetic findings, and age at diagnosis. Am J Med Gen et A. 2013; 161A (9): 
2197-2203. 
x Ovid Therapeutics Inc. Gaboxadol (OV101). Investigator’s Brochu re, 3rd ed. New York 
(NY); 2018. 87 p. 
x Ovid Therapeutics Inc. (New York, USA). OV101-16-001: A phase 1  single dose PK 
study in adolescent subjects with Fragile X syndrome or Angelma n syndrome. 2018. 
 
 
 
x Petersen MB, Brondum-Nielsen K, Hansen LK, et al. Clinical, cyt ogenetic, and 
molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish 
county. Am J Med Genet. 1995; 60:261-2. 
 
x Ramamoorthi K, Lin Y. The contribution of GABAergic dysfunction  to 
neurodevelopmental disorders. Trends Mol Med. 2011; 17(8):452-6 2. 
 
x Sparrow SS, Cicchetti DV, and Balla DA. Vineland II: Vineland A daptive Behavior 
Scales. Circle Pines, MN, American Guidance Service 2005. 
 
x Sparrow SS, Cicchetti DV and Saulnier CA. Vineland Adaptive Beh avior Scales, third 
edition (Vineland-3). Circle Pines, MN, American Guidance Servi ce. 2016. 
 
x Steffenburg S, Gillberg CL, Steffenburg U, et al. Autism in Ang elman syndrome: a 
population-based study. Pediatr Neurol. 1996; 14(2):131-136. 
 
x


x

x Williams CA, Beaudet AL, Clayton-Smith J, et al. Angelman syndr ome 2005: updated 
consensus for diagnostic criteria. Am J Med Genet A. 2006; 140( 5):413-8. Neurol. 2005; 47(9):592-7.23(8):1043-51.  psychometric properties of a survey instrument for school-aged children. Sleep. 2000;  
Varni JW, Sherman SA, Burwinkle TM, et al. The PedQoLI™ Family Impa ct Module:  Varni JW, Burwinkle TM, Sherman SA, et al. Health-related quali ty of life of children  
Family Impa ct Module:™Varni JW, Sherman SA, Burwinkle TM, et al. The PedQoLI I™x
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 101  
 13 Pandemic Addendum 
The purpose of this addendum is to safeguard the safety of study subjects, ensure continuation of 
study conduct, and preserve the integrity of the study, in case of a general public health crisis or 
pandemic such as COVID-19. This addendum addresses situations in which scheduled in person 
clinic visits are not feasible due to local, regional or national restrictions. 
Specifically, the addendum aims to ensure: 
 Continued safe study conduct and participation of existing patients 
 Uninterrupted supply of study treatment 
 Integrity of data capture and minimization of missing data 
Written communication from sponsor Medical Advisor or Clinical Operations Lead is required 
before any portion of this addendum is put into effect. The communication shall be documented 
and captured in the Trial Master File. 
The Principal Investigator, holds the ultimate responsibility for the safety and well-being of 
study subjects and as always, shall maintain compliance with the current local and health 
authority guidelines and recommendations pertaining to the pandemic. 
This guidance is categorized below by the different stages of subject participation in the 
NEPTUNE study: 
 
Guidance for subjects scheduled to undergo study screening 
 For subjects 4-12 years old who are unable to attend a clinic visit in person 
o Remote screening via telehealth and/or telephone may be performed at the discretion 
of the Principal Investigator. The choice of telehealth platform is the Principal 
Investigator’s discretion but must be consistent with local policies and standard 
practice. T he requirements for data protection, must be adhered to.  
o Informed Consent may be sent to the subject either electronically (pdf format) or by 
mail prior to the scheduled screening visit 
o Informed consent can be performed via telehealth or telephone during the screening 
visit and documented in the source document with the date and time of the verbal 
consent. Wet ink signature on ICF should be returned to the site via courier. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 102  
 and Sleep diary  x For remote sc reening
o Site must ensure that subject has access to a weighing scale, f or determination of 
weight band assignment 
o Screening visit clinical labs may be performed at a local labor atory. Reference ranges 
must be documented 
o Home visits may be conducted by a trained mobile healthcare pro fessional to perform 
study assessments e.g. vital signs, body weight assessment, cli nical lab draws, 
review/collection of study materials 
o Instructions should be provided verbally or in writing to the c aregiver 
o 
 
o 
 
o Copies of Seizure forms should be sent to caregiver. Electronic  
copies may be provided if caregivers can make physical copies. 
o Pre-paid envelopes will be provided to support the shipping of the diaries 
o Update EDC as soon as possible to allow planning of IP shipment  
o Notify Sponsor/CRA to plan support with shipment arrangement 
x For subjects 2-3 years old 
o Screening shall be performed on-site. If pandemic restrictions preclude on-site visits, 
then screening of subjects 2-3 yrs old shall be placed on a tem porary hold until 
permissible under local and investigative site’s guidelines 
o Informed Consent may be sent to the subject either electronical ly (pdf format) or by 
mail prior to the scheduled screening visit. The signed consent  should be returned by 
the subject to the site and appropriately filed. If Informed Co nsent is completed 
remotely, a wet ink signature on ICF should be returned to the site via courier. 
Guidance for subjects scheduled for Randomization/Baseline Visi t 
x Randomization visits can only occur when patients can physicall y be present on-site 
x If the baseline visit cannot be conducted within 28 days of scr eening, it should be captured as 
a protocol deviation due to pandemic restrictions but do not au tomatically screen fail the 
subject. IWRS and EDC will not automatically screen fail subjec ts in this case 
x Every attempt should be made to follow procedures at the random ization visit as per study 
protocol. Any deviation should be appropriately documented and reported to each site’s 
IRBs/ECs per their reporting guidelines 
x Additional instructions pertaining to the randomization visit w ill be provided for subjects 
who are still in the screening phase when pandemic restrictions  are scaled back, and subjects 
are able to attend clinic visits in person Caregivers should contact the site team promptly should they ha ve any questions or 
concerns pertaining to the actigraphy device or other study acc essories. Actigraphy devices, related accessories including charging equi pment, data hub, 
bands, and instructions should be sent to subject from the site  via courier. 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 103  
 remotely  actigraphy website portal.  Resetting  monitoring period  for actigraphy device  can be done  monitor  thecompliance of sleep  data collection from the actigraphy  device, as usual viathe subject’s possession  ifthefamily cannot  travel  tosite. However, thesite staff should closely  The actigraphy device may remain in thex 

x IP will be provided to subject at the site 
x 

x Seizure and sleep diaries must be collected and reviewed as per  protocol procedures and 
Epilepsy Consortium instructions including SIF and DRF forms. P hysical/electronic PDF 
copies of diaries (including medication diary) should be provid ed in preparation of week 6 
and week 12 visits 
x Preprinted shipment labels and envelopes should be provided to caregivers to receive diaries 
x Upon retrieval of diaries, EDC should be updated accordingly 
Guidance for established subjects completing Week 6 Study Visit  
x Schedule the visit as close as possible to Week 6 date to allow  time to ship IP. 
x When on-site visits are not feasible, remote assessment of the CGI-I-AS, CGI-S-AS, VABS3, 
and other PROs) may be performed via your institution-approved (HIPAA compliant) 
telehealth system. Telehealth assessments must be consistent wi th local policies and 
standards. The requirements for data protection of Personal Hea lth Information (PHI) must 
be adhered to. 
x In the absence of a telehealth system, a remote assessment is t o be completed by utilizing a 
unified communication software such as Skype, Microsoft Teams o r Zoom
x Provide a script to a local lab as required per clinical labs p er protocol 
x Home visits may be conducted by a trained mobile healthcare pro fessional to perform study 
assessments e.g. vital signs, body system assessment, clinical labs draws, review/collection 
of study materials 
x If the site visits become possible/permissible at any point bet ween Week 6 and Week 12, the 
subject should be scheduled for an on-site, unscheduled visit p rior to week 12 time point and 
all safety assessments should be completed at this visit 
x IP with kit number will be assigned to each subject. Where allo wed, a preferred courier will 
be assigned to pick up and deliver the IP to subject. 
 
   
 
 
Guidance established subjects completing Week 12 Study Visit 
x Whenever possible, all week 12 visits should be completed onsit e
x If an onsite visit is not possible, a remote visit should be co mpleted to collect assessments via 
telehealth system. A unified communication software such as Sky pe, Microsoft Teams or should they need  toreset sleep  monitoring period viaActigraph  Caregivers must be instructed that they need to contact site st aff at their earlie st convenience,non-collection  must  bedocumented.PK lab draw collections should be performed where possible. If not collected, the reason for
and sleep 
Ovid Therapeutics Inc. 
Protocol OV101-19-001 Version 6.0  OV101  
26 January 2021  
Page 104  
 Zoom may be utilized unless prohibited by local guidelines. Tel ehealth assessments must be 
consistent with local policies and standards. The requirements for data protection, must be 
adhered to. 
x Provide a script to a local lab for clinical labs required per protocol
x Home visits may be conducted by a trained mobile healthcare pro fessional to perform study 
assessments e.g. vital signs, body system assessment, clinical labs draws, review/collection 
of study materials 
x For subjects intending to immediately transition into ELARA, th e week 12 (NEPTUNE 
EOT) visit may be considered as ELARA Baseline if ELARA protoco l criteria are met. 
x Unused IP should be shipped back to s ite for reconciliation.  
x 


x Ensure subject diaries are collected and reviewed appropriately .
x If any patient is enrolling into the ELARA study immediately af ter week 12 visit, EOS week 
14 visit (over the phone) should be completed prior to enrollme nt into ELARA 
If at any time during the conduct of the NEPTUNE study /a subje ct contracts COVID-19 
infection or any reportable infectious disease, the local healt h authority requirements regarding 
treatment/reporting/quarantine should be followed. The event sh ould be reported as an AE/SAE 
and the investigator should determine if study treatment should  be continued, temporarily 
interrupted, or discontinued. your site.successfully  andprovide shipping label  to caregivers tosend the actigraphy device  back  toEnsure sleep data collection via actigraphy device for week 12 has been collected